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Abstract 
Prostate cancer (PCa) is the most common malignancy in men in the UK. However, the 
5-year survival rate of stage IV PCa is 30% and the median survival for the castrate 
resistant phenotype is less than 2 years. This illustrates a clinical need for improved 
therapies for metastatic castrate resistant prostate cancer. Chimeric antigen receptor 
(CAR) T cell therapy has shown unprecedented success in blood cancers. The application 
of this platform in solid cancers, including PCa, has been less efficacious. A 2nd 
generation CAR, P28z, has previously been developed to retarget T cells to PSMA. When 
co-expressed with the IL-4 responsive 4αβ chimeric cytokine receptor, the resultant P4 
transduced T cells proliferate and enrich in the presence of IL-4. The aim of my project 
was to develop an IL-4 immunocytokine targeted to the tumour microenvironment to 
provide P4 CAR T cells with a proliferative signal and thereby increase anti-tumour 
efficacy. Fibroblast activation protein (FAP) was chosen as the target for the 
immunocytokine because of its overexpression in the stroma of epithelial cancers. An 
immunocytokine designed from a published anti-FAP single chain variable fragment 
(scFv) sequence, eFAP-4, showed FAP specificity and signalling capabilities through the 
4αβ receptor. For drug development, PCa cell lines were characterised and developed to 
express PSMA and reporter genes. Additionally, FAP+ stromal cell lines were 
characterised and engineered with a reporter gene. When P4 CAR T cells were cultured 
on PSMA+FAP+ PCa/stroma monolayers in the presence of eFAP-4, increased T cell 
proliferation, cytokine secretion and persistence were observed. However, when PCa 
xenografts were established in vivo, stromal engraftment was insufficient. To model this 
interaction, PCa cells were transduced with FAP. In a pilot study using this PSMA+FAP+ 
PCa xenograft model, increased survival and tumour control was seen in the group treated 
with P4 + eFAP-4. This study has indicated the potential for the improvement of CAR T 
cell immunotherapy of PCa using tumour microenvironment targeted immunocytokines. 
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 Chapter 1: General Introduction 
1.1 Immunotherapy for cancer 
1.1.1 History 
The potential beneficial association between infection and tumour control has been 
recorded as far back as ancient Egypt (Ebbell, 1937). Studies evaluating the use of 
infectious agents to treat tumours were documented in 1891 when William Coley 
recorded the effect of injecting cancer patients with Streptococcus strains to induce 
erysipelas. He first described the trials of Dr. Friedrich Fehleisen, credited for the 
isolation of the microbe responsible for the erysipelas infection, and his seven patients 
with different sarcoma and carcinoma malignancies. These patients were injected with 
bacteria to cause erysipelas; six developed infection and three had visible reduction in 
both swollen glands and tumour size. Independent of this, Coley reported seven more 
cases of complete tumour regression or decrease in tumour size following accidental or 
intentional induction of erysipelas (Coley, 1891). Based on these observations, Coley 
went on to treat ten patients with intratumoural injections of Streptococci and seven 
manifested some degree of tumour regression/growth control. In most cases, an 
incapacitating erysipelas infection preceded anti-tumour events including high fever, 
chills, vomiting, malaise and fatigue (Coley, 1893). Known as “the father of 
immunotherapy”, Coley treated nearly 1,000 patients in his lifetime with Coley’s Toxins 
(a mixture of heat-inactivated Streptococci and Serratia marcescens). However due to 
poorly controlled experiments and the severity of infections, Coley’s Toxins were no 
longer regarded as a viable treatment for cancer by the mid-20th century (McCarthy, 
2006). The role of immunology in cancer progression or treatment had not been described 
by that time and consequently it wasn’t completely understood why Coley’s Toxins 
appeared to induce tumour regression. Building on this concept, the first widely 
established cancer immunotherapy was the Bacillus Calmette-Guerin (BCG) vaccine, 
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which was originally administered to prevent tuberculosis. The BCG vaccine was first 
used to treat superficial bladder cancer in 1976 and this live attenuated vaccine is still in 
use for non-invasive bladder cancer (Chang et al., 2016, Morales, 2017, Morales et al., 
1976).  
 
It is now understood that the immune system is involved in the control of malignancy 
through ‘immunosurveillance’ and, paradoxically, contributes to cancer progression 
through ‘immunoediting’. This impact of the immune system on tumour evolution is 
characterised by 3 states: elimination, equilibrium and escape of the malignant cells 
(Dunn et al., 2002). Immunologic control of tumour formation/growth was debated for 
most of the 20th century, but expansion of the field of immunology and further 
development of tissue-specific transgenic mouse models has allowed for a more thorough 
investigation into the immunosurveillance theory. An initial study using fibrosarcoma 
cells expressing a dominant negative IFN-γ receptor rendering the cells IFN-γ insensitive 
in immunocompetent mice resulted in a loss of tumour control in the model (Dighe et al., 
1994). Additional investigations using transgenic mice lacking the crucial cell-mediated 
cytotoxicity molecules or receptors for IFN-γ and perforin led to a higher rate of 
chemically induced tumour development, increased tumour growth of syngenic 
xenografts and an elevated proportion of metastases (Street et al., 2002, Street et al., 2001, 
van den Broek et al., 1996). This loss of IFN-γ/perforin dependent tumour elimination 
was amplified by additionally knocking out the tumour suppressor gene p53 (Kaplan et 
al., 1998, Smyth et al., 2000b). Observational studies of immunosuppressed organ 
transplant recipients and patients with Acquired Immunodeficiency Syndrome (AIDS) 
show an increased incidence of both viral and non-viral associated malignancies 
compared to the general population, further supporting the concept of cancerous cell 
elimination through immunosurveillance (Biggar et al., 1987, Birkeland et al., 1995, 
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Frisch et al., 2001, Penn, 1999). One report showed a remission rate of 32% and 60% for 
sarcoma patients with superficial and visceral lesions, respectively, in whom post-
transplantation immunosuppressive drugs were discontinued without any additional 
therapeutic intervention (Penn, 1995). Additionally, multiple studies have shown a 
beneficial association between overall survival and tumour-infiltrating lymphocyte count 
(Clark et al., 1989, Clemente et al., 1996, Epstein and Fatti, 1976, Lipponen et al., 1992). 
 
Elimination is considered the first phase of immunoediting. This phase corresponds to the 
immunosurveillance theory previously described involving immune-mediated control of 
mutated cells. The second phase in the immunoediting process is equilibrium, which 
hypothesises that immune cells can positively select for cancerous cells that are more 
resistant to killing and thus shape the microenvironment to promote tumour cell survival. 
This ultimately leads to the third phase, the escape/outgrowth of these evolved cancerous 
cells into a clinical disease capable of producing an immunosuppressive factor milieu. 
The immune-driven selection of robust variants was described in an early study 
evaluating the effect of IFN-γ and lymphocytes in the process of tumour formation. In 
this report, chemically induced tumours were harvested from either wildtype or RAG2-/- 
immunosuppressed mice and subsequently injected into either wildtype or RAG2-/- mice. 
Tumour progression was seen for all mice in each condition apart from the wildtype mice 
receiving RAG2-/- tumours in which 40% of tumours were rejected. This is consistent 
with the evolution of more immunogenic tumour variants in the absence of a functioning 
immune system (Shankaran et al., 2001). Since then, murine studies have shown that 
pressure from the innate and adaptive immune system can result in tumour cell 
dormancy/cell cycle arrest and lead to later tumour progression (Koebel et al., 2007, 
Muller-Hermelink et al., 2008, O'Sullivan et al., 2012, Teng et al., 2012). The 
maintenance of this state of equilibrium is reliant on a balance between pro-tumour and 
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anti-tumour cytokines and leukocytes within the microenvironment that is distinct from 
the escape phase (Wu et al., 2013). Tumours that escape control and progress have been 
shown to express a number of factors to dampen down immune regulation and promote 
tumour cell survival, growth and motility. Such factors include vascular endothelial 
growth factor (VEGF), galectin-1, transforming growth factor β (TGF-β), indoleamine-
pyrrole 2,3-dioxygenase (IDO), programmed death ligand 1 (PD-L1), prostaglandin E2, 
arginase and metalloproteinase 2 and 9 (MMP-2/9) (Dublin et al., 1993, Gobin et al., 
2019, Kremer et al., 1992, Mittal et al., 2014, Reed et al., 1991, Rubinstein et al., 2004, 
Senger et al., 1986). There is also an increase of immunosuppressive cell types in the 
tumour microenvironment such as regulatory T cells (Tregs), M2 macrophages, cancer-
associated fibroblasts (CAFs) and myeloid-derived suppressor cells (MDSCs) (Bhome et 
al., 2016). Cancerous cells can also show downregulation or aberrant expression of major 
histocompatibility complex I (MHC I) enabling avoidance of recognition by T cells 
(Garrido et al., 1997). 
 
The emergence of lower immunogenicity variants has also been seen in different 
malignancies undergoing immunotherapeutic intervention. In patients with New York 
oesophageal squamous cell carcinoma-1 (NY-ESO-1)-expressing melanoma or breast 
cancer who were vaccinated against this antigen, disease relapse was characterised by 
downregulation of NY-ESO-1 in 11/17 cases (Nicholaou et al., 2011). One relapsed 
melanoma patient displayed continuous expression of two cancer associated antigens, 
melanoma antigen gene family member C1 (MAGE-C1) and Melan-A, throughout the 
duration of disease; however, loss of expression of NY-ESO-1 was noted in metastases. 
This loss of expression of the vaccine target antigen was associated temporally with an 
observed immune response to NY-ESO-1 (von Boehmer et al., 2013). This has also been 
documented in B-cell acute lymphoblastic leukaemia (B-ALL) patients treated with 
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CD19-specific chimeric antigen receptor (CAR) T cell therapy resulting in a number of 
relapses with CD19- disease (Grupp et al., 2013, Lee et al., 2015, Maude et al., 2016). 
Evidence of immunological influence on malignancy development has impacted 
immunotherapy/trial design and emergence of antigen negative disease has highlighted a 
need for multi-targeted therapies. 
 
1.1.2 Monoclonal antibodies and immune checkpoint blockade 
Monoclonal antibodies are the immunotherapeutic class with the greatest number of Food 
and Drug Administration (FDA) approvals to date [Table 1.1]. Antibodies have been used 
in a clinical setting since the late 19th century. Emil von Behring first described ‘anti-
toxin’; the phenomenon whereby serum from an immunised animal conferred protection 
against infection in an un-immunised animal (Behring, 1890). This polyclonal therapy 
heralded the use of intravenous immunoglobulin (IVIG) in humans, both to treat 
immunodeficiency and for the management of some auto-immune conditions (Hooper, 
2015). With the introduction of hybridoma technology (Kohler and Milstein, 2005), it 
became possible to create large libraries of monoclonal antibody-producing clones in 
order to specifically target antigens of interest. This method was translated into the clinic 
by monoclonal antibody generation targeted against B-cell lymphoma patient-derived 
tumour cells in two separate case studies (Miller et al., 1982, Nadler et al., 1980). With 
the discovery of a B-cell specific antigen, CD20, that was also present on all assessed B-
cell cancers (Stashenko et al., 1980), the anti-CD20 monoclonal antibody Rituximab was 
developed by IDEC pharmaceuticals and became the first FDA approved cancer 
therapeutic monoclonal antibody (Maloney et al., 1997). This was followed by a cascade 
of FDA approvals for therapeutic antibody treatment in multiple blood cancers and solid 
tumours.  
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While initial antibody development was targeted against tumour-associated molecules, 
there was a paradigm shift towards development of antibodies that instead disrupted 
natural immune checkpoints which would otherwise suppress immune responses. The 
application of checkpoint inhibitors (CPIs) has led to the largest class of approved 
antibodies to date with the most indications in advanced solid tumours [Table 1.1]. This 
class of monoclonal antibodies target and block inhibitory immune checkpoints that 
naturally dampen down immune responses. So far, monoclonal antibody therapies 
targeting the immune checkpoints CTLA-4, PD-1 and PD-L1 have become commercially 
available. Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) was first described as 
a T-cell specific immunoglobulin superfamily marker that is highly expressed in activated 
T cells (Brunet et al., 1987). Later, it was established that CTLA-4 is structurally related 
to the co-stimulation receptor CD28 and, like CD28, it binds to CD80/86 (Harper et al., 
1991, Linsley et al., 1991). Further investigation revealed that administration of soluble 
CTLA-4 could halt transplant rejection in mice, suppress T cell expansion/activation and 
protect against the development of multiple sclerosis in in vivo models (Cross et al., 1995, 
Lin et al., 1993, Linsley et al., 1992). Owing to its higher affinity, CTLA-4 outcompetes 
CD28, displacing it from co-stimulatory ligands, leading to inhibition of T cell responses. 
A key early observation was the demonstration that antagonistic anti-CTLA-4 antibodies 
inhibit its interaction with its ligands permitting tumour rejection and development of 
anti-tumour memory. This study which involved a colon cancer model marked the 
beginning of the development of CPIs for cancer therapy (Krummel and Allison, 1995, 
Leach et al., 1996). In 2011, the anti-CTLA-4 antibody ipilimumab was approved for the 
treatment of advanced unresectable melanoma after a phase III trial illustrated an increase 
in overall survival of 4 months for patients receiving the drug. This was also accompanied 
by high grade adverse events in 10-15% of patients in the ipilimumab treatment groups, 
resulting in 14 drug-related deaths (Hodi et al., 2010). A 2015 report encompassing the 
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data from multiple trials for melanoma showed a median overall survival of 11.4 months, 
but a 3-year overall survival of 22% accompanied by a plateau of the survival curve 
extending to 10 years. This suggests that ipilimumab conveys long term survival benefits 
surpassing 3 years for almost a quarter of patients treated (Schadendorf et al., 2015). 
 
The programmed cell death protein 1 (PD-1) receptor was first described as a new 
immunoglobulin superfamily member that was restricted to the murine thymus and 
upregulated in programmed death induced cells (Ishida et al., 1992). Later studies 
demonstrated PD-1 upregulation on activated leukocytes, not solely on dying cells. 
Programmed cell death protein 1 knockout mice develop autoimmune-type features with 
an increase in circulating leukocytes, highlighting a role for PD-1 in immune tolerance 
(Nishimura et al., 1998, Nishimura et al., 1999, Vibhakar et al., 1997). The ligands for 
PD-1 are known as PD-L1 and PD-L2 and are naturally expressed on antigen presenting 
cells, in addition to certain epithelial tissues such as lung and heart. Activation of PD-1 
by its ligands results in the inhibition of co-stimulation signalling, reduced T cell 
proliferation and control of inflammation in healthy tissues  (Freeman et al., 2000, 
Latchman et al., 2001). It is also apparent that PD-L1/2 are expressed on a wide variety 
of solid tumours and blood cancers. The presence of PD-L1/2 in a tumour 
microenvironment enabled the induction of apoptosis of T cells in vitro (Dong et al., 
2002). In mouse models of leukaemia in which PD-L1 was either naturally expressed or 
induced, in vivo progression of the tumour and abrogation of T cell responses were 
associated with its expression. This was reversed by targeting antibodies to PD-L1 and 
the enhanced tumour progression was lost in a PD-1 knockout model (Iwai et al., 2002). 
These observations led to the clinical development of antibodies targeting PD-1/PD-L1. 
An initial phase I trial of the anti-PD-1 antibody nivolumab in patients with advanced 
solid tumours indicated a tolerable safety profile with no grade 4 toxicities and 5/39 
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clinical responses (Brahmer et al., 2010). A phase I trial of pembrolizumab (which also 
targets PD-1) in advanced solid tumours also showed acceptable toxicity with no grade 
3/4 adverse events, although one patient died of infection after prolonged corticosteroid 
administration due to drug-related gastric inflammation. There were 2 complete 
responses, 3 partial responses and 15 cases of stable disease out of 30 treated patients 
(Patnaik et al., 2015). Pembrolizumab was the first anti-PD-1 drug approved for clinical 
use and was followed soon thereafter by nivolumab [Table 1.1]. Both drugs are 
humanised IgG4 antibodies that block the interaction of PD-1 with its ligands. Initially 
approved for the treatment of advanced melanoma, they both have since gained approvals 
for the treatment of a variety of malignancies. Anti-PD-1 CPIs have a better safety profile 
than ipilimumab and have shown efficacy in PD-L1- tumours. Monoclonal antibodies 
against PD-L1 such as atezolizumab, avelumab and durvalumab have also been approved 
(Alsaab et al., 2017).   
 
Not all patients treated with CPIs respond to treatment. In fact, across all indications, 
most patients do not respond or relapse. Because CTLA-4 and PD-1 inhibit T cell 
cytotoxicity via different cellular signalling pathways involving pre- and post-
engagement of the TCR (Carter and Carreno, 2003, Parry et al., 2005), combinations of 
CTLA-4 and PD-1 checkpoint blockade antibodies have been investigated in order to 
augment anti-tumour efficacy. A combination of ipilimumab and nivolumab has been 
approved to treat advanced melanoma after a phase III trial reported an almost doubling 
of overall survival in the combination group compared to ipilimumab alone (Wolchok et 
al., 2017). This combination has also been approved for the treatment of metastatic 
colorectal carcinoma with high microsatellite instability or mismatch repair deficiency 
and for renal cell carcinoma after observations of increased efficacy in response rates and 
survival (Motzer et al., 2018, Overman et al., 2018). However, this increased anti-tumour 
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activity is accompanied by a higher toxicity profile and the occurrence of immune related 
adverse events (Zhou et al., 2019). Additional combinations are being investigated for 
CPIs including new checkpoint blockade antibodies targeted against lymphocyte-
activation gene 3 (LAG-3) and agonistic tumour necrosis factor receptor superfamily 
member 4 (OX40), vascular targeting drugs and small molecule inhibitors (Ascierto et 
al., 2017, Infante et al., 2016, Mitchell et al., 2018, Siu et al., 2017, Wallin et al., 2016). 
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CD33 Adult/pediatric AML 2017
Alemtuzumab CD52 B-cell CLL 2001
Ibritiumomab 
Tiuxetan (ADC)












Panitumumab EGFR/Her1/ErbB1 mCRC 2006











Pertuzumab Her2/ErbB2 Breast carcinoma 2012
Ado-Trastuzumab 
emtansine (ADC)
Her2/ErbB2 Metastatic breast carcinoma 2013
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Antibody Name Target Disease Year of 
approval


















Adult/pediatric B-cell ALL 2014










Dinutuximab GD2 Pediatric neuroblastoma 2015
Daratumumab CD38 Multiple myeloma 2015
Necitumumab EGFR/Her1/ErbB1 mNSCLC 2015
Elotuzumab SLAMF7 Multiple myeloma 2015






Olaratumab PDGFRα Soft tissue sarcoma 2016
Avelumab PD-L1 Adult/pediatric metastatic MCC
Advanced/metastatic urothelial carcinoma
2017










Cemiplimab PD-1 Advanced/metastatic CSCC 2018
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Table 1.1 United States Federal Drug Administration (FDA) approved cancer 
therapeutic antibodies.  
Targets, indicated diseases and year of approval for antibodies. Abbreviations for targets 
include EGFR: epidermal growth factor receptor, VEGF: vascular endothelial growth 
factor, CTLA-4: cytotoxic T-lymphocyte associated protein 4, RANKL: receptor 
activator of nuclear factor kappa-B ligand, VEGFR2: vascular endothelial growth factor 
receptor 2, PD-1: programmed cell death protein 1, GD2: disialoganglioside, SLAMF7: 
signalling lymphocytic activation molecule family member 7, PD-L1: programmed cell 
death ligand 1, and PDGFRα: platelet derived growth factor receptor alpha. 
Abbreviations for diseases include NHL: non-Hodgkin’s lymphoma, FL: follicular 
lymphoma, DLBCL: diffused large B-cell lymphoma, CLL: chronic lymphocytic 
leukaemia, GEJ: gastro-esophageal junction, AML: acute myeloid leukaemia, mCRC: 
metastatic colorectal carcinoma, HNSCC: head and neck squamous cell carcinoma, 
NSCLC: non-small cell lung carcinoma, mRCC: metastatic renal cell carcinoma, HL: 
Hodgkin’s lymphoma, ALCL: anaplastic large cell lymphoma, MSI-H: high 
microsatellite instability, dMMR: deficient DNA mismatch repair, PMBCL: primary 
mediastinal B-cell lymphoma, HCC: hepatocellular carcinoma, mMCC: metastatic 
Merkel cell carcinoma, ALL: acute lymphoblastic leukaemia, mSCLC: metastatic small 
cell lung carcinoma, mTNBC: metastatic triple negative breast carcinoma, HCL: hairy 
cell leukaemia, and CSCC: cutaneous squamous cell carcinoma. Cross-referenced at  
https://www.accessdata.fda.gov/scripts/cder/daf/, 
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/default.htm; 
accessed on 3rd May, 2019. 
 
1.1.3 Cancer vaccines and oncolytic viruses 
Another area of cancer immunotherapy aims to elicit a systemic anti-tumour response 
through the principles of vaccination. Theoretically, injection of cancer-specific antigens 
would recruit the immune system to respond similarly as it would to pathogens, and thus 
target and destroy the malignant cells. Attempts to achieve this have included vaccination 
with whole tumour cells, proteins/peptides derived from viruses and cancer neo-antigens, 
carbohydrates, DNA, mRNA and antigen-loaded dendritic cells. Cytokines, adjuvants 
and antigen expression on bacterial/viral vectors are often utilised in order to increase the 
body’s response to the antigen. Pre-clinical studies have achieved tumour eradication, but 
clinical trials have been less successful (Goldman and DeFrancesco, 2009). Cancers 
caused by viral infection are theoretically more accessible to this platform as they often 
express foreign antigens that are immunogenic. However, difficulty arises from the need 
to overcome the mechanisms of central tolerance to self-antigens, a process that deletes 
or inactivates most self-reactive T cell and B cell clones (Kang et al., 2013, Kumai et al., 
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2017). A further important challenge in the cancer vaccine field is presented by the 
immunosuppressive tumour environment. Approaches to enhance vaccine efficacy by co-
targeting the microenvironment have been investigated (Ohshio et al., 2015, Rice et al., 
2015). The first major success story in this field is the FDA approval of the prostate cancer 
vaccine, Provenge. This dendritic cell-based vaccine involves loading autologous 
dendritic cells with a fusion protein derived from the pro-inflammatory cytokine 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and the prostate cancer 
associated protein, Prostatic Acid Phosphatase (PAP). In a phase III clinical trial in 
metastatic castrate resistant prostate cancer, a modest 4-month increase in median 
survival was seen for the vaccine compared to the placebo. There was an observed 
increase in T cell proliferation and antibody titre in the vaccine arm. The toxicity profile 
was tolerable with high grade adverse reactions occurring in only 6.8% of patients 
receiving Provenge, most of which resolved within 48 hours after vaccine administration 
(Kantoff et al., 2010). This pivotal study led to its approval for clinical use in 2010, 
although its application clinically remains low due to high treatment cost and a moderate 
therapeutic benefit. Investigations into optimising cancer vaccines as a viable treatment 
modality are ongoing. 
 
A more recent development in vaccination strategy is the use of oncolytic viruses. This 
therapy uses viruses that have been attenuated for growth in healthy cells, but 
preferentially infect and replicate in tumour cells. Studies into underlying therapeutic 
mechanisms have indicated that anti-tumour activity derives from the inherent cytolytic 
component of viral replication as well as the recruitment of the immune system targeted 
towards tumour-derived antigens that become available after cell death (Kaufman et al., 
2015). Different viruses that have been investigated for their anti-tumour capabilities 
include adenoviruses, vaccinia viruses, herpes viruses, Newcastle disease virus, measles 
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virus, polio virus, coxsackievirus and reovirus (Andtbacka et al., 2015, Au et al., 2011, 
Breitbach et al., 2013, Dispenzieri et al., 2017, Freeman et al., 2006, Garcia-Carbonero 
et al., 2017, Kicielinski et al., 2014, Toyoda et al., 2011). Wildtype viruses achieve 
tumour specific replication as the process of malignant transformation often includes 
dysregulation in the cell’s intrinsic anti-viral pathways. Cellular distress signalling 
through the protein kinase R (PKR) pathway normally alerts the cell to viral infection and 
disrupts protein synthesis/viral replication. The aberrant regulation of signalling via this 
pathway, due to mutated oncogenes encoding Ras and mitogen-activated protein kinase 
kinase (MEK), is one mechanism by which viruses evade detection and continue to 
replicate preferentially in cancer cells (Farassati et al., 2001, Smith et al., 2006, Strong et 
al., 1998). Related to the PKR pathway, type I interferon signalling (a key regulator of 
viral survival and replication) is often down-regulated in cancer cells allowing for 
unchecked growth. Oncolytic viruses can also take advantage of this mutated pathway for 
tumour-specific replication (Pansky et al., 2000, Zhang et al., 2010). Some oncolytic viral 
strains also enter the cell via receptors that are consistently overexpressed in cancer, 
including herpes virus entry mediator (HVEM), intercellular adhesion molecule 1 
(ICAM-1), CD46, integrin α2β1 or CD155 (Anderson et al., 2004, Montgomery et al., 
1996, Shafren et al., 2004, Shafren et al., 2005, Tsang et al., 2017, Zhand et al., 2018). 
Other viruses have been genetically engineered to preferentially infect cancer cells 
through modifications in tropism targeting tumour-associated antigens such as human 
epidermal growth factor 2 (Her2), EGFR and fibroblast growth factor receptor (FGFR) 
(Petrovic et al., 2018, Uusi-Kerttula et al., 2015). Additionally, viruses can be attenuated 
in healthy cells and directed to tumour cell-specific replication via mutations in virulence 
proteins such as E1B and ICP34.5 (Braidwood et al., 2014, Heise et al., 1997). Although 
oncolytic viruses can directly destroy cancer cells, it is the recruitment of the immune 
response following cell death that is crucial for sustained anti-tumour efficacy. Greater 
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efficacy is seen with oncolytic viruses that express cytokines/chemokines to induce and 
attract a systemic immune response (Bernt et al., 2005, Li et al., 2011). Talimogene 
laherparepvec (T-VEC), a GM-CSF expressing herpes simplex virus 1 (HSV-1) oncolytic 
virus with deleted virulence genes ICP34.5 and ICP47, was approved in 2015 for the 
treatment of metastatic melanoma. Approval was based on a phase III trial in patients 
with unresectable advanced melanoma. Complete responses were seen in 47% of injected 
lesions in 277 patients. Evidence of systemic anti-tumour immunity was seen with 22% 
of un-injected non-visceral and 9% of un-injected visceral lesions disappearing 
completely. The safety profile was acceptable, with high grade toxicity occurring in only 
2.1% of those receiving T-VEC (Andtbacka et al., 2015, Andtbacka et al., 2016). Further 
investigations into increasing the efficacy of T-VEC are being evaluated and include 
combination therapy with ipilimumab in advanced melanoma patients. In a phase I study, 
no dose-limiting toxicities were seen although 26.3% of treated patients experience grade 
3-4 adverse events. Fifty percent of patients demonstrated a progression free survival 
(PFS) of greater than 1.5 years (Puzanov et al., 2016). Additionally, T-VEC in 
combination with pembrolizumab yielded a 62% overall response rate in melanoma 
patients. This was accompanied by a greater than 60% PFS extending to 19 months and 
no dose limiting toxicities in a phase Ib clinical study (Ribas et al., 2017). This 
combination therapy is being evaluated in comparison to pembrolizumab alone in a phase 
III/IV clinical trial for melanoma (Ribas et al., 2015). 
 
1.1.4 Adoptive cellular therapy; advances in CAR T cells 
The natural ability of T cells to control and target cancer has led to their development as 
therapeutic agents. Allogeneic haematopoietic stem cell transplantation (aHSCT) for 
haematopoietic malignancies was the first adoptive cell therapy to be developed. This 
procedure is undertaken to reconstitute the haematopoietic and immune system of patients 
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undergoing lympho/myeloablative therapy. A second early example of the use of 
adoptive T cell immunotherapy entails the use of donor lymphocyte infusion (DLI). This 
may be performed in the event of relapse following aHSCT and serves to induce a graft-
versus-leukaemia effect through donor T cell recognition of allogeneic malignant cells 
(Bonini and Mondino, 2015, Caldemeyer et al., 2017, Mitani et al., 2019). The discovery 
of interleukin 2 (IL-2), and its role in T cell expansion, enabled ex vivo culture and 
expansion of T cells for therapeutic use (Mochizuki et al., 1980, Morgan et al., 1976). 
Early studies compared systemic IL-2 with autologous ‘lymphokine activated killer’ 
(LAK) cells in the context of solid tumours. Cells isolated from peripheral blood were 
expanded ex vivo in IL-2 and infused back with co-administered IL-2. While there were 
objective responses in both treatment arms, there wasn’t a significant increase in survival 
or responses in patients given both LAK cells and IL-2 compared to IL-2 alone. 
Additionally, IL-2 infusion was associated with high levels of severe toxicity highlighted 
by a 3.3% treatment related mortality rate (Rosenberg et al., 1993). The observation that 
tumour infiltrating lymphocytes (TILs) were seen to be at least 50-times more effective 
in killing cancer cells than LAK cells in vivo lead to the development of protocols 
isolating and ex vivo expanding TILs for cancer therapy. When applied to a murine 
sarcoma and colon cancer model, in conjunction with IL-2 and conditioning 
chemotherapy, TILs were able to ablate all micrometastases in contrast to LAK cells 
(Rosenberg et al., 1986). A small single centre trial of TILs, IL-2 and chemotherapy for 
patients with metastatic melanoma, renal cell, breast and colon carcinoma demonstrated 
tolerable toxicity. Partial responses were observed in 3/12 patients treated (Topalian et 
al., 1988). Soon after, a larger study in 20 metastatic melanoma patients reported a 55% 
objective response rate (Rosenberg et al., 1988). While no TIL therapies have been 
approved by the FDA for clinical application, the expansion of the endogenous tumour-
specific T cell population that can be isolated from patients’ tumours has undergone 
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extensive investigation. Efforts to improve clinical responses have included the use of 
various conditioning chemotherapy regimens, depletion of Tregs, co-administration of 
IL-7/15, development of minimal ex vivo culture methods and CD8+ T cell enrichment. 
Lymphodepletion has become standard conditioning therapy prior to adoptive cell 
therapy after it was shown to increase efficacy of the treatment in melanoma patients 
(Dudley et al., 2002). Observations have indicated that this is partially due to a depletion 
of endogenous Tregs and creating a physical niche for the adoptive cells to populate 
without competition for resources (Antony et al., 2005, Gattinoni et al., 2005). One study 
in metastatic melanoma patients reported prolonged disease remission which, in some 
responders, continued beyond 10 years (Feldman et al., 2015, Rosenberg et al., 2011). 
However, major limitations of this therapy include insufficient/failed TIL expansion and 
the need for cumbersome manufacturing protocols. 
 
Genetic re-programming of whole T cell populations using T-cell receptors (TCRs) 
engineered towards tumour-associated antigens has also been explored. Tumour specific 
TCR clones have been identified through the expansion of TILs and genetically 
transferred to polyclonal populations, resulting in larger numbers of cancer targeting T 
cells. Early trials in melanoma led to the identification of TIL TCR clones specific for 
glycoprotein 100 (gp100) and melanoma antigen recognised by T cells 1 (MART-1) 
(Kawakami et al., 1994a, Kawakami et al., 1994b). These two proteins were described as 
cancer-associated antigens that are overexpressed in melanoma, but which are also 
present in healthy tissue. Because of this, it has been difficult to safely and effectively 
direct T cells to target only malignant cells (Bonini and Mondino, 2015). Early pre-
clinical studies in which a MART-1 targeting TCR was delivered using a retroviral vector 
into the Jurkat human T-cell leukaemia cell line established the functionality of this 
approach (Cole et al., 1995). When transduced into human peripheral blood mononuclear 
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cells (PBMCs), these MART-1 specific clones demonstrated cytolytic activity and 
increased IFN-γ/GM-CSF secretion upon culture with a melanoma cell line, when 
compared with non-transduced MART-1 specific T cells (Clay et al., 1999, Hughes et al., 
2005). In a murine melanoma model, utilising the B16 cell line that endogenously 
expresses gp100, adoptive transfer of gp100 directed TCR-engineered T cells 
demonstrated marked tumour regression (Abad et al., 2008). However, a pilot trial in 15 
melanoma patients with MART-1 TCR engineered peripheral blood T cells resulted in 
low clinical efficacy with only two partial responses. No significant toxicity was reported 
(Morgan et al., 2006). A different trial utilising a TCR with higher affinity for MART-1 
yielded greater clinical efficacy with a 30% partial response rate. This was accompanied 
by an 18.7% objective response rate with gp100 transgenic TCR T cells. There was also 
an increase in skin, ear and eye toxicity as these antigens are also expressed in these 
healthy tissues (Johnson et al., 2009). Continued investigation into TCRs engineered to 
target MART-1 showed 11/14 objective responses in patients with metastatic melanoma. 
None of these responses continued beyond 6 months and severe respiratory toxicities 
occurred in two patients treated at the higher T cell dosages (Chodon et al., 2014). 
Engineered TCRs have also been clinically investigated that target other antigens such as 
Wilms’ Tumour 1 (WT-1), MAGE-A3, MAGE-A4, NY-ESO-1 and carcinoembryonic 
antigen (CEA) in patients with an array of carcinomas, sarcomas and haematological 
cancers (Kageyama et al., 2015, Linette et al., 2013, Lu et al., 2017, Morgan et al., 2013, 
Parkhurst et al., 2011, Robbins et al., 2011, Tawara et al., 2017). However, severe 
toxicities have been associated with targeting MAGE-A3. Illustrating this, one group 
treated melanoma patients with MAGE-A3 specific TCR engineered T cells and observed 
neurological toxicity in 3/9 patients. Two of these patients subsequently died. It was later 
discovered that the engineered TCR could cross-react with MAGE-A9/A12. Expression 
of these family members was discovered in brain tissue by quantitative RT-PCR (Morgan 
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et al., 2013). A second group found severe toxicity in cardiac tissue resulting in the death 
of a melanoma and a myeloma patient. It was determined that this was due to off-target 
recognition of titin, a protein expressed in cardiomyocytes, by the affinity matured 
engineered MAGE-A3-specific TCR (Linette et al., 2013). Mismatched pairing of 
endogenous and transgenic αβ TCR chains leading to the potential for novel specificity 
is also a theoretical concern with TCR gene modification of T cells. In practice this has 
not, as yet, been shown to cause clinical toxicity. Attempts to mitigate this risk include 
knocking out the endogenous α and β chains using zinc finger nucleases, interfering RNA 
and more recently CRISPR/Cas9 technology (Bunse et al., 2014, Knipping et al., 2017, 
Legut et al., 2018, Provasi et al., 2012).  
 
In an attempt to improve tumour specificity and reduce ‘on target, off tumour’ toxicity, 
tumour specific neo-antigens are being studied as potential targets. Effective methods for 
discovery of personalised neo-antigens expressed solely on cancerous tissue and not in 
health are being extensively explored (Chheda et al., 2018, Lu et al., 2018, Tubb et al., 
2018). Whole exome sequencing of tumours in gastrointestinal carcinoma patients found 
unique neo-epitopes that were recognized by the patient’s TILs. One patient experienced 
partial tumour regression following two injections of the neo-antigen specific expanded 
TILs (Tran et al., 2015, Tran et al., 2014). Recently, a breast cancer patient treated with 
ex vivo expanded TILs that were specific for 4 different tumour neo-antigens resulted in 
a complete response reaching 22 months (Zacharakis et al., 2018). 
 
Major limitations of engineered TCR adoptive cell therapy are the requirement for HLA 
restriction and the downregulation of co-stimulation in malignancy. In order for 
transgenic TCR recognition of cognate antigen, processing and presentation of peptide 
antigens via the human leukocyte antigen (HLA) pathway is required by the cancer cells 
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along with co-stimulation. However, antigen processing is consistently downregulated in 
malignant tissue, and dysregulation of trafficking of processed peptides to MHC I for cell 
surface presentation has been partially attributed to decreased expression of genes 
encoding for HLA, transporter associated with antigen processing 1 and 2 (TAP-1/2) and 
low molecular mass protein 2 and 7 (LMP-2/7) (Garrido et al., 1997, Restifo et al., 1993). 
 
Chimeric antigen receptor (CAR) T cells offer a solution to the challenge imposed by 
HLA restriction, as seen with TCR engineering. Chimeric antigen receptors are artificial 
fusion receptors that combine the targeting of native cell surface antigens in an antibody-
like manner with T cell activation. Engineering of CARs has led to many different formats 
but, critically, CARs include an antigen recognition portion (most commonly a single 
chain variable fragment, or scFv, derived from a monoclonal antibody) fused to a 
transmembrane and intracellular signalling domain. In the simplest ‘first generation’ 
form, the signalling domain generally takes the form of the CD3𝜁 signalling portion of 
the TCR/ CD3 complex [Figure 1.1]. T cells transduced with a CAR-encoding vector can 
theoretically target and induce cytolysis against extracellular antigens independent of 
HLA processing and presentation. Initial studies involved the design of chimeric TCRs 
in which the variable heavy and light chain domains of phosphorylcholine, digoxin or 
TNP-specific antibodies were individually fused to the α and β chains of TCRs. These 
chimeric receptors were successfully expressed in T cells and induced TCR signalling 
and cytotoxicity against target cells. Mismatched pairing of endogenous and transgenic 
chains also occurred (Becker et al., 1989, Goverman et al., 1990, Gross et al., 1989, 
Kuwana et al., 1987). The TNP targeting chimeric receptor was subsequently applied in 
the context of cancer treatment and reactivity to a TNP-transduced murine lymphoma cell 
line was observed (Eshhar and Gross, 1990). Non-functional mispairing of CD3 complex 
chains was avoided by adopting the format of an scFv linked directly to the signalling 
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CD3𝜁 or the FcR chain and continued to show MHC-independent targeting of antigen 
expressing cells (Eshhar et al., 1993, Gross and Eshhar, 1992). Comparison of the CD3𝜁 
and Fc𝜀RI-γ signalling domains of a CEA-specific CAR demonstrated the superiority of 
CD3𝜁 for T cell activation (Haynes et al., 2001). Application of CAR expressing T cells 
directed towards tumour associated antigens including different members of the ErbB 
family, folate binding protein (FBP), CEA and tumour associated glycoprotein 72 
(TAG72) indicated antigen specific targeting and lysis in vitro and in vivo (Altenschmidt 
et al., 1996, Darcy et al., 1998, Hombach et al., 1997, Hwu et al., 1993, Hwu et al., 1995, 
Moritz et al., 1994, Stancovski et al., 1993). One study suggested a ligand for the ErbB 
receptors could be used as the binding portion of a CAR instead of an scFv (Altenschmidt 
et al., 1996). Early studies also reported the importance of a hinge region between the 
scFv and the CD3𝜁, allowing for antigen accessibility. Commonly, the Fc portion of 
antibodies or the CD8α hinge/ spacer region is used for this purpose (Abken et al., 1997).  
 
 
 - 45 - 
 
Figure 1.1 Evolution of chimeric antigen receptors (CARs).  
Chimeric antigen receptors have been defined by generational distinctions that are 
illustrated here. TCR: T-cell receptor; VH: antibody heavy chain variable region; VL: 
antibody light chain variable region; Co-stim 1: co-stimulatory region 1; Co-stim 2: co-
stimulatory region 2. 
 
Signalling through the scFv-CD3𝜁 alone was not enough to stimulate the activation of 
naive primary murine T cells (Brocker and Karjalainen, 1995). The additional delivery of 
co-stimulation signals to the T cell via the introduction of a second chimeric receptor 
could increase T cell activation and cytokine secretion after antigen specific CAR 









































 - 46 - 
generation’ CARs that included the intracellular signalling domain of the CD28 co-
stimulation molecule in the same construct as the CAR; downstream of the hinge and 
upstream of CD3𝜁. Functionality of this platform was first demonstrated in Jurkat cells 
using a CD33-targeting CAR and exhibited a marked increase in IL-2 production for the 
2nd generation CAR compared to the original CAR (Finney et al., 1998). Validation of 
2nd generation CAR technology in primary human T cells was first shown using the 
prostate-specific membrane antigen (PSMA) CAR that is the subject of this PhD project. 
In that setting, it was observed that inclusion of the CD28 co-stimulatory domain enabled 
PSMA-activated human T cells to proliferate and to release IL-2, properties that were not 
seen with 1st generation CAR T cells. Tumour cell killing was seen at equivalent levels 
with both 1st and 2nd generation CAR T cells (Maher et al., 2002). This CD28-containing 
2nd generation CAR platform is now marketed as axicabtagene ciloleucel (Yescarta), 
which is one of the two FDA-approved CAR T cell products for the treatment of B cell 
malignancy. 
 
Investigations have explored the use of different co-stimulatory molecules such as tumour 
necrosis factor receptor superfamily member 9 (4-1BB), inducible T-cell co-stimulator 
(ICOS), CD27 and OX40 for increased CAR T cell therapeutic potential (Finney et al., 
2004, Imai et al., 2004, Pule et al., 2005, Song et al., 2012). Debate between the 
superiority of CD28 or 4-1BB as co-stimulatory regions has been ongoing. CD28 appears 
to produce a more immediate effector response and 4-1BB provides a more persistent 
population of CAR T cells; both aspects being important for efficacious durable clinical 
responses (van der Stegen et al., 2015). Studies comparing CAR constructs with different 
co-stimulatory domains have indicated that CD28 containing CARs show increased 
proliferation, greater cytotoxic effect in vitro and secrete enhanced levels of cytokine, 
while CARs incorporating 4-1BB have a slower initial response, but persist longer in vivo 
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and express less exhaustion markers as a result of tonic CAR signalling (Finney et al., 
2004, Guedan et al., 2014, Long et al., 2015, Milone et al., 2009). This increased 
persistence leads to improved tumour control in murine models. Clinical trials for CD19 
directed CARs have indicated that incorporation of 4-1BB into the construct increases 
the longevity of the T cells in patients (Lee et al., 2015, Maude et al., 2014, Maude et al., 
2016). Investigations into the mechanisms behind the differences in CAR co-stimulation 
have illuminated diverging metabolic pathways associated with CD28 and 4-1BB. One 
study illustrated the increased proliferative capacity, survival and central memory 
phenotype of 4-1BB CARs compared to CD28 CARs targeting CD19 and mesothelin. 
Chimeric antigen receptor T cells with CD28 co-stimulatory domains produced a more 
effector memory phenotype. Metabolically, 4-1BB CARs yielded higher fatty acid 
oxidation (FAO), spare respiratory capacity (SRC) and mitochondrial mass which is 
characteristic of long-term memory cells. Comparatively, CD28 CARs exhibit an 
increased rate of glycolysis, which has been associated with effector T cells (Kawalekar 
et al., 2016). Another study showed an increase in memory-associated gene expression in 
4-1BB CARs and a more effector cell gene signature in CD28 CARs. Chimeric antigen 
receptors incorporating CD28 also had a higher signalling intensity in terms of the 
number of phosphorylated proteins and it was determined that this was due to tonic 
signalling through Lck association (Salter et al., 2018). 
 
There is some evidence for a benefit of 3rd generation CARs combining CD28 and 4-
1BB. Enhanced anti-tumour cytotoxicity through 4-1BB and CD28 combination in CAR 
constructs has been reported for T cells redirected towards prostate cancer and lymphoma 
in pre-clinical models. These studies show an increased persistence, greater tumour 
control and increased expression of the anti-apoptotic marker Bcl-XL for 3rd generation 
CARs compared to 2nd generation CARs (Tammana et al., 2010, Zhong et al., 2010). 
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However, a mesothelioma mouse model showed similar anti-tumour capabilities between 
2nd and 3rd generation CAR constructs utilising 4-1BB and CD28 co-stimulatory domains 
(Carpenito et al., 2009). A CD19-specific CAR in a NALM6 leukaemia model compared 
CD28 and 4-1BB containing 3rd generation CARs with a CD28 2nd generation CAR that 
constitutively expresses 4-1BBL and addition of 4-1BBL expression in the CD19-specific 
CD28𝜁 generation CAR resulted in increased tumour regression, CAR T cell persistence 
and survival compared to the 3rd generation CAR (Zhao et al., 2015). This indicates 
insufficient signalling of the 4-1BB domain in the 3rd generation constructs. Inclusion of 
both CD28 and 4-1BB co-stimulation in a CD19 CAR showed a 23-fold greater 
expansion and longevity in lymphoma patients than the 2nd generation CAR with CD28 
alone (Gomes da Silva et al., 2016). Further safety analysis of the 3rd generation CARs in 
lymphoma indicate tolerability and 6/15 complete responses (Enblad et al., 2018). 
Application of this approach in pre-clinical solid tumour models has been inconclusive.  
 
Co-stimulation regions including CD28, 4-1BB, OX40 and ICOS have been arranged 
variably into 3rd generation CARs targeting antigens such as prostate stem cell antigen 
(PSCA), mesothelin, prostate specific membrane antigen (PSMA) and GD2. Reports have 
suggested enhanced persistence of CAR T cells in vivo with or without an accompaniment 
of greater tumour control compared to 2nd generation CARs (Carpenito et al., 2009, 
Guedan et al., 2018, Hillerdal et al., 2014, Quintarelli et al., 2018, Zhong et al., 2010). A 
3rd generation CAR-specific for GD2 is currently being investigated in neuroblastoma 
patients. Data published to date demonstrates no dose limiting toxicity, but the best 
response has only been stabilisation of disease. The addition of anti-PD-1 blockade did 
not enhance efficacy (Heczey et al., 2017). In contrast, one group found that a 3rd 
generation CEA-targeting CAR, incorporating CD28 and OX40 co-stimulation domains, 
led to increased activation-induced cell death and worse function in vivo than the CD28 
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2nd generation CAR (Hombach et al., 2013). This illustrates the variable outcomes of 
different CAR construct designs and the need for optimisation. 
 
There has been significant clinical success with CAR modified T cells for haematological 
malignancies. Two different CD19-targeting 2nd generation CAR T cell products, 
Tisagenlecleucel-T and Axicabtagene ciloleucel, have been approved for B-ALL and 
diffuse large B-cell lymphoma (DLBCL) (Maude et al., 2018, Neelapu et al., 2017). 
These are the first ever genetically modified cells licensed for cancer therapy. 
Tisagenlecleucel-T was first reported as a case study in two patients with paediatric ALL. 
One patient showed elevated liver enzymes aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) indicating toxicity and the other patient experienced cytokine 
release syndrome (CRS), a toxicity associated with activation of immune cells and 
subsequent secretion of inflammatory cytokines manifesting by fever, headache, fatigue, 
malaise, myalgia, nausea, hypotension, hypoxia, tachycardia and organ toxicity. The 
patient entered into complete remission one month after treatment. One of the patients 
relapsed within two months. The relapsing leukaemia was found to have lost expression 
of the CAR target CD19 (Grupp et al., 2013). The trial was continued and 30 patients 
received CAR therapy. Ninety percent achieved complete response initially with 19 
remaining in remission at 6 months. High grade CRS was seen in all patients. A 
correlation was observed between CRS and disease burden. This was effectively treated 
with tocilizumab, an anti-IL-6R monoclonal antibody (Maude et al., 2014). Cytokine 
release syndrome is a common adverse event in CAR T cell therapy. A grading and 
management guide was recently published to address CRS scoring/treatment in the clinic 
and trials (Lee et al., 2019). High grade CRS is treated with vasopressors, oxygen and 
anti-cytokine interventions including tocilizumab, etanercept (TNFα recombinant 
receptor), infliximab (anti-TNFα) and anakinra (IL-1R antagonist) (Lee et al., 2014). In 
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some cases, corticosteroids may be used although there are concerns that this may 
compromise therapeutic benefit. A larger study reported a 93% complete remission rate 
and a 55% relapse-free survival at 12 months, reaffirming the CD19-CAR T cell efficacy 
in B-ALL (Maude et al., 2016). However, in a cohort of 27 adult patients, 3 patients died 
due to refractory CRS. No additional fatal toxicities were seen when the CAR T cell dose 
was separated across different injection time points (Frey et al., 2016). A trial in DLBCL 
demonstrated an overall response rate of 59%. Chimeric antigen receptor T cells were 
detected in responders almost 1 year after treatment (Schuster et al., 2017). These trials 
led to regulatory approvals in paediatric and young adult B-ALL and DLBCL. This CAR 
has also been evaluated in chronic lymphocytic leukaemia (CLL) patients with a 57% 
response rate, but has not yet achieved clinical approval (Porter et al., 2015).   
 
While Tisagenlecleucel-T incorporates a 4-1BB co-stimulation domain, the Axicabtagene 
ciloleucel CAR construct utilises CD28. Similar to Tisagenlecleucel-T, this CAR was 
first reported in a case study involving treatment of a single patient with relapsed 
follicular lymphoma (FL). The patient demonstrated a partial response durable for 32 
weeks (Kochenderfer et al., 2010). When the trial was expanded to 8 patients with FL or 
CLL, 6 experienced objective responses (Kochenderfer et al., 2012). A large trial in 
DLBCL demonstrated efficacy with an 82% response rate and an 80% survival rate at 6 
months. There were 3 deaths from adverse events in this study (Locke et al., 2017). The 
amounting evidence of clinical efficacy for the CAR in B-cell lymphomas led to its FDA 
approval for treatment of DLBCL. Although it is not yet approved for this disease, studies 
have explored its anti-leukemic capabilities in a dose escalation for ALL patients 
achieving a 66.7% complete response rate and 6/21 patients experiencing high grade 
reversible CRS (Lee et al., 2015). A caveat of the CD19-targeting CARs appears to be a 
high rate of toxicity. However, there is also a high relapse rate partially due to insufficient 
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CAR T cell persistence. Methods to improve the therapeutic window of these CARs in 
the clinic have explored dual targeting to avoid antigen escape, decreasing T cell 
exhaustion and improving persistence through co-treatment with a Bruton tyrosine kinase 
(BTK) inhibitor, which has shown to decrease T cell PD-1 expression and increase ex 
vivo CAR T cell expansion (Fraietta et al., 2016, Ruella et al., 2016). Patient stratification 
is also being investigated to predict serious adverse reactions (Teachey et al., 2016). 
 
Solid tumour CAR T cell therapy has demonstrated less success to date. Similar to 
engineered TCRs, selection of an appropriate target antigen has proven difficult. Tumour-
associated antigens are often expressed on healthy tissue as well and cases of normal 
tissue destruction by CAR T cells have highlighted this obstacle. One patient died after 
treatment with Her2-targeting CAR T cells due to low antigen expression in lung tissue 
(Morgan et al., 2010). Treatment was halted in another trial using carbonic anhydrase 9 
(CAIX)-specific CAR T cells because of high grade liver toxicity seen in half of the 
patients caused by unexpected on-target-off-tumour destruction of bile duct tissue 
(Lamers et al., 2013). The CD19-specific CARs also target normal pre-B cells leading to 
B cell aplasia. This toxicity however is manageable with regular antibody replacement 
with IVIG (Doan and Pulsipher, 2018). Demonstrated challenges to successful solid 
tumour CAR T cell therapy include poor tumour trafficking and penetration, as well as 
an inability for CAR T cells to proliferate and function in immunosuppressive tumour 
microenvironments. Methods to improve these deficiencies have explored CAR T cell 
expression of chemokines/chemokine receptors, pro-inflammatory cytokines and 
targeting the vascular network (Adachi et al., 2018, Bocca et al., 2017, Craddock et al., 
2010, Yeku et al., 2017b). Alternatively, intratumoural delivery may be employed in 
some selected indications (Tchou et al., 2017). Improving efficacy is covered in more 
detail later [section 1.3]. Insufficient persistence of CAR T cells has also been reported 
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in some of the CD19 CAR trials (Knochelmann et al., 2018). Many CAR T cell therapies 
have undergone or are currently in clinical trial for solid cancers. Therapies targeting solid 
tumours have not progressed past phase I clinical trials and many of the preliminary 
reports have indicated low efficacy and persistence (Yeku et al., 2017a). A GD2-targeting 
CARs expressed in EBV-specific T cells were administered to 19 neuroblastoma patients 
and 3/11 with active disease had complete responses. No dose limiting toxicities occurred 
(Louis et al., 2011). Recently an abstract at American Society of Clinical Oncology 
(ASCO) annual meeting reported a phase I trial for the intrapleural treatment of 20 
patients with mesothelin-specific CAR T cells. No CAR T cell related toxicities above 
grade 1 were observed and 14 received subsequent anti-PD-1 monoclonal antibodies. 
Among the anti-PD-1 co-treated patients, this resulted in 2 patients with durable complete 
responses extending to 62 and 39 weeks (ongoing), 5 with partial responses and 4 patients 
with stable disease (Adusumilli et al., 2019).  Continued investigations into CAR T cell 
immunotherapy for solid tumours seeks to overcome these limitations in efficacy and 
illustrate the viability of this treatment modality in non-haematological malignancies. 
 
1.2 Prostate Cancer 
1.2.1 Prevalence 
Prostate cancer is the most common malignancy in men in the UK and Europe and is 
second only to lung carcinoma worldwide. While the incidence rate is high, with over 
47,000 new cases in the UK each year, the prognosis of this disease is generally good 
compared to other cancers with an 84% 10-year survival in men diagnosed with any stage 
prostate cancer (www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/prostate-cancer, viewed 3 May 2019). Further 
dissection of this statistic shows that the survival for late stage metastatic prostate cancer 
differs drastically from early stage disease. The 5-year survival rate of stage I-III prostate 
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cancer patients is over 90% in the UK and United States. The 5-year survival rate drops 
to 29-34% for men of any age diagnosed with stage IV metastatic prostate cancer 
(Howlader et al., 2019) (www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/prostate-cancer, viewed 3 May 2019). This illustrates 
an unmet need for improved treatments in advanced stage prostate cancer. 
 
1.2.2 Prostate cancer development 
Prostate adenocarcinoma is the most common form of prostate cancer and arises from the 
glandular epithelium of this male organ. This pathology is associated with an older 
population as the median age at diagnosis is 67. The incidence of prostate cancer increases 
with age. Factors that have been identified as contributors to the development of disease 
are family history (a close family member’s diagnosis at least doubles an individual’s 
risk), a high-fat diet and aberrant hormone levels (Grozescu and Popa, 2017).   
 
Prostate cancer progression is defined in stages using the tumour, lymph node and 
metastasis (TNM) I-IV staging system. Progression occurs by spreading to surrounding 
tissue, draining lymph nodes and ultimately metastasise to distant sites in late stage 
disease, most commonly bone tissue. The Gleason scoring system is a prostate cancer 
specific diagnostic that indicates how aggressive the cancer from a histopathological 
perspective. The technique was developed in 1966 and involves haematoxylin and eosin 
(H&E) staining and morphological analysis of prostate needle biopsies. The calculated 
grade is based on cell differentiation and can predict how quickly the cancer will progress. 
This score is presented on a scale of 1-5 and encompasses a score of the two largest areas, 
meaning that the highest possible score is 10. The Gleason index is still universally used 
for prognostic assignment and treatment decisions in prostate cancer (Epstein et al., 2016, 
Gleason, 1966). 
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The prostate is made up of glandular tissue and is involved in the production and secretion 
of seminal fluid. This process is driven by androgen hormones like testosterone. 
Mutational disruption of the androgen pathway is often involved in malignancy and has 
become the target of therapies. This pathway is critical for healthy prostate development, 
but overexpression/activation of the androgen receptor in disease correlates with 
progression, drug resistance and increased cell growth (Schrecengost and Knudsen, 
2013). The androgen receptor is a transcription factor responsible for the translation of 
genes associated with proliferation and resistance to apoptosis. The crucial role of the 
androgen receptor in the pathogenesis of prostate cancer has made androgen signalling a 
key focus of therapeutic intervention. As early as the 1940’s, physicians observed a 
regression in prostate cancer when androgen deprivation was initiated through surgical 
castration (Huggins, 1967, Huggins and Hodges, 1941). However, while this treatment is 
often effective at the start, cancer will progress to a castrate-resistant phenotype. 
Exploration into the mechanisms underlying this drug resistance have identified 
additional mutations in the androgen signalling pathway, allowing evasion of therapy. It 
is believed that signalling through the androgen receptor (AR) is achieved via higher 
expression of the receptor, mutations allowing for non-specific ligand binding, and/or cell 
survival/proliferation signalling independent of AR-ligand interactions altogether (Arora 
et al., 2013, Culig et al., 1994, Koivisto et al., 1997, Veldscholte et al., 1990). Progression 
to castrate-resistant prostate cancer (CRPC) is associated with poor prognosis and a 
median overall survival of between 14 and 26 months (Halabi et al., 2014, James et al., 
2016a). 
 
1.2.3 Current treatment options 
There are a number of treatments available for prostate cancer patients depending on 
disease stage and prognosis. Population data shows that 65-80% of men diagnosed with 
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prostate cancer in the UK or United States present with localised disease (Li et al., 2018, 
National Collaborating Centre for Cancer (UK)). These early stage diagnoses are often 
indolent and slow-growing. Therefore, a common management option for low risk 
patients is active surveillance. This avoids unnecessary complications of active treatment 
such as incontinence and impotence. Studies have shown that there is no significant 
increase in prostate cancer associated mortality for patients between 5-10 years with 
localised malignancy that undergo active surveillance compared to definitive therapy. 
However, 27-53% converted to require active therapy within the evaluation period 
(Hamdy et al., 2016, Klotz et al., 2015). Active surveillance generally includes frequent 
digital rectal exams (DREs), prostate specific antigen (PSA) testing, magnetic resonance 
imaging (MRI) scans and biopsies. Higher-risk early stage patients, or those that have 
experienced tumour progression during active surveillance, are candidates for external 
beam radiation/brachytherapy, or prostatectomy. External beam radiotherapy is generally 
a well-tolerated outpatient procedure. There are long term complications such as rectal 
toxicity, incontinence and impotence associated with treatment (Pickles et al., 2010). The 
implantation of radiation-emitting seeds into the prostate (brachytherapy) requires short 
term hospitalisation, which is often a deterrent. The brachytherapy approach has the 
benefit of limiting radiation exposure to surrounding healthy tissue with resultant 
reduction in complications of therapy (Cesaretti et al., 2007, Keyes et al., 2009). 
Prostatectomy is a more invasive procedure. Surgery is associated with a greater risk than 
radiotherapy of long term side effects including incontinence and erectile dysfunction 
(Alemozaffar et al., 2011, Mettlin et al., 1997). 
 
Locally advanced prostate cancer refers to tumours that begin to invade the surrounding 
tissue and have a high risk of progressing. Treatment options available include the 
definitive treatments described above in addition to hormone therapy. Current best 
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practice for this stage of disease is still undetermined, but usually involves a combination 
approach. Radical prostatectomy is generally less utilised due to its invasive nature, high 
rate of side effects and the difficulty of obtaining negative resection margins. However, 
there is evidence that surgical removal of the prostate increases the overall survival 
outcomes of patients (Engel et al., 2010, Heidenreich et al., 2011). The standard treatment 
for locally advanced prostate cancer is radiotherapy plus hormone therapy. Clinical 
studies have shown a significant increase in progression-free survival and overall survival 
in patients receiving combination therapy versus monotherapy (Fahmy et al., 2017, Fossa 
et al., 2016). 
 
As previously stated, metastatic prostate cancer is associated with poor long-term 
survival. First line treatment for advanced disease is life-long hormone therapy, which is 
usually effective for a few years before escape of a hormone resistant phenotype. This 
therapy includes surgical (removal of the testes) or chemical (luteinizing hormone 
releasing hormone agonists and antagonists) androgen deprivation, thereby removing the 
proliferative signals delivered by androgen hormones when they interact with the AR on 
prostate cancer cells (Nevedomskaya et al., 2018). Androgen deprivation therapy is now 
generally administered in conjunction with the chemotherapeutic agent docetaxel. This 
approach has been substantiated by a large clinical trial which showed improved survival 
for patients who received this combination therapy (James et al., 2016b). When 
progression to a metastatic CRPC (mCRPC) disease state occurs, alternative drugs are 
available such as Sipuleucel-T (not widely utilised), the chemotherapy agent cabazitaxel, 
radium-223 for bone metastases (common in this disease), and the androgen synthesis 
inhibitor, abiraterone acetate or androgen receptor blocker, enzalutamide. Because AR 
mutations cause a refractory cancer type, stronger blockade of this pathway is required. 
Mutations that increase the expression of AR and therefore the sensitivity to androgen 
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hormones could benefit from abiraterone acetate that blocks androgen production in the 
testes, tumour and adrenal glands (Barrie et al., 1997, Potter et al., 1995). Additionally, 
targeting the AR pathway directly with enzalutamide can circumvent mutations that 
enable ligand independent signalling (Tran et al., 2009). Both of these second line anti-
androgen therapeutics have demonstrated improved overall survival compared to 
standard of care in advanced disease (Dreicer et al., 2014, Scher et al., 2012). Treatment 
of mCRPC improves duration of overall survival, but ultimately the median survival of 
these patients is approximately 2 years (Francini et al., 2019). 
 
1.2.4 CAR T cell immunotherapy for prostate cancer 
Immunotherapy for mCRPC has not achieved clinical success to date. Because of the 
heterogeneity of the disease there is motivation for improved clinical trial design to 
optimally target patients that might have a higher response to immunotherapy. The 
dendritic vaccine Sipuleucel-T is still the only approved immunotherapeutic for use in 
mCRPC, but production is expensive and survival benefit modest. Overall survival 
improvement was 31.7% for patients at 3-years compared to 23% for the placebo group 
(Kantoff et al., 2010). Prostate cancer has been identified as a good candidate for targeted 
immunotherapy due to tumour-associated markers commonly expressed in the tissue. 
However, the microenvironment has been described as immunosuppressive and needs to 
be addressed for effective immunotherapeutic intervention (Pasero et al., 2016, Sfanos et 
al., 2008, Zhang et al., 2011b). Investigation of ipilimumab therapy in mCRPC showed 
no improved overall survival and 9 treatment related deaths out of 399 ipilimumab treated 
patients. An increase in progression free survival was reported (Beer et al., 2017). These 
shortcomings illustrate a need for novel immunotherapeutic approaches to mCRPC. 
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Chimeric antigen receptors have been developed to target prostate cancer through 
recognition of PSMA, prostate stem cell antigen (PSCA), mucin-1 (MUC-1), Her2 and 
epithelial cell adhesion molecule (EpCAM) (Deng et al., 2015, Ma et al., 2014, Maher et 
al., 2002, Morgenroth et al., 2007, Pinthus et al., 2003, Sanchez et al., 2013). The primary 
targets for CARs directed against prostate cancer are PSMA and PSCA, which are 
commonly overexpressed in prostate neoplasms. Prostate specific membrane antigen 
expression correlates with disease stage and is found on the vasculature of most solid 
tumours, making it a versatile target (Bostwick et al., 1998, Chang et al., 1999a). Every 
completed clinical trial for CAR T cell treatment of mCRPC to date has utilised PSMA-
targeting constructs. Results from one trial indicated tolerable toxicity of the CAR T cells 
with significant adverse reactions being attributed to the conditioning chemotherapy 
rather than the CAR activation and cytokine release syndrome (CRS). While not the 
primary objective of the study, two partial responses in PSA levels were seen in the five 
patients treated (Junghans et al., 2016). Another phase I trial, using the same CAR 
construct presented in the current project, indicated that patients could be safely treated 
with up to 30 million CAR+ T cells/kg with reports of manageable pyrexia and increased 
levels of circulating cytokines. Out of seven patients treated, two displayed stable disease 
for over 6 months and CAR T cells persisted in patients for 2 weeks (Slovin et al., 2013). 
A phase I trial has been designed to evaluate a PSMA-targeting CAR co-expressing a 
dominant-negative TGF-β receptor providing resistance to TGF-β signalling (Narayan et 
al., 2019). Three phase I trials are planned to assess the safety of PSCA- and EpCAM-
targeting CAR T cells in metastatic prostate cancer (clinicaltrials.gov NCT03873805, 
NCT02744287 and NCT03013712, viewed on 3 May 2019). So far, CAR T cell trial 
results suggest acceptable safety without clinically meaningful efficacy in prostate 
patients. This highlights the need to improve efficacy for PSMA targeting of solid 
tumours with CAR T cells. 
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1.3 Methods from improving CAR T cell therapy in solid tumours 
1.3.1 Improving specificity and safety 
Because antigens targeted by immunotherapy are often not entirely restricted to tumour 
tissue, efforts have been made to increase the specificity and safety of adoptive T cell 
therapy. One approach involves the inclusion of ‘suicide genes’ in the CAR expression 
constructs. These genes are expressed alongside the CAR in the construct and permit 
inducible cell death in case of severe toxicities. One such suicide gene is inducible 
Caspase 9 (iCas9), a fusion protein of the human caspase 9 and FK506 binding protein 
(FKBP). The FKBP region binds to the dimerising drug AP1903 and causes a signalling 
cascade within the transduced cell that results in rapid apoptosis of 99% of the engineered 
population (Straathof et al., 2005). This system is well described for control of adoptive 
cellular therapy. In a clinical trial, patients’ graft-versus-host disease (GvHD) was 
reversed within 24-hours of AP1903 administration and >90% of the transgenic cells 
were ablated (Di Stasi et al., 2011, Iuliucci et al., 2001). The iCas9 suicide system has 
been applied to CAR T cell therapy as a means to treat uncontrollable toxicity due to T 
cell activation. Inducible elimination of transduced cells in vivo has been demonstrated 
(Hoyos et al., 2010). Additional suicide genes that have been included with CAR 
constructs for adoptive cell therapy are the herpes simplex virus thymidine kinase (HSV-
tk) and an inert/truncated version of EGFR (tEGFR). Elimination of transduced cells 
expressing HSV-tk is achieved by administration of the anti-viral agent, ganciclovir, and 
this has been shown to be effective in patients who developed GvHD following donor 
leukocyte infusion (Bonini et al., 1997). The tEGFR suicide system is activated through 
complement-dependent cytotoxicity (CDC)/antibody-dependent cellular cytotoxicity 
(ADCC) which may be induced using anti-EGFR antibodies like cetuximab. Pre-clinical 
studies demonstrate that this system can be used to effectively target and kill CD19 CAR 
T cells expressing this gene (Kao et al., 2019). These approaches afford some degree of 
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therapeutic control for clinicians at the onset of severe T cell mediated toxicity. It is 
hypothesised that the use of suicide systems may also avoid the development of fatal 
toxicities as seen in earlier trials (Lamers et al., 2013, Morgan et al., 2010). Suicide genes 
are currently in use in a number of CAR T cell clinical trials (Adusumilli et al., 2019, 
Brown et al., 2015). Limitations of suicide systems include the loss of all therapeutic 
adoptive cells upon activation of the suicide gene and immunogenicity, particularly with 
viral proteins such as HSV-tk. 
 
Inducible activation of CARs has also been developed to improve the safety of this 
therapy. The strategy employs ‘switches’ in order to activate and de-active the CAR, 
allowing for control of possible acute toxicities without eliminating the CAR T cells and 
curtailing potential future therapeutic effects. The concept of a universal CAR (UniCAR) 
renders activation a two-step process in which a CAR that recognises non-tumour 
associated structures is inactive until the administration of a CAR-specific targeting 
molecule. This targeting molecule is either an antibody specific for a tumour-associated 
antigen or a fusion of a CAR-recognising protein and an antibody fragment specific for 
the tumour. This type of CAR has been developed to bind molecules such as biotin, 
antibodies/fragments, fluorescein, peptide neoepitopes or the human nuclear protein 
La/SS-B. The targeting molecules then recognise tumour markers including CD19, 
CD20, CD33, CD123, mesothelin, EpCAM, folate receptor (FR), EGFR, Her2, PSCA 
and PSMA (Cartellieri et al., 2016, Feldmann et al., 2017, Koristka et al., 2014, Raj et al., 
2019, Rodgers et al., 2016, Tamada et al., 2012, Urbanska et al., 2012). This platform has 
shown efficacy in a number of xenograft models. Efficacy can be titrated such that the 
level of anti-tumour response can be controlled by the quantity of target molecule injected 
(Feldmann et al., 2017). This can also combat disease recurrence after antigen loss by 
adjusting the specificity of the targeting molecule, avoiding laborious and expensive 
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additional production of a different CAR vector or T cell population. Using a murine 
CD19+ B-cell lymphoma model, one study demonstrated that the ability to give the CAR 
T cell intermittent breaks from activation using a CD19-specific targeting molecule 
resulted in increased expansion of CAR T cells, adoption of a higher effector memory 
phenotype and longer persistence of central memory CAR T cells (Viaud et al., 2018). 
Controllable activation has also been achieved using a CD19-specific CAR design to 
express the intracellular co-stimulation and CD3𝜁 signalling regions separately. These 
regions are induced to dimerise on exposure to a mutant rapamycin (rapalog), activating 
the signalling cascade upon drug administration (Wu et al., 2015). 
 
Other attempts to improve tumour specificity and reduce on-target-off-tumour effects 
have involved dual targeting CAR constructs. Transduced T cells express two chimeric 
receptors, one encompassing CD3𝜁 (CAR) and one encompassing the co-stimulation 
signal (CCR), that each target unique tumour-associated antigens with engagement of 
both necessary to fully activate anti-tumour cytotoxicity (Kloss et al., 2013). This 
increases the tumour specificity of the CAR T cells by requiring the tumour cells to 
express multiple markers and reduces the chance of toxicity to healthy tissues. In a model 
targeting mesothelin (CAR) and FR (CCR), dual targeting T cells showed similar 
cytotoxicity in vitro and in vivo as a 2nd generation CAR when the malignancy expressed 
both antigens and diminished effects similar to a 1st generation CAR when the cell only 
expressed one of the antigens. More importantly, healthy tissue that only expressed 
mesothelin was spared (Lanitis et al., 2013). Illustrating the variability between CAR 
constructs, another group targeting ErbB2 (CAR) and MUC-1 (CCR) in the same manner 
found that the dual targeting CAR produced less cytokine in vitro compared to the 2nd 
generation equivalent CAR. Elimination of cells expressing ErbB2 alone was similar to 
dual expressing cells, indicating no increase in tumour specificity. Proliferation, however, 
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was increased when the dual targeting CAR T cells were co-cultured with dual expressing 
cell lines specifically (Wilkie et al., 2012). Combination of a CAR with suboptimal 
tumour killing and a CCR incorporating both a CD28 and 4-1BB co-stimulation sites 
resulted in enhanced tumour specificity. Targeting PSCA with the CAR and PSMA with 
the CCR led to tumour regression in vivo of cells expressing both antigens only. This 
study also warns that the antigen with less tumour restriction should only be targeted 
using the CCR to lower the risk of off-tumour toxicity (Kloss et al., 2013). With the use 
of dual targeting, fully functional 2nd generation CARs, antigen escape can be tempered 
through destruction of the cancer cells based on two tumour-associated antigens (Lee et 
al., 2018). 
 
Apart from controllable activation, inducible CAR expression has also been described in 
the context of dual targeting. A synthetic Notch receptor developed to target a specific 
antigen cleaves an intracellular transcription factor that explicitly promotes expression of 
a CAR gene with specificity for a different antigen. SynNotch receptors illustrate another 
method of increasing tumour specific lysis and reducing cell death in healthy tissue 
(Roybal et al., 2016).   
 
The use of dual targeting receptors has also incorporated an inhibitory function to increase 
CAR T cell safety. By targeting less restrictive tumour antigens with a CAR and a healthy 
tissue marker with an inhibitory CAR (iCAR), CAR signalling/T cell activation can be 
interrupted upon dual receptor binding on healthy tissue and remain active on tumour 
tissue. This was demonstrated using CD19-specific CAR T cells co-expressing a PSMA-
specific iCAR utilising either the PD-1 or CTLA-4 signalling domains. This dual 
targeting approach achieved complete CD19+ tumour cell destruction and abrogation of 
cytotoxic activity on cells that expressed both CD19 and PSMA. Control of T cell 
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activation by the iCAR was superior with a PD-1 signalling domain compared to CTLA-
4 (Fedorov et al., 2013). Ultimately, clinical trials will define the role of these safety 
approaches. 
 
1.3.2 Improving efficacy 
While safer CAR T cell application has been discussed, one of the more confining 
obstacles for CAR therapy is a lack of efficacy against solid tumours. Attempts to 
improve efficacy have focused on persistence, cytotoxicity, trafficking and overcoming 
suppressive factors. Fourth generation ‘Armoured’ CARs or T-cell redirected universal 
cytokine killing (‘TRUCKs’) utilise co-expression of cytokines/chemokines/receptors 
alongside the CAR. Previously described TRUCKs deliver a payload to the tumour site 
and not only further stimulate CAR T cell anti-tumour performance, but potentially 
recruit and encourage surrounding TILs to also attack the malignant tissue (Yeku et al., 
2017b). This could be helpful in avoiding recurrence of disease due to antigen escape by 
inducing a polyclonal anti-tumour response. Interleukin-12 is a relevant cytokine of 
choice for its potent ability to promote expansion and cytotoxicity of NK cells and T cells 
and IFN-γ production (Smyth et al., 2000a, Zhao et al., 2012). Initial reports of inducible 
IL-12 under the control of a nuclear factor of activated T cells (NFAT) promoter in TCR 
and CAR engineered T cells demonstrated enhanced tumour growth control and an influx 
of activated macrophages (Chmielewski et al., 2011, Zhang et al., 2011a). In the CAR 
study, macrophages activated by the inducible IL-12 were able to kill an antigen negative 
cell line demonstrating potential epitope spreading and the scope to control a solid tumour 
consisting of diverse cell populations (Chmielewski et al., 2011). However, 
administration of the IL-12 inducible engineered TCR T cells to metastatic melanoma 
patients resulted in increased circulating IL-12 levels, accompanied by limited responses 
and severe liver and haematopoietic toxicity (Zhang et al., 2015). Construct designs for 
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solid tumour treatment have extended to include constitutive or inducible production of 
cytokines, including IL-15 and IL-18, to enhance the efficacy and persistence of the CAR 
T cells. Interleukin-15 supports differentiation of CD8+ memory T cells and recruits 
leukocytes, while IL-18 activates T cells/NK cells and enhances IFN- γ production 
(Lodolce et al., 1998, Mortier et al., 2009, Okamura et al., 1995). In CEA+ pancreatic and 
lung tumours in vivo, CARs co-expressing IL-18, but not the CARs alone, ablated 
xenografts and skewed the tumour microenvironment towards a pro-inflammatory state 
(Chmielewski and Abken, 2017). Interleukin-15 promoted increased CAR mediated anti-
tumour activity against glioma murine models compared to the CAR alone. However, 
tumours escaped with antigen negative/low disease (Krenciute et al., 2017). Co-
stimulatory ligands such as CD40L or 4-1BBL co-expressed in CAR transduced T cells 
further stimulate activation and cytotoxicity (Curran et al., 2015, Zhao et al., 2015). 
Cytokines in addition to IL-2 have also been co-administered with CAR T cells (Dwyer 
et al., 2019). 
 
Co-expression of receptors to further enable CAR T cell persistence and trafficking have 
been developed. Investigations indicate that traditionally immunosuppressive signals can 
be translated into T cell stimulatory signals. One such study evaluated a dominant 
negative transforming growth factor-β receptor (TGF-βR) that is preferentially expressed 
in a CAR T cell system targeting PSMA+ prostate cancer. By sequestering TGF-β from 
signalling through its endogenous receptor, CAR T cells exhibited greater persistence in 
a generally immunosuppressive tumour microenvironment (Kloss et al., 2018). This 
conversion of signals has also been shown using IL-4 chimeric receptors that induce an 
IL-2/15 or IL-7 intracellular signal upon ligand binding (Mohammed et al., 2017, Wilkie 
et al., 2010). These IL-4 chimeric receptors are further described in chapter 3. 
Chemokines and their receptors co-expressed with CARs can enhance CAR T cell 
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trafficking to the tumour. Investigations show that CAR T cell co-expression of 
chemokine receptors CCR2b and CCR4 enable the cells to home to tumours that naturally 
express their respective ligands CCL2 and CCL22 (Craddock et al., 2010, Rapp et al., 
2016). Expression of chemokines themselves in CAR T cells such as CCL19 and the IL-
7 cytokine resulted in higher leukocyte and antigen-presenting cell infiltration and 
increased tumour clearance (Adachi et al., 2018). One study modified the tumour to 
express the chemokine CXCL11 using an oncolytic virus and preferentially increased 
CAR T cell presence in the tumour in comparison to the CAR T cells co-expressing 
CXCL11 (Moon et al., 2018). 
 
A limitation of CAR T cell therapy is the inability to recognise intracellular peptides, 
which make up the majority of tumour-associated antigens. T-cell receptor-like CARs 
have been developed using the same structure as 2nd generation CARs, but incorporating 
an scFv that recognises MHC-bound peptide. Potent killing was demonstrated when 
directed towards intracellular targets including gp100 and MART-1 in melanoma models 
(Walseng et al., 2017, Zhang et al., 2014). 
 
Signalling through CAR engagement with antigen differs from physiological TCR/CD3 
complex signalling on engagement of antigen-MHC. Endogenous TCRs are more 
sensitive than CARs with the same specificity and affinity and produce more cytokines 
in response to lower levels of antigen stimulation (Harris et al., 2018). It is believed that 
this is due to inherent differences in the structure between CARs and TCRs. The 
endogenous TCR signalling machinery includes more domains with a total of 10 
immunoreceptor tyrosine-based activation motifs (ITAMs), whereas CARs usually only 
contain the CD3𝜁 domain with 3 ITAMs in each CAR monomer. Increasing the number 
of ITAMs in the signalling complex of CARs could enhance the activation to mimic an 
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endogenous TCR (James, 2018). Chimeric antigen receptors have also exhibited constant 
activation in the absence of antigen, or tonic signalling, correlated to the intensity of CAR 
surface expression, resulting in antigen-independent proliferation and eventual 
exhaustion (Frigault et al., 2015). Tonic signalling in CARs has also been partially 
explained by aggregation of the scFv domains in CD28 containing constructs (Long et 
al., 2015). 
 
Manufacturing cell products is complex and costly. It is also open to intervention to 
enhance the functional efficacy of the resultant cell product. Various amendments to 
production protocols have been made to increase the anti-tumour capacity of the therapy. 
Expansion of CAR T cells in IL-4, IL-7, IL-21 and/or IL-15 can result in a more memory 
or stem-cell like phenotype enabling greater proliferative capacity (Gargett and Brown, 
2015, Ptackova et al., 2018). Decreasing ex vivo production time has shown to increase 
efficacy. Chimeric antigen receptor T cells against CD19 demonstrated a more naïve 
phenotype and had greater anti-leukaemia efficacy when cultured for only 3 days 
compared to 9 days (Ghassemi et al., 2018). Concentrating effort on the manufacturing 
conditions might help augment the therapeutic efficacy of CAR T cells. 
 
1.3.3 Targeting the tumour microenvironment  
The tumour microenvironment has been widely accepted to play a key role in suppressing 
the immune system’s endogenous anti-cancer mechanisms. It also plays a key role in 
limiting the efficacy of cancer immunotherapy. These effects are largely mediated 
through the non-malignant cells (stroma) that reside within the tumour and which secrete 
factors that dampen down inflammatory conditions necessary for adequate cancer 
elimination [Figure 1.2]. The stroma can be classified into various cellular categories 
including mesenchymal, vascular and immune and these elements can adversely affect 
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CAR T cell immunotherapy in numerous ways. The density of tissue and erratic vessel 
formation facilitate hypoxic conditions and impede penetration of tumour-infiltrating 
cells and drugs. Tumour-associated macrophages (TAMs), regulatory T cells (Tregs) and 
cancer-associated fibroblasts (CAFs) express anti-inflammatory molecules which 
decrease immune recognition and activation. Cancer cells and stroma express inhibitory 
ligands such as PD-L1/2 to attenuate T cell cytotoxicity (Bhome et al., 2016). The more 
that tumours exhibit these characteristics, the more resistant they are to immunotherapy 
(Gasser et al., 2017). Many combination therapies have investigated the potential to 
permit CAR T cells to overcome these obstacles. Targeting the inhibitory checkpoint 
interaction between PD-1 and PD-L1 through co-administration of CPIs or oncolytic 
viruses expressing antibody fragments to PD-L1 have been investigated. Combination 
approaches enhance efficacy of PSMA and Her2 CAR T cells in solid tumours for which 
CAR T cells alone had limited anti-tumour effects (Serganova et al., 2017, Tanoue et al., 
2017). Increased penetration and migration was seen for CAR T cells rendered insensitive 
to the inhibitory protein kinase A or co-injected with bevacizumab to reorganise the 
vasculature (Bocca et al., 2017, Newick et al., 2016). Regulatory immune cells can also 
be targeted to yield greater combination therapy results. Sarcoma patient-derived 
xenograft (PDX) models were treated with all-trans retinoic acid which ablated the 
substantial numbers of myeloid-derived suppressor cells (MDSCs) in the tumour, 
allowing for control of tumour growth with CAR T cells (Long et al., 2016). Chimeric 
antigen receptors are also being developed against the aberrant vascular networks within 
the tumour microenvironment. Prostate specific membrane antigen is overexpressed in 
the neo-vasculature of many tumours and a 3rd generation CAR directed against PSMA 
exhibited vessel specificity and tumour control in vivo (Santoro et al., 2015). Another 
vasculature target that has recently emerged is C-type lectin domain family member 14a 
(CLEC14a). Targeting CLEC14a with a CAR T cell platform demonstrated efficacy in 
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Figure 1.2 Suppressive stroma and factors within the tumour microenvironment.  
Cancer cells are surrounded by stroma of different cell origins in the tumour. Along with 
the cancer cells, they each express proteins/molecules to dampen down the anti-tumour 
immune response and aid in cancer progression and metastasis. CAF: cancer-associated 
fibroblast; TAM: tumour-associated macrophage; Treg: regulatory T cell; MDSC: 
myeloid-derived suppressor cell; PDGF-β: platelet-derived growth factor β; HIF-1α: 
hypoxia inducible factor 1 α; VEGF: vascular endothelial growth factor; MMP: matrix 
metalloproteinase; IDO: indoleamine-pyrrole 2,3-dioxygenase; TGF-β: transforming 
growth factor β; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; PD-L1: 
programmed death ligand 1; LOX: lysyl oxidase; IL-10: interleukin 10; Arg1: arginase 1; 
NO: nitric oxide. 
 
Cancer-associated fibroblasts (CAFs) are considered any fibroblast within the tumour 
stroma. These cells have been described as having an activated phenotype, similar to 
myofibroblasts found in acute injury, in that they are metabolically active, proliferate, 
express ⍺	 smooth	 muscle	 actin	 (⍺SMA) and produce extracellular matrix (ECM) 
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proteins. However, studies have shown that CAFs phenotypically differ from normal 
myofibroblasts and remain chronically activated partially due to epigenetic regulation of 
gene expression (Bechtel et al., 2010, Bozoky et al., 2013, Sadlonova et al., 2009). 
Generally, CAFs promote tumour proliferation, survival and metastasis through cell-cell 
contact, ECM manipulation and cytokine/chemokine/growth factor secretion (Erdogan et 
al., 2017, Gaggioli et al., 2007, Hodkinson et al., 2006, Orimo et al., 2005, Otomo et al., 
2014). Exosomes released by chemoresistant CAFs in pancreatic ductal adenocarcinoma 
were able to deliver transcription factor Snail and miRNA-146a to cancer cells, increasing 
their chemoresistance and proliferation (Richards et al., 2017). Additionally, CAFs aid in 
tumour immunity evasion by creating a protumour, immunosuppressive environment. 
This is partly accomplished through CAF secreted chemokines/cytokines including 
CCL2, CXCL16, Chitinase 3-like-1 (Chi3L1) and IL-6 that recruit and drive 
immunosuppressive phenotypes such as MDSCs and M2 polarised macrophages (Allaoui 
et al., 2016, Chomarat et al., 2000, Cohen et al., 2017, Yang et al., 2016). Cancer-
associated fibroblast secreted factors such as tryptophan 2,3 dioxygenase (TDO), VEGF, 
arginase II (Arg2) and MMPs affect dendritic cell maturation, T cell metabolism and 
NKG2D ligand expression on tumour cells leading to a loss of functional immune 
response (Gabrilovich et al., 1998, Hsu et al., 2016, Ino et al., 2013, Ziani et al., 2017). 
Supernatant from CAFs of head and neck squamous cell carcinoma significantly 
increased the proportion of Tregs in PBMC cultures compared to matching normal 
fibroblasts from patients (Takahashi et al., 2015). Another study showed that CAFs in 
colorectal carcinoma samples expressed high levels of the immunoregulatory marker 
CD70 and this correlated with increased Treg accumulation in the tumour. Fibroblasts 
expressing high levels of this protein were also superior to low expressers for supporting 
Treg expansion in culture (Jacobs et al., 2018). Transforming growth factor-b (TGF-b) 
has been widely implicated in immunosuppression. This factor has been shown to activate 
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CAFs to a myofibroblastic phenotype and sustain activation via autocrine signalling 
(Kojima et al., 2010, Tang et al., 2019). In addition to self-sustainment, TGF-b decreases 
cytokine secretion and cytotoxicity of CD8+ T cells and reduces their penetration into the 
tumour (Ahmadzadeh and Rosenberg, 2005, Mariathasan et al., 2018, Thomas and 
Massague, 2005). Further to this immunosuppressive milieu, CAFs create a physical 
barrier against infiltrating immune cells and therapies through increased ECM deposition 
and tissue tension, leading to poor vascularisation and hypoxic conditions (Chauhan et 
al., 2013, Salmon et al., 2012). 
 
The fibroblast compartment is widely heterogenous and not well understood to date. 
Heterogeneity of CAFs may be intrinsic of the cell origin. Resident tissue fibroblast 
phenotypes differ between organs and fibroblasts can be induced from precursor cells 
including bone marrow MSCs (BM-MSCs), adipocytes, endothelial cells, epithelial cells 
and pericytes (Chang et al., 2002, Marangoni et al., 2015, Quante et al., 2011, Sun et al., 
2016). Single-cell RNA data showed that wound-derived fibroblasts clustered into 12 
distinct genetic expression profiles (Guerrero-Juarez et al., 2019). In a cancer context, the 
MMTV-PyMT transgenic murine model of breast cancer showed 4 subtypes of CAFs 
with varying genetic expression, protein markers, function, origin and location within the 
tumour (Bartoschek et al., 2018). In patients with breast cancer, CAFs with a 
downregulated caveolin-1 phenotype were correlated with a worse disease-free survival 
rate. Caveolin-1 silencing in fibroblast cell lines increased the invasive potential of the 
breast cancer cell lines MDA-MB-468 and T47D (Simpkins et al., 2012). A new subset 
of CAFs in breast and lung tumours has been identified by the expression markers CD10 
and GPR77. These CAFs promote chemoresistance and enrichment of cancer stem cells 
(Su et al., 2018). In contrast to the described active myofibroblast, studies have exposed 
a subset of CAFs that acquire senescence, in which they remain metabolically active but 
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no longer divide. These senescent CAFs are able to promote tumorigenesis and cell 
proliferation through various factor secretion (Bavik et al., 2006, Pazolli et al., 2009). A 
study utilising oesophageal squamous cell carcinoma cultures demonstrated that a 
genetically unstable disease variant correlated with an increased senescent CAF 
population. Senescence was induced through reactive oxygen species secreted by the 
cancer cells and an increase in TGF-b expression in the fibroblasts. The senescent CAF 
phenotype was able to increase invasive capabilities of tumour cells in vitro and was 
partially explained by an increase of CAF-derived MMP-2 (Hassona et al., 2013, 2014).  
 
Emerging evidence indicates that targeting the CAF compartment with therapeutic 
intervention can increase treatment efficacy. A strategy currently being investigated 
involves reversing the cancer-promoting phenotype of CAFs to a less active, more 
quiescent state. Knocking down NADPH oxidase 4 (NOX4) using either a selective NOX 
inhibitor or shRNA reverted myofibroblast differentiation in human foetal foreskin 
fibroblasts in vitro and reduced myofibroblast presence and tumour growth in a xenograft 
model of head and neck cancer (Hanley et al., 2018). All-trans retinoic acid (ATRA) 
induced a quiescent phenotype in the pancreatic stellate cell line PS1, as assessed by gene 
expression. Treatment with ATRA also induced PS1-dependent cancer cell apoptosis, 
diminished invasion potential and slowed proliferation in pancreatic cancer cells in 3D 
cultures via Wnt-b-catenin signalling disruption (Froeling et al., 2011). Similar effects 
have been observed with pancreatic stellate cells treated with a vitamin D receptor ligand, 
increasing the efficacy of the chemotherapy drug gemcitabine in a pancreatic cancer 
transgenic mouse model (Sherman et al., 2014). Cytotoxic drug targeting to CAFs has 
also been investigated. Exploitation of the off-target uptake of therapeutic nanoparticles 
in tumour fibroblasts was designed to deliver plasmids encoding secreted TNF-related 
apoptosis-inducing ligand (sTRAIL) to CAFs, triggering apoptosis in the neighbouring 
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cancer cells. A xenograft model of bladder cancer co-injected with NIH3T3 fibroblasts 
showed accumulation of the nanoparticles in the fibroblasts, reduction in tumour growth 
and decreased fibroblast activation (Miao et al., 2017). A phase I trial exhibited increased 
anti-tumour efficacy in 3/12 patients with a combination therapy of  the Hedgehog 
signalling inhibitor Sonidegib and docetaxel. Investigation into the mechanism 
determined that Hedgehog signalling in CAFs results in upregulation of ECM 
remodelling and supports a cancer stem cell phenotype (Cazet et al., 2018). Further 
development of therapies targeting CAFs may illustrate greater clinical efficacy for 
combination cancer treatments. 
 
1.3.4 Fibroblast Activation Protein (FAP) as a therapeutic target 
The 170kDa homodimer Fibroblast Activation Protein (FAP) is a serine protease in the 
Dipeptidyl Peptidase IV (DPPIV) family. While dipeptidyl peptidase activity is a feature 
of all DPPIV members, FAP is also uniquely capable of endopeptidase cleavage 
(Aertgeerts et al., 2005). The physiological expression pattern of this protease is well 
characterised in embryonic mesenchyme, scar formations/wound healing and bone 
marrow-derived mesenchymal stromal cells (Bae et al., 2008, Rettig et al., 1988). 
Although abundant in embryonic tissue, its role seems to be non-essential in the 
development of the foetus as FAP knockout mice exhibit a healthy phenotype 
(Niedermeyer et al., 2000). The role of FAP in cell biology and the discovery of its 
substrates are still under investigation. Neuropeptide Y, B-type natriuretic peptide, 
peptide YY and substance P are among the natural substrates identified for FAP 
dipeptidyl peptidase activity (Keane et al., 2011). The ECM proteins α2-antiplasmin, type 
I collagen and gelatin are known substrates of soluble and membrane-bound FAP 
endopeptidase activity (Lee et al., 2006, Park et al., 1999). This enzymatic ECM 
remodelling activity is central to FAPs role in scar resolution and cancer progression. 
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In contrast to the highly restricted presence of FAP in health, the enzyme is widely 
expressed in diseased tissues. In 1986, FAP was first identified through the relative 
restriction of binding of a monoclonal antibody to astrocytomas, sarcomas and fibroblasts 
(Rettig et al., 1986). It was further characterised while analysing biopsies from 18 
different tumour types. Overexpression of FAP was detected in the stroma of epithelial 
cancers including colorectal, breast, ovarian, bladder, lung, mesothelioma, skin, gastric, 
pancreatic, endometrial and melanoma, but not in the surrounding healthy tissue (Garin-
Chesa et al., 1990). Overexpression of FAP in the tumour microenvironment is associated 
with increased invasiveness of the cancer, which could be due to its collagenolytic 
activity. Forced expression of FAP in the HT1080 sarcoma cell line results in increased 
migration of the cells in chambers containing different types of ECM, as well as an 
upregulation of integrin-related intracellular signalling proteins. These changes are 
abrogated upon treatment with an antibody that causes FAP internalisation (Baird et al., 
2015). Knocking down endogenously expressed FAP in cancer-associated fibroblasts 
decreases the migratory capacity of the cancer cells (Teichgraber et al., 2015). A meta-
analysis of 15 different studies of FAP expression in multiple solid tumour types 
identified a statistically significant correlation between FAP overexpression and lymph 
node metastases, distant metastases and poorer overall survival. Notably, worsened 
overall survival was only significant in cases where tumour cells, as opposed to stroma, 
expressed FAP (Liu et al., 2015). Numerous carcinomas show significantly increased 
levels of TGF-β (Friess et al., 1993, Travers et al., 1988, Truong et al., 1993) which is a 
primary upregulator of FAP (Chen et al., 2009). Illustrating this, TGF-β containing 
conditioned media from colorectal cancer cells upregulated FAP expression in fibroblasts 
(Henriksson et al., 2011). The expression of FAP in the tumour microenvironment 
highlights its potential as a target for cancer therapy.  
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Cancer-associated fibroblasts (CAFs) are genetically stable cells within the tumour 
microenvironment (Qiu et al., 2008, Walter et al., 2008). Many immunotherapies have 
been developed to take advantage of this stability by targeting CAF antigens including 
FAP. In an early phase I study, the F19 antibody used to discover FAP was radiolabelled 
with iodine-131 in order to image liver metastases originating from colorectal cancer. In 
15/17 patients who received the tracer, metastases were successfully imaged by single-
photon emission computed tomography (SPECT) in the absence of dose-limiting toxicity. 
Moreover, imaging findings correlated to the extent of disease as identified at the time of 
subsequent resection (Welt et al., 1994). The antibody was subsequently humanised and 
underwent evaluation of safety and therapeutic efficacy in a phase I trial in FAP+ tumours 
and a phase II trial in metastatic colorectal carcinoma patients. In both studies the 
immunotherapy was well-tolerated, but exhibited little clinical efficacy (Hofheinz et al., 
2003, Scott et al., 2003). Dendritic cell and DNA vaccines directed against FAP have 
been tested in animal models of colon and breast carcinoma, melanoma and lymphoma. 
Significant slowing of tumour growth, reduction in metastases and CD8+ T cell mediated 
anti-FAP responses were seen (Lee et al., 2005, Loeffler et al., 2006, Wen et al., 2010). 
One study noted there was a slight delay in wound healing ability in vaccinated mice, 
although this difference was short lived (Lee et al., 2005). However, none of these studies 
demonstrated that tumour regression could be induced after vaccination alone. Chimeric 
Antigen Receptor (CAR) engineered T cells directed against FAP have also been 
investigated in mouse models of lung cancer and mesothelioma. Slowing of tumour 
growth was observed in these studies which was further enhanced by combination with 
other therapies (Kakarla et al., 2013, Wang et al., 2014). Treatment of lung tumour 
bearing mice with co-injections of two separate CAR+ T cell populations, targeting FAP 
and lung carcinoma associated antigen ephrin type-A receptor 2 (EphA2), resulted in an 
improved anti-tumour efficacy beyond that seen with either CAR construct alone. By 
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contrast, FAP-specific CAR T cells elicited weak or negligible anti-tumour activity in 
models of melanoma, colon cancer, fibrosarcoma, breast and kidney cancer. In these 
studies, animals exhibited bone necrosis and cachexia which was attributed to the 
targeting of FAP expressed on bone-marrow mesenchymal stromal cells (Tran et al., 
2013). Similar toxicity was not seen with FAP directed CARs in other studies (Kakarla 
et al., 2013, Wang et al., 2014). Despite these disappointing results, a F19 derived FAP-
specific CAR T cell immunotherapy is currently under study in a phase I trial in patients 
with malignant mesothelioma (Petrausch et al., 2012).  
 
Although FAP tends to localise in epithelial cancer stroma, the aforementioned studies 
suggest that the targeting of FAP expression alone may not be sufficient to result in 
tumour clearance. These studies indicate that combination therapies that include a FAP-
directed therapeutic agent could lead to enhanced anti-tumour activity. 
 
1.3.5 Utilising immunocytokines 
As a method of targeted cytokine delivery, antibody-cytokine fusion molecules termed 
‘immunocytokines’ [Figure 1.3] have been widely developed and assessed in clinical 
trials involving a variety of cancers [Table 1.2]. Pre-clinical studies have demonstrated 
the efficient targeting capabilities of immunocytokines to the tumour site. Given the 
toxicity profiles of many systemically delivered cytokines, use of an immunocytokine 
approach can often broaden the therapeutic window of the cytokine under study (Borsi et 
al., 2003, Carnemolla et al., 2002). Immunocytokines incorporating IL-4 have been 
investigated in vivo, but they have primarily been assessed in the treatment of auto-
inflammatory conditions including arthritis, endometriosis and psoriasis (Hemmerle et 
al., 2014a, Hemmerle et al., 2014b, Kawalkowska et al., 2016, Quattrone et al., 2015). 
However, one study described an IL-4 immunocytokine targeted to an alternatively 
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spliced extra-domain A of fibronectin that is aberrantly expressed in a range of cancers. 
This agent demonstrated anti-tumour activity in mouse models of teratocarcinoma, 
lymphoma and colon cancer (Hemmerle and Neri, 2014). The use of FAP as a target for 
immunocytokine delivery has also been validated using a number of cancer models. 
Illustrating this, FAP-specific immunocytokines carrying the inflammatory cytokine 
tumour necrosis factor-a (TNF) or a trans-signalling variant of IL-15 demonstrated good 
localisation to the tumour microenvironment, leading in turn to the induction of potent 
anti-tumour immune responses (Bauer et al., 2004, Kermer et al., 2012). A bi-specific 
molecule coupling a FAP-specific scFv to the co-stimulatory ligand 41BB-L also elicited 
enhanced co-stimulation in co-cultures of T cells with FAP-expressing tumour cells 
(Muller et al., 2008).  
 
Immunocytokines have been investigated previously in combination with CAR T cells in 
a CD19+ CD20+ plasma cell leukaemia model. Increased persistence in vivo was described 
for CD19-specific CAR T cells co-administered with a CD20-targeting IL-2 
immunocytokine compared to CAR alone, CAR with untargeted IL-2 or an irrelevant 
GD-2-specific IL-2 immunocytokine. Tumour eradication achieved in the CAR T cell 
plus CD20 IL-2 immunocytokine group continued for 83 days (Singh et al., 2007). This 
study has highlighted the potential to support and improve CAR T cell therapy with 
tumour targeted immunocytokines. 
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Figure 1.3 Structure of an immunocytokine.  
An example of an immunocytokine format is shown. In this case, a full-length native 
antibody conformation has been conjugated to the cytokine payload which has been 
attached to the C-terminus of the heavy chain. Immunocytokines can incorporate a variety 
of antibody fragments including Fab and scFv domains. They can also differ in the 
location at which cytokine attachment is situated (blue boxes = antibody variable regions; 
green boxes = constant regions; grey lines = hinge domain; black dotted lines = disulphide 
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IL-2 (Albertini et al., 2012, 
Albertini et al., 2018, 
King et al., 2004, Ribas 
et al., 2009, Shusterman 
et al., 2010) 




IL-2 (Catania et al., 2015) 
EpCAM Solid tumours 
Small cell lung 
carcinoma 
Prostate carcinoma 
IL-2 (Connor et al., 2013, 
Gladkov et al., 2015, Ko 
et al., 2004) 
ED-B isoform of 
fibronectin 
Melanoma 





(Danielli et al., 2015, 
Eigentler et al., 2011, 
Johannsen et al., 2010, 
Papadia et al., 2013, 
Rudman et al., 2011, 
Spitaleri et al., 2013, 
Weide et al., 2014) 
DNA fragments Solid tumours 
Non-small cell lung 
carcinoma 
IL-2 (Gillessen et al., 2013, 
van den Heuvel et al., 
2015) 
Table 1.2 Clinical trials utilising immunocytokines.  
Targets, diseases, delivered cytokines and references that describe clinical trials involving 
immunocytokines. Antigen targets include GD2: disialoganglioside, EpCAM: epithelial 
cell adhesion molecule, ED-B: extra-domain B. 
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1.4 Project hypothesis and objectives 
I hypothesised that the efficacy of PSMA-targeted CAR T cell immunotherapy for 
prostate cancer could be significantly improved through the delivery of a tumour stroma-
specific immunocytokine. The objectives of this PhD thesis were to:  
• Develop a functional FAP-specific IL-4 immunocytokine. 
• Generate a prostate cancer/stroma model for in vitro and in vivo experimentation. 
• Observe the effects of the immunocytokine on CAR T cell anti-tumour 
capabilities in vitro and in in vivo xenograft models. 
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 Chapter 2: Materials and methods 
2.1 Media and solutions 
D10 Media = 500 mL Dulbecco’s Modified Eagle Medium (DMEM) + 4.5 g/L glucose 
(Lonza) 
50 mL Foetal Bovine Serum (Autogen Bioclear) 
3.6 mM L-Glutamine (Lonza)  
R5 Media = 500 mL Roswell Park Memorial Institute (RPMI) Medium without L-
Glutamine  
(Lonza) 
25 mL Foetal Calf Serum 
  3.6 mM L-Glutamine 
PS1 Media = 500 mL DMEM/Ham’s F-12 50/50 mix with 2.5 mM L-glutamine 
(Corning) 
  50 mL Foetal Bovine Serum (Autogen Bioclear) 
Expi293F™ Expression Media (Gibco) 
EX-CELL® Hybridoma Media (Sigma) 
Trypsin-Versene = 25 mL 2x Trypsin (Pierce)  
25 mL 2x Versene  
1X PBS = 9.55 g/L phosphate-buffered saline in deionised water (Biochrom AG) 
1X HBS = 8.76 g/L NaCl and 2.38 g/L hepes in deionised water (Provided by Dr. Jim 
McDonnell) 
Tissue Digestion Buffer = 500 mL RPMI (Lonza) 
  1 mg/mL collagenase (Sigma) 
  0.1 mg/mL Deoxyribonuclease I (Sigma) 
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2.2 Cell cultures 
All cells were maintained in incubators at 37˚C and 5% CO2 apart from Expi293F™ cells 
which were maintained at 37˚C and 8% CO2 in 120 RPM shaking conditions. Cells were 
passaged once ≥ 90% confluency was reached. All cell lines were kept in D10 media 
during culture. Exceptions were PS1 cells cultured in PS1 media, Expi293F™ kept in 
Expi293F™ Expression Media and hybridomas which were cultured in serum free EX-
CELL media. H29 cultures in D10 were supplemented with 2 μg/mL tetracycline to 
suppress expression of the cytotoxic VSVG env protein that is under control of a 
tetracycline repressed promoter. H29 cultures were also supplemented with 3 μg/mL 
puromycin and 6 μg/mL G418 for gag/pol suppression. 
 
2.2.1 Cell lines 
Cell Line Derived From (Envelope 
Protein) 
Source 
H29 Human embryonic kidney 





293vec-RD114 (RD114) Human embryonic kidney 
(RD114 endogenous feline 
virus) 
BioVec Pharma 
DU145 Human prostate  CRUK 
PC3-LN3 (PL) Human prostate Dr. Sue Eccles (Institute 
of Cancer Research, 
Sutton) 
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PC3-LN3-PSMA (PLP) Human prostate Dr. Sophie Papa 
(Research Oncology, 
King’s College London) 
LT-PLPFAP Human prostate; transduced 
to express LT and FAP 
Developed in the lab 
MRC5hT (hTERT 
transduced) 
Human foetal lung fibroblast Dr. Gabriele Saretzki 
(Institute for Ageing 
and Institute for Cell 
and Molecular 
Biosciences, Newcastle) 
PS1 (hTERT transduced) Pancreatic stellate cells Dr. Hemant Kocher 
(Centre for Tumour 
Biology, Bart’s Cancer 
Institute) 
HT1080/HT1080-FAP Human sarcoma Ulf Petrausch 
(OnkoZentrum, Zürich) 
Hybridomas FAP-specific splenocytes 
and myeloma 
GenScript 
CTLL-2/4αβ Murine T cell Dr. Alastair Noble 
(King's College 
London) 
Expi293F™ Suspension human 
embryonic kidney cells 
Dr. Sophia Karagiannis 
(King’s College 
London) 
Table 2.1 Cell lines used in this study.  
Includes the name, their origin and where they were sourced from. 
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2.2.2 Peripheral blood mononuclear cells (PBMCs) 
Blood was collected into 5 mL of anticoagulant citrate-dextrose solution (Sigma) from 
healthy volunteer donors under approval of the Guy’s Hospital Research Ethics 
Committee (09/H0804/92; Use of Donor Blood Samples for Pre-Clinical Development 
of Active and Passive Immunotherapy for Cancer). Fifteen millilitres of Ficoll-Paque 
(Sigma) was aliquoted into a 50 mL Falcon tube and 25 mL of blood was slowly layered 
on top. This was centrifuged at 800 x g for 35 minutes with the acceleration and brakes 
turned off. A Pasteur pipette was used to transfer the buffy coat of PBMCs into a new 
Falcon tube. The cells were washed with PBS and spun at 400 x g for 10 minutes twice. 
The pellet was resuspended in R5, counted and diluted to 3 x 106 cells/mL. 
Phytohemagglutinin-L (PHA) (Sigma) was added at 5 μg/mL and cells were plated across 
6 well plates and incubated overnight. Twenty-four hours later, 100 IU/mL IL-2 was 
added and cultures were supplemented with IL-2 every 2-3 days. 
 
2.3 Molecular biology techniques 
2.3.1 Construct design 
Gene constructs in the SFG vector were previously developed and used to transduce cell 
lines for this project [Figure 2.1]. Fibroblast activation protein (FAP) was cloned into 
SFG for experiments in this thesis and is described later [section.2.3.2]. The variable 
regions of the B1 and C11 hybridomas generated for this project by GenScript were 
initially sequenced by GenScript. The Snapgene software was used for scFv-Fc and 
immunocytokine design and Genedesigner (ATUM) was utilised for codon optimisation 
of the B1HL, B1LH and C11 scFv-Fc constructs. All leader sequences for the scFv-Fc 
and immunocytokine constructs were derived from the heavy chain of the C11 hybridoma 
or the CSPG4 antibody, kindly gifted by Dr. Sophia Karagiannis. The ESC11 VH and VL 
sequences were sourced from a patent application for the anti- human and murine FAP 
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antibody (application no.: 13/499,718) 
(https://patents.google.com/patent/US20120258119A1/en). The VH and VL domains 
were connected by a 15-amino acid serine-glycine linker in each scFv-Fc and 
immunocytokine construct.  The immunocytokine was designed to link recombinant 
human IL-4 to the C-terminus of the ESC11 scFv by a 15-amino acid serine-glycine 




Figure 2.1 Constructs for stable transduction of cell lines. 
The constructs for SFG plasmids containing P4, P4Tr, PSMA, FAP, mNeptune and 
ffLuciferase-tdTomato (LT) are illustrated. LTR: long terminal repeats; SD: splice donor; 
SA: splice acceptor; 𝚿: packaging signal; T2A: furin cleavage site; CD8α L: CD8α leader 
sequence. 
 
2.3.2 Subcloning FAP into SFG 
The commercially available plasmid FAP-pcDNA3.1-(k)DYK (GenScript) was used as a 
source of Fibroblast Activation Protein DNA sequence which was subcloned into the SFG 
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and SFG were both amplified using the polymerase chain reaction (PCR) technique with 
primers harbouring overlapping regions to insert FAP into the SFG cloning site. The FAP-
pcDNA3.1-(k)DYK and SFG plasmids were diluted to 1 ng/μL in nuclease free water and 
primers [Table 2.2] were diluted to a working concentration of 10 μM. A master mix was 
generated with 10 μL Q5® Reaction Buffer (NEB), 10 μL GC enhancer (NEB), 1 μL 
dNTP (NEB) and 0.5 μL Q5® High Fidelity DNA Polymerase (NEB) into 21.5 μL water. 
The master mix was used at 21.5 μL/reaction with 0.5 μM forward/reverse primers and 1 
ng plasmid DNA templates. The FAP and SFG reactions were carried out as follows: a 
3-minute denaturation period at 98˚C followed by 35 cycles of 15 seconds denaturation 
at 98˚C, 15 seconds annealing at 67˚C and a 30 seconds/kilobase extension at 72˚C. A 
final extension was run at 72˚C for 2 minutes and reactions were held at 10˚C. Reactions 
were visualised on an agarose gel [section 2.3.6] for correct size and template strands 
were digested with 0.5 μL DpnI enzyme at 37˚C for 15 minutes. The SFG and FAP 
amplicons were mixed together and transformed into competent bacteria [section 2.3.3]. 
Colonies were chosen, expanded and a miniprep [section 2.3.4] was performed to extract 
plasmid DNA for sequencing. 
 
PCR Forward Primer Reverse Primer Size of 
Fragment 










taacagccactcgagggatccg ggcagtctagaggatggtccac 6,358 bp 
Table 2.2 Primers used for the FAP-SFG PCR reactions.  
The sequences of the primers used for each reaction are listed along with the expected 
size of the fragment. bp = base pair. 
 
2.3.3 PIPE cloning 
This technique was used to produce the eFAP-4 and scFv-Fc recombinant antibodies. A 
UCOE02 (Merck Millipore) plasmid containing the sequence for a human IgG1 heavy 
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chain was donated by Dr. Sophia Karagiannis, King’s College London. The eFAP-4 
immunocytokine or scFv was sourced from a pUC57 plasmid (GenScript) containing the 
relevant sequence. The UCOE backbone was used as the template for 3 PCRs to generate 
3 different fragments and the pUC57-scFv/immunocytokine plasmids were used to 
generate the insert fragment. All reactions included 10 ng of template DNA, 10 μM of 
forward primer, 10 μM of reverse primer and a 1X concentration of Phusion™ Flash High-
Fidelity PCR Master Mix (Thermo Scientific) diluted to 50 μL in nuclease free water. 
Generation of the scFv-Fc was carried out as follows: a 30 second denaturation at 98˚C 
followed by 30 cycles of 1 second denaturation at 98˚C, 5 seconds annealing at 60˚C and 
15 seconds/kilobase extension at 72˚C. Amplicons were visualised on 1% agarose gels 
[section 2.3.6]. The template strands in each reaction were digested in 1X CutSmart® 
buffer with DpnI (NEB) at 37˚C for 2 hours. One microliter each of the 3 UCOE backbone 
products were mixed with 1 μL of the relevant insert fragment in 4 μL nuclease free water 
and left overnight at room temperature. Competent bacteria were transformed the 
following day. 
 
2.3.4 Bacterial transformation 
Competent K12 ER2925 E. coli (NEB) were thawed on ice for 30 minutes and 4μL DNA 
was added. Cells were incubated on ice for 30 minutes and heat shocked at 42°C for 1 
minute. Bacteria were allowed to rest briefly, then 300μL super optimal broth with 
catabolite repression (SOC) media (Invitrogen) were added and cells were shaken at 
200RPM, 37°C for 1 hour. Bacteria was then pelleted down at 13,000RPM for 3 minutes. 
Three-hundred microliters of supernatant were removed and the cells were resuspended. 
Cells were added to an agar plate containing 100μg/mL ampicillin and spread. The plate 
was incubated at 37°C overnight. Colonies were selected and added to 5mL 100μg/mL 
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The QIAprep spin Miniprep kit (Qiagen) for bacteria colonies was used and instructions 
provided were followed. Colonies were grown overnight in 5mL 100μg/mL ampicillin 
LB and pelleted at 3,000 x g. Pellets were resuspended in 250 μL Buffer P1. Resuspended 
bacteria were then mixed with 250 μL Buffer P2 and gently mixed by inverting. Cell lysis 
was neutralised by invert mixing in 350 μL Buffer N3 and pelleted at 16,800 x g for 10 
minutes. The supernatant was applied to a spin column and centrifuged for 1 minute. The 
spin column was washed with 500 μL Buffer PB and centrifuged for 1 minute. The 
column was washed with 750 μL Buffer PE and centrifuged for 1 minute. An additional 
1 minute centrifugation was applied to remove any liquid. The column was then placed 
in a clean Eppendorf and the plasmid DNA was eluted with 50 μL Buffer EB. The 
membrane was allowed to stand for 1 minute and then centrifuged for 1 minute. 
Concentrations were analysed using a Nanodrop. The plasmids were stored at -20°C. 
 
2.3.6 Maxiprep 
Colonies grown overnight in 5mL 100μg/mL ampicillin LB were transferred to 200 mL 
of the same broth and expanded overnight in the orbital shaker at 200RPM and 37°C. The 
QIAprep spin Maxiprep kit (Qiagen) for bacteria colonies was used and instructions 
provided were followed. Harvested cultures were split into aliquots of 50 mL and pelleted 
at 3,000 x g for 15 minutes at 4˚C. Pellets were resuspended in 20 mL Buffer P1 and 
vortexed. Equal volume of Buffer P2 was added, mixed by inverting and incubated at 
room temperature for 5 minutes. Twenty millilitres cold Buffer P3 was added and mixed 
by inverting before incubating on ice for 20 minutes. Solutions were centrifuged at 3,000 
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x g for 30 minutes at 4˚C. Supernatant was applied to equilibrated QIAGEN-tips and 
allowed to flow through the membrane. Tips were washed twice with 30 mL Buffer QC. 
DNA was eluted in 15 mL Buffer QF and precipitated by adding 10.5 mL isopropanol. 
Precipitated DNA was centrifuged at 3,000 x g for 90 minutes and the supernatant 
discarded. The DNA pellet was washed with 70% ethanol, centrifuged at 3,000 x g for 60 
minutes and the supernatant discarded. The pellet was dried at 37˚C for 10 minutes and 
the DNA was dissolved in 500 μL TE Buffer. Concentrations were analysed using a 
Nanodrop. The plasmid was stored at -20°C. 
 
2.3.7 Agarose gel 
Digestions with relevant restriction enzymes were incubated at 37°C for 1 hour. A 1% 
agarose gel was made in 1X TBE buffer and a 1:10,000 concentration of SYBR™ safe 
(Invitrogen). Samples were prepared with 6X gel loading dye and loaded with 10μL 1kb 
DNA ladder (NEB). Electrophoresis was run at 150 volts for ~1 hour and the gel was 
imaged using UV light. 
 
2.4 Protein purification, quantification and characterisation 
2.4.1 Purification 
Hybridoma and recombinant scFv-Fc antibodies were purified using Protein G GraviTrap 
columns (GE Healthcare) and instructions provided were followed. Purification of the 
eFAP-4 immunocytokine was achieved using the AminoLink Immobilisation Kit 
(Thermo Scientific) and 1.5 mg of purified mouse anti-human IL-4 (Biolegend UK: 8D4-
8) was immobilised on the column. Company instructions were followed for protein 
coupling and purification. Eluents were concentrated and buffer was exchanged to 1X 
PBS using Amicon Ultra centricons (Merck Millipore) with a 3,000 MW cutoff. 
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Concentrations were analysed using a Nanodrop. The extinction coefficient for eFAP-4 
was calculated to be 72475 M-1cm-1 using the ExPaSy ProParam tool online. 
 
2.4.2 Western blot 
Pre-cast NuPAGE Gel (Invitrogen) was used and 50 ng of protein was loaded. Samples 
were prepared with 4X NuPAGE loading buffer (Invitrogen), containing 1 mM 
dithiothreitol in reduced conditions, protein sample and PBS. Reduced samples were 
boiled for 5 mins at 94°C. Samples were loaded alongside the PageRuler Plus Prestained 
Protein Ladder (Thermo Scientific) and run in 1X NuPAGE MOPS running buffer 
(Invitrogen) at 150 volts for 1 hour. The proteins were transferred to a nitrocellulose 
membrane (GE Healthcare) in 1X transfer buffer in the cold room at 100 volts for 1 hour. 
The membrane was washed in 1X TBST. Blocking was done in 3% milk for 1 hour. 
Primary antibody was diluted in 3% milk and stained for 1 hour. The membrane was 
washed, the HRP-conjugated secondary antibody was diluted in blocking buffer and 
incubated for 1 hour. The membrane was washed before incubation with developing 
reagents 1 and 2 from the ECL kit (GE Healthcare) for 1 minute. The membrane was 
wrapped and taped inside a developing case. High performance chemiluminescent 
hyperfilm (GE Healthcare) was used. 
 
2.4.3 Coomassie stain 
Pre-cast NuPAGE Gel (Invitrogen) was used and 3 μg of protein was loaded unless 
otherwise specified. After running the gel (as with the western blot), it was submerged in 
InstantBlue Coomassie stain (Expedeon) overnight. The gel was rinsed with distilled 
water and visualised. 
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2.4.4 Bicinchoninic acid (BCA) assay 
The Pierce BCA Protein Assay Kit (Thermo Scientific) was used and bovine serum 
albumin (BSA) concentration standards were made. Reagents A and B were mixed at a 
50:1 ratio. In a plate, 25μL of each standard and sample were used in replicates of 2. Two-
hundred microliters of the reagent mixture were added quickly and incubated at 37°C for 
30 minutes. The plate was read at a 562nm wavelength. 
 
2.4.5 Biacore binding kinetics 
A Biacore T100 instrument was used to assess the binding kinetics of proteins. 
Recombinant ESC11 scFv-Fc was immobilised on Series S Protein A sensor chip (GE 
Lifesciences) at a 50 nM concentration diluted in 1X HEPES Buffered Saline (HBS) 
running buffer. Recombinant hFAP (R&D Systems) was washed over the chip at 
decreasing doses starting at 50 nM and ranging to 0 nM also diluted in 1X HBS. 
Regeneration was carried out according to the manufacturer’s guidelines. The binding 
data was plotted in GraphPad Prism and non-linear regression curve analysis was used to 
determine the dissociation constant. 
 
2.5 Transfection and transduction of cells 
2.5.1 Transfection of H29 
Tetracycline, G418 and puromycin were removed two hours prior to transfection. A 
polyethylenimine (PEI) solution (1.5mL serum-free DMEM, 1.5μL of 1mM PEI and 
20μL DNA plasmid) was incubated at room temperature for 30 minutes. The cells were 
washed with serum-free media and the PEI solution was added for two hours at 37°C. 
D10 was added and incubated at 37°C for 72 hours. The media was changed 72-hours 
post transfection. Supernatant (3mL) was harvested daily. 
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2.5.2 Transduction of RD114-pseudotyped HEK293vec (RD114) 
Supernatant from transfected H29 cells was placed on pantropic RD114-pseudotyped 
HEK293vec cells. After 72 hours, flow cytometry was performed to assess transgene 
expression analysis. 
 
2.5.3 Transduction of cancer and stroma cell lines 
Cells were plated at 25-30% confluency on a 6 well plate treated with 200 μg of 
RetroNectin® (Takara) in D10. The relevant RD114-pseudotyped packaging cell line was 
plated at ~30% confluency in 2 mL D10. Twenty-four hours later, supernatant harvested 
from transduced RD114 cells was added to the cancer/stromal cell lines. Cells were 
repeatedly exposed to RD114 supernatant until transgene expression levels were >90%, 
as assessed by flow cytometry. 
 
2.5.4 Transduction of PBMCs 
The relevant RD114-pseudotyped packaging cell line was plated at 30-35% confluency 
in 2 mL D10. Twenty-four hours later, supernatant was harvested from RD114 cells and 
the media replaced. Harvested supernatant was added to 6 well plates treated with 200 μg 
RetroNectin® (Takara) and kept at 4˚C for 4 hours. Supernatant was then aspirated and 
replaced with 2 mL of freshly harvested RD114 supernatant and 48 hour PHA-activated 
PBMCs were added at 1 x 106 cells/well. Wells were topped up to 3 mL with fresh R5 
media and given 100 IU/mL IL-2 (Novartis). Transduced PBMCs were continuously 
expanded in R5 media supplemented with 30 ng/mL IL-4 (Peprotech) and transgene 
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2.5.5 Transfection of Expi293F cells 
Expi293F cells (Gibco) were transfected with plasmid DNA encoding recombinant scFv-
Fc or immunocytokine protein. Protocol for transfection was provided by the supplier. 
Cells were seeded at 7.5 x 107 cells in 25.5 mL of Expi293™ Expression Medium. Eighty 
microliters ExpiFectamine™ Reagent was diluted in 1.5 mL Opti-MEM™ Medium and 
incubated at room temperature for 5 minutes. At the same time, 30 μg DNA was diluted 
in 1.5 mL Opti-MEM™ Medium at room temperature for 5 minutes. The DNA solution 
and the ExpiFectamine™ Reagent solution were mixed and incubated at room temperature 
for 20 minutes. This DNA-Reagent mixture was added to the cells and incubated for 16 
hours at 37˚C and 8% CO2 in 120 RPM shaking conditions. The following day, 150 μL 
ExpiFectamine™ 293 Transfection Enhancer 1 and 1.5 mL ExpiFectamine™ 293 
Transfection Enhancer 2 were added to the transfected cells and incubated at 37˚C and 
8% CO2 in 120 RPM shaking conditions. On day 8 post transfection, cells were pelleted 
at 300 x g for 5 minutes and the supernatant was transferred to a new Falcon tube. The 
cells were pelleted again at 3571 x g for 50 minutes at 4˚C. Supernatant was collected 
and filtered through 0.2 μm syringe filters. Sterile supernatant was stored at 4˚C until 
purification. 
 
2.6 Flow Cytometry 
Primary antibodies [Table 2.3] were diluted in 1X PBS and incubated with cells in 100 
μL volume for 45 mins on ice unless otherwise specified. Flow cytometric analysis of 
autofluorescent cells was performed without antibody incubation. Corresponding isotype 
control antibodies were used to detect non-specific antibody binding. Cells were washed 
with PBS, centrifuged and the supernatant decanted. Samples were incubated with 
appropriate secondary antibody [Table 2.3] in 100 μL 1X PBS for 25 minutes on ice. 
Cells were washed, resuspended in PBS and kept in the dark until analysis on a BD 
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LSRFortessa™ (BD Biosciences). In samples that were incubated with multiple colour 
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human CD124 PE 
BD Pharmingen 
(hIL4R-M57) 
20 μL/test FC 
Mouse IgG1 κ 
isotype PE  
BD Pharmingen 
(MOPC-21) 
20 μL/test FC 
Mouse anti-
human CD3 APC 




BioLegend (Ki-67) 5 μL/test FC 
Mouse IgG1 κ 
isotype APC/ 
PE/Cy7 
BioLegend (MOPC-21) 5 μL/test FC 
Mouse IgG 
isotype control 
Life Technologies 1:100 FC 
Human IgG 
isotype control 
Invitrogen 1:100 FC 
Mouse anti-
human CD8 FITC 
BioLegend (OKT8) 5 μL/test FC 




BioLegend (OKT4) 5 μL/test FC 
Mouse anti-
human PD-1 PE 
BioLegend (EH12.2H7) 5 μL/test FC 
Rat anti-human 
CD44 PE/Cy7 
BioLegend (IM7) 1:100 FC 
Mouse IgG1 κ 
isotype PE 
BioLegend (MOPC-21) 1:100 FC 
Rat IgG2b κ 
isotype PE/Cy7 






















GenScript (23D7G11) Neat,  
1:10, 1:100 
FC 








































GenScript (22F8C6) 0.1 mg/mL,  
0.15 mg/mL, 
0.01 mg/mL,  
0.015 mg/mL,  
0.005 mg/mL,  
0.0075 mg/mL,  
50 ng 
FC; WB 




GenScript (23D7D5) 0.1 mg/mL,  
0.15 mg/mL,  
0.01 mg/mL,  
0.015 mg/mL,  
0.005 mg/mL,  






GenScript (30E9C11) 0.1 mg/mL,  
0.15 mg/mL,  
0.01 mg/mL,  
0.015 mg/mL,  
0.005 mg/mL,  






GenScript (30H2B1) 0.1 mg/mL,  
0.15 mg/mL,  
0.01 mg/mL,  
0.015 mg/mL,  
0.005 mg/mL,  









0.1 mg/mL,  
0.01 mg/mL,  
0.001 mg/mL,  
0.0001 mg/mL  
FC 





Dako 1:500 WB 
Goat anti-mouse 
(GAM) PE 
Dako 1:100 FC* 
Goat anti-mouse 
FITC 
Dako 1:100 FC 
Goat anti-
human/mouse 
Alexa Fluor 647 
Jackson 
ImmunoResearch 






5 μL/test FC 
Table 2.3 Common antibodies used during the project.  
Primary and secondary antibodies used in various experiments are outlined by their 
specificity, clone name, company source, dilution and application. Hyb S.C. = Hybridoma 
Subclone; FC = flow cytometry; Co = Coomassie; WB = Western Blot. 
*This antibody was also used as a directly conjugated detection reagent for PSMA-
targeted CARs. 
 
2.7 Growth kinetics and antigen expression studies 
2.7.1 CTLL-2 and PBMCs 
The functionality of eFAP-4 was assessed by measuring the growth kinetics of CTLL-2 
and healthy donor PBMCs expressing the 4αβ chimeric receptor. The samples were 
diluted 1:4 in trypan blue and counted in a haemocytometer. Total cells/mL were 
calculated by [Average cells of squares counted]x(dilution factor)=cell number x 104/mL. 
CTLL-2 and PBMCs were plated in 48-well plates at 5x104 cells/well in 500 μL. Cultures 
were treated every 48-hours with either 100 IU/mL of IL-2 (Novartis), stated 
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concentrations of IL-4 (Peprotech) or eFAP-4, or no cytokine. After 4 days, 250 μL media 
was added. Cells were counted using a haemocytometer at various time points. 
Transduced PBMCs were analysed for proportions of CD8+ and CD4+ cells using flow 
cytometry. 
 
2.7.2 Prostate cancer (PCa) cells  
Wells of a 6-well plate were seeded with 105 cells in 2 mL of D10 media and cultured at 
37°C for pre-determined time points. Antigen expression was analysed after 24 hours in 
wells seeded at 5 x 105 cells in 2 mL. 
 
2.7.3 Conditioned media  
The prostate cancer cell lines were plated at 9 x 103 cells/well in a 24-well plate in D10 
media. PS1 cells were plated similarly at 3.6 x 104 cells/well and MRC5hT cells were 
plated at 8 x 104 cells/well.  Conditioned media was generated by plating cells at 105 per 
well in a 24-well plate in 1 mL D10 media. Twenty-four hours later the media was 
collected, spun at 800 x g for 10 mins and added 0.6 mL to respective cell cultures to 
assess growth kinetics or diluted 1:2 for 50% conditioned media cultures.  Cells were 
cultured in conditioned media for 24, 48, 72 and 96 hours. The fold change in growth of 
conditioned media cultures compared to fresh D10 cultures was analysed using MTT 
assay [section 2.8.3]. Fibroblast Activation Protein expression in PS1 and MRC5hT was 
assessed by flow cytometry at 24 and 72-hour time points. 
 
2.7.4 Co-culture ratio determination 
mNeptune transduced PS1 or MRC5hT and firefly Luciferase-tandem dimer (td)Tomato 
(LT) transduced PL, PLP, DU145 and DU145P cells were plated at various ratios in 24-
well plates in D10 media. Each well contained a total of 4 x 104 cells and co-cultures were 
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plated at stroma:prostate cancer ratios of 1:1, 2:1, 4:1, 8:1 and 16:1. Cultures were grown 
for 24 and 96 hours and then assessed by flow cytometry. The fluorescent reporters were 
used to identify each population and their relative percentage of the whole culture. Final 
values were presented as percentages of total cells that were single positive for either 
tdTomato or mNeptune. 
 
2.7.5 Prostate cancer and stroma co-culture growth kinetics 
mNeptune transduced PS1 and LT transduced PCa cells were plated at a 4:1 ratio in 24-
well plates in D10 media for a total of 4 x 104 cells/well. Cell lines were also plated as 
monocultures at 4 x 104 cells/well or at co-culture densities (PS1 = 3.2 x 104 cells/well; 
PCa = 0.8 x 104). mNeptune transduced MRC5hT and LT transduced PCa cells were 
plated similarly, but at an 8:1 ratio and with monoculture of 4 x 104 cells/well and 
corresponding co-culture densities (MRC5hT = 3.6 x 104; PCa = 0.4 x 104). Cells were 
cultured for 24, 48, 72 and 96 hours and cell number at each time point was assessed by 
flow cytometry using CountBright™ beads (Invitrogen). Cells were resuspended in 300 
μL PBS and 25 μL beads were added. Cell count was determined using the equation: (# 
cell events expressing relevant fluorescent reporter/ # bead events) X (Lot # 
concentration/ volume of sample). At 24 and 72 hours, FAP expression was assessed in 
the stromal cell lines by gating on mNeptune+ events. 
 
2.8 Killing assays 
2.8.1 Specification of cell death populations in killing assays 
The prostate cancer cell lines LT-PL, LT-PLP, LT-DU145 and LT-DU145P and the 
stromal cell line mN-MRC5hT were plated either alone or as mixed MRC5hT:PCa co-
cultures. This was performed at an 8:1 MRC5hT:PCa ratio for a total of 1 x 105 cells/well 
in a 24 well plate in 500 μL D10. Twenty-four hours later, 0.5 x 105 P4 or P4Tr CAR 
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[Figure 2.1] transduced T cells were washed with PBS, resuspended in 500 μL R5 and 
added to the MRC5hT/PCa monolayers for a 1:2 effector to target (E:T) ratio. Twenty-
four hours later, 200 μL supernatant was collected for cytokine analysis and the 
monolayers were trypsinised and resuspended in 300 μL D10 with 25 μL CountBright™ 
beads (Invitrogen) and analysed using flow cytometry. Cell number of each population 
(identified by their individual fluorescent reporters) was calculated as stated before 
[section 2.7.5] and compared to T cell untreated monolayers to determine the percent 
viability. 
 
2.8.2 Enzyme-Linked Immunosorbent Assay (ELISA) 
Cytokines secreted during the killing assays were quantified by ELISA. T cell production 
of the pro-inflammatory cytokine interferon-γ (IFN-γ) was analysed using the DuoSet® 
Human IFN-γ kit (R&D Systems) and manufacturer’s instructions were followed. 
Samples collected were diluted 1:30 with reagent diluent for the assay.  Additionally, the 
production of the proliferative cytokine IL-2 was measured using the Human IL-2 
Uncoated ELISA kit (Invitrogen) and manufacturer’s instructions were followed. 
Samples collected were diluted 1:15 with ELISA diluent for the assay. For both ELISA 
procedures, capture antibody was diluted and coated on 96 well plates. Plates were 
washed with wash buffer and blocked at room temperature for 1 hour with the appropriate 
reagent. Diluted samples and standards were added to the plates and incubated overnight 
at 4˚C. The detection antibody was added to washed plates and incubated at room 
temperature for 1 hour (IL-2) or 2 hours (IFN-γ). Plates were washed and a working 
dilution of streptavidin-HRP was added for 20 minutes (IFN-γ) or 30 minutes (IL-2) at 
room temperature in the dark. Plates were washed and incubated at room temperature in 
the dark with the substrate solution until the plate developed according to the standard 
curve (20-30 minutes). The stop solution was added and plates were read immediately. 
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The absorbance of both ELISAs were read on a FLUOstar Omega (BMG LABTECH) 
plate reader at 450 nm wavelength. 
 
2.8.3 Cell viability assay 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was 
used to determine cell viability of monolayers by the processing of MTT in metabolically 
active cells to produce purple formazan crystals. Cell supernatant was aspirated and cells 
were washed with PBS before 500 μg/mL MTT (Sigma) in D10 was added at 500 
μL/well. Cells were incubated at 37˚C for 1.5 hours. The MTT was aspirated and the 
resulting formazan crystals were dissolved in 300 μL dimethyl sulfoxide (DMSO) 
(VWR). Absorbance was read on a FLUOstar Omega (BMG LABTECH) plate reader at 
570 nm and the percentage of viability was calculated as: (absorbance/absorbance of 
untreated) x 100. 
 
2.8.4 Restimulation assays  
Continuous killing assays were set up to determine the persistence and proliferation 
capacity of CAR T cells with and without cytokine/immunocytokine supplementation. 
Monolayers of PCa/MRC5hT were plated as before [section 2.8.1]. Twenty-four hours 
later, 0.001 mg/mL eFAP-4 was added to the media of respective wells and incubated at 
37˚C for 1 hour. The media was aspirated and replaced with 500 μL fresh D10. P4 or 
P4Tr CAR T cells were washed with PBS, resuspended in 500 μL R5 media and added 
at 0.5 x 105 cells/well. Interleukin-4 (Peprotech) was added to the corresponding cultures 
at a 2 nM concentration. Twenty-four hours later, 100 μL supernatant was collected for 
cytokine analysis. At 72-96 hours after addition to monolayers, CAR T cells were 
collected, centrifuged at 800 x g for 5 mins, resuspended in 500 μL fresh R5 and counted 
using trypan blue. All of the CAR T cells were added onto fresh monolayers that had been 
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plated the day before and treated as above with either eFAP-4 or IL-4. T cell 
restimulations onto new monolayers were continued until killing was no longer observed.  
After the removal of CAR T cells, monolayers were subjected to MTT assays [section 
2.8.3] to determine killing capacity with and without eFAP-4/IL-4 addition. After 3 
antigen stimulations on monolayers and the last stimulation, CAR T cells were collected 
for flow cytometric analysis of markers including CD8, CD4, PD-1 and CD44. The 
CD8:CD4 ratio was recorded as the percentage of CD8+ cells/CD4+ cells and the 
deviation from the baseline. 
 
2.9 In vivo experiments 
All animal experiments were in accordance with the UK Home Office guidelines as 
outlined in project licence numbers 70/7794 and P23115EBF and under the authority 
granted by personal licence number, I31DF0FE0. The mice used were male NOD scid 
gamma (NSG) mice with ages ranging from 7-20 weeks old. Mice used for fluorescent 
imaging were kept on an alfalfa-free 5V75 diet (LabDiet®). 
 
2.9.1 Establishment of PCa/MRC5hT xenograft models 
The prostate cancer lines LT-PL, LT-PLP, LT-DU145 and LT-DU145P and the fibroblast 
line mN-MRC5hT were trypsinised, washed with PBS and mixed at an 8:1 ratio of 
MRC5hT:PCa. Complete matrigel matrix (BD BioSciences) was thawed overnight on ice 
in the cold room. A total of 9 x 105 mixed cells were resuspended in either 200 μL PBS, 
or resuspended in 100 μL PBS and mixed with 100 μL matrigel. Mice aged 11-20 weeks 
were injected with the tumour cells subcutaneously (SC) into the right flank using 23G 
needles (Terumo). Each group consisted of 3-4 mice. Tumour growth was monitored 
using bioluminescent imaging (BLI) and in vivo fluorescence imaging on an IVIS® 
Lumina Series III (Perkin Elmer) system. Bioluminescence imaging was performed after 
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administration of 200 μL of the substrate D-luciferin (Source BioScience) at 15 mg/mL. 
This was injected intraperitoneally (IP) using 29G insulin needles (Terumo). Mice were 
anaesthetised using vaporised isofluorane and imaged 12 minutes post injection. In order 
to image MRC5hT engraftment, mN-MRC5hT, PLP and DU145P were trypsinised, 
washed with PBS and mixed at an 8:1 ratio of MRC5hT:PCa. A total of 9 x 105 mixed 
cells or mN-MRC5hT alone were resuspended in 100 μL PBS and mixed with 100 μL 
matrigel and injected SC into the right flank of mice. Mice were anaesthetised and imaged 
using in vivo fluorescence imaging on an IVIS® Lumina Series III (Perkin Elmer). Weight 
was monitored as indications of toxicity. At the end of the in vivo experiment, mice were 
sacrificed using cervical dislocation and tumours were resected and temporarily stored in 
PBS. Tumour tissue was cut in half using a scalpel and either snap frozen in Tissue-Tek® 
OCT compound (Sakura) on dry ice and stored at -80˚C, or digested for flow cytometric 
analysis. Digestion involved weighing the tissue and mincing finely using a scalpel, 
followed by shaking incubation at 37˚C for 1 hour in Tissue Digestion Buffer at 3 mL/0.5 
g of tissue. Tissue was strained through 40 μm cell strainers (Fisher Scientific), washed 
with PBS, and single cell suspensions were stained for flow cytometry. 
 
2.9.2 In vivo efficacy study 
The prostate cancer cell line LT-PLPFAP, transduced to express the FAP antigen and the 
reporter gene LT, was trypsinised, washed with PBS and resuspended to a total of 2.5 x 
105 cells in 200 μL PBS. Mice aged 7-9 weeks were injected with the cells SC into the 
right flank using 23G needles (Terumo). Each group consisted of 3 mice. On day 12 post 
tumour inoculation, 250 pmols of either IL-4 (Peprotech) or eFAP-4 diluted in 200 μL 
PBS was injected IP into relevant treatment groups. T cells transduced with either P4 or 
P4Tr and expanded for 11 days in IL-4 [section 2.5.4] were washed with PBS and 
resuspended to 1 x 106 CAR+ T cells in 200 μL. CAR T cells were injected intravenously 
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(IV) 20 minutes after IL-4/eFAP-4 injection into corresponding treatment groups. Control 
group mice received 200 μL PBS injections IP and IV. A subsequent 3 IP injections of 
IL-4/eFAP-4 were administered 2, 4 and 7 days after CAR T cell injection. Tumour 
growth was monitored using BLI and weight recorded as stated above [section 2.9.1]. 




2.10.1 Haematoxylin and Eosin (H&E) staining 
Frozen tumours were cut into 6 μm sections using a cryostat and stained with 
Haematoxylin and Eosin by the Pathology Services at Bart’s Cancer Institute. 
 
2.10.2 Immunohistochemistry (IHC) 
Frozen tumours were cut into 6 μm sections using a cryostat and stained for mouse 
αSmooth Muscle Actin (αSMA) and mouse/human FAP (Abcam) by the Pathology 
Services at Bart’s Cancer Institute. 
 
2.10.3 Fluorescence microscopy 
Frozen tumours were cut into 6 μm sections using a cryostat by the Pathology Services at 
Bart’s Cancer Institute. Slides were fixed in 4% formaldehyde (VWR Chemicals), 
washed 3-times in PBS and mounted using ProLong™ Gold Antifade Mountant with 
DAPI (Invitrogen). After drying in the dark for 24 hours, slides were imaged on an A1R 
Confocal microscope (Nikon) using a 10x or 20x objective lens. DAPI was used to 
visualise nuclei and was excited by the 405 nm laser and read in the 450/50 detection 
range. For tdTomato and mNeptune, the 561nm laser was used to excite both 
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fluorophores. The tdTomato reporter was detected in the 525/50 range and mNeptune was 
detected with the 595/50 filter.  
 
2.11 Statistics 
Investigation for statistical significance was performed using GraphPad Prism software 
(version 7) and p values < 0.05 were considered significant. Data was subjected to a 
student’s unpaired t-test or a two-way ANOVA when stated. A Log-rank and Gehan-
Wilcoxon statistical test was applied to survival curve data to determine significance. 
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 Chapter 3: Development of a FAP-specific Interleukin-4 immunocytokine 
3.1 Introduction 
3.1.1 Role of Interleukin-4 in tumour immunology 
Amounting data has depicted opposing effects of endogenous and exogenous IL-4 on 
tumour biology. There is considerable evidence to suggest that endogenous (e.g. tumour-
associated) IL-4 can play an important role in cancer progression, contrasting with many 
anti-tumour activities that have been ascribed to exogenous IL-4. Pre-clinical models 
indicate that IL-4 promotes tumour progression and metastasis through multiple pathways 
(Venmar et al., 2014). Interleukin-4 polarises immunity towards a Th2 response which is 
generally considered to be less favourable to anti-tumour activity (Kumar et al., 2017). 
Illustrating this, higher levels of IL-4 have been detected in the tumour draining lymph 
node in a CT26 mouse colon cancer model, associated with skewing of the response 
towards a Th2 phenotype through increased expression of Th2 associated cytokines 
including IL-5, IL-10, IL-13 and TGF-b. The same upregulation of IL-4 in the draining 
lymph node is present in mouse tumour models of TC-1 lung and 4T1 breast carcinoma. 
When IL-4 is knocked down in the lymph nodes, a reduction in tumour growth is seen. 
In the same study, macrophages within the tumour microenvironment are polarized 
towards a M2 immunosuppressive phenotype as a result of IL-4 (Shirota et al., 2017). 
Analysis of the tumour microenvironment of primary breast cancer shows an expansion 
of IL-4 and IL-13 secreting CD4+ T cells. Dendritic cells within the breast cancer samples 
also express OX40L, which promotes a Th2 response, and supernatant from these breast 
cancer tissues polarize healthy dendritic cells further propagating the Th2 arm of 
immunity (Pedroza-Gonzalez et al., 2011). Moreover, IL-4 causes CD8+ T cells to 
become less cytotoxic (Erard et al., 1993, Kienzle et al., 2005). Tumour associated 
macrophages are a primary source of the protease cathepsin B and S which enhances the 
progression in vivo of RT2 tumours of a transgenic model of pancreatic cancer. These 
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tumours express IL-4 which is responsible for the upregulation of these cathepsins in the 
macrophages (Gocheva et al., 2010). In addition to dampening the host’s immune 
response to the cancer, IL-4 has been shown to promote cancer cell survival by inhibiting 
apoptotic pathways. Primary cancer cells from breast, colon, lung, prostate and bladder 
samples all have increased expression of the anti-apoptotic proteins phosphoprotein 
enriched in diabetes (PED), cellular FLICE-inhibitory protein (cFLIP), B-cell lymphoma-
extra large (Bcl-xL) and B-cell chronic lymphocytic leukaemia/lymphoma 2 (Bcl-2) as 
well as IL-4, consistent with autocrine/paracrine survival promotion. Following the 
abrogation of IL-4 signalling with a blocking antibody, there was a decrease in the 
expression of these anti-apoptotic proteins, accompanied by tumour cell sensitisation to 
chemotherapy and CD95 (Fas)-induced cell death (Conticello et al., 2004, Todaro et al., 
2008). Many cancer types exhibit an increased expression of IL-4Ra that correlates to 
tumourgenicity including colon, thyroid, pancreatic, colon cancer stem cells and 
fibrosarcoma cancer models (Koller et al., 2010, Li et al., 2008, Prokopchuk et al., 2005, 
Todaro et al., 2007, Todaro et al., 2006). Some evidence for IL-4 autocrine/paracrine 
signalling has been shown in various pancreatic cell lines and the lung carcinoma cell line 
A549 due to IL-4 expression and the effects that knocking down IL-4 has on the 
proliferation and stemness characteristics of the cancer cells (Prokopchuk et al., 2005, 
Zhao et al., 2018). However, these studies do not address the expression of IL-13Ra 
which is necessary for IL-4 signalling in non-hematopoietic cells (Aman et al., 1996, 
Palmer-Crocker et al., 1996). High serum levels of IL-4 are found in colon, gastric, 
oesophageal and metastatic melanoma cancer patients (Baier et al., 2005, Cardenas et al., 
2018, Gao et al., 2014b, Nevala et al., 2009). Circulating IL-4 levels are correlated with 
more advanced disease in renal cell carcinoma, pulmonary adenocarcinoma and prostate 
cancer and is linked to increased chances of relapse in NSCLC patients after resection 
(Goldstein et al., 2011, Li et al., 2014a, Onishi et al., 2001, Takeshi et al., 2005). 
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In contrast to the effects of endogenous IL-4, several studies suggest that exogenous IL-
4 exerts anti-tumour effects against different solid tumours. In part, this is mediated 
through direct interaction with the cancer cells and is further contributed indirectly via 
the recruitment of eosinophils and CD8+ T cells to the site of disease (Golumbek et al., 
1991, Obiri et al., 1993, Tepper et al., 1992, Topp et al., 1995). Studies have shown 
exogenous IL-4 significantly inhibits the growth of colon and breast carcinoma cell lines. 
Furthermore, IL-4 reverses the growth advantage effects of oestradiol in breast carcinoma 
similar to tamoxifen and, together, IL-4 and tamoxifen elicit an additive response (Toi et 
al., 1992). Interleukin-4-induced growth inhibition and an increase in apoptosis has been 
observed in breast cancer cells which is partially explained by phosphorylation of STAT6 
(Gooch et al., 2002). There is a reduction in volume of established colon cancer tumours 
when mice are vaccinated with IL-4 expressing colon carcinoma cells. Granulocytes are 
implicated in early anti-tumour response in this model, while CD8+ and CD4+ T cells are 
responsible for long-term immunity. When tumour cell vaccines are engineered to release 
IL-4 together with IFNa, Th1 polarised anti-tumour responses are induced (Eguchi et al., 
2005). A further potential therapeutic action of exogenous IL-4 relates to its anti-
angiogenic properties (Volpert et al., 1998). One study has shown that an IL-4 secreting 
plasmacytoma tumour causes stromal fibroblasts to acquire a less angiogenic phenotype 
in the tumour microenvironment, thereby facilitating IL-4 mediated tumour rejection 
(Schuler et al., 2003). These pre-clinical studies prompted early clinical trials involving 
administration of exogenous IL-4, which disappointingly resulted in low anti-tumour 
efficacy. Nonetheless, administration of IL-4 was generally well-tolerated with few 
adverse effects, establishing a safe dose range for this agent (Gilleece et al., 1992, Majhail 
et al., 2004, Margolin et al., 1994, Prendiville et al., 1993, Stadler et al., 1995, Taylor et 
al., 2000).  
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The contradictory role of IL-4 in cancer progression is still being investigated. In part, 
the contrasting effects reported for IL-4 could be related to the study of different cancer 
types, cell lines and/ or model systems (Olver et al., 2007). Additionally, as indicated 
above, there is considerable evidence that the divergent effects of this cytokine are due to 
the source of IL-4 – in other words, whether it is of endogenous (intratumoural) or 
exogenous (therapeutic) origin. In the former case, while levels are elevated, they 
generally do not reach very high concentrations. By contrast, therapeutic delivery of 
overexpressed quantities of the cytokine can achieve local concentrations that vastly 
exceed those that occur in physiological or pathological states (Li et al., 2009). Therefore, 
high levels of intratumoural IL-4 achieved through the targeted administration of this 
cytokine could provide therapeutic benefit in the treatment of malignancies. 
 
3.1.2 Use of IL-4 to support CAR T cell expansion 
In order to harness endogenous IL-4 in the microenvironment of tumours, the chimeric 
cytokine receptor 4αβ was developed. To construct 4αβ, the ectodomain of IL-4Rα has 
been coupled to the βc endodomain subunit of IL-2R/IL-15R. Upon binding of IL-4, this 
synthetic receptor co-localises with and signals together with the common-gamma chain 
via the JAK/STAT pathway (Wilkie et al., 2010). When co-expressed with a CAR, IL-4 
binding to 4αβ will produce an IL-2-like proliferation signal and CAR T cell specific 
expansion is achieved. Therapeutically, this cytokine receptor can harness increased 
endogenous IL-4 within tumours in order to support CAR T cells at this location. This 
chimeric cytokine receptor system also offers the possibility that CAR T cells may benefit 
from exogenous IL-4 administration. A third potential use of 4αβ is to achieve selective 
enrichment of CAR transduced T cells during ex vivo manufacture of cell products. This 
application of 4αβ is currently being used to enable CAR T cell manufacture from a blood 
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draw rather than a leukapheresis in a phase I clinical trial in patients with relapsed 
refractory head and neck cancer (van Schalkwyk et al., 2013). Early studies used this type 
of chimera to test the signalling capacity of the IL-2Rβ subunit in various T cell subsets 
(Gasser et al., 2000, Izuhara et al., 1993). More recently, a related chimeric receptor has 
been designed to take advantage of the increased levels of IL-4 associated with 
malignancy. Akin to 4αβ, this receptor utilizes the ectodomain of IL-4Rα, but is 
genetically conjugated to the endodomain of IL-7Rα. In animal models, this chimeric 
cytokine receptor promotes anti-tumour activity and T cell proliferation when expressed 
in EBV-specific T cells (Leen et al., 2014) and PSCA-targeted CAR T cells (Mohammed 
et al., 2017). 
 
To ensure the CAR T cell specific proliferation and persistence in vivo for which the 4αβ 
receptor was designed, it may be beneficial to deliver additional rIL-4 to the tumour 
microenvironment in a targeted fashion. Conceptually, this would be preferable to IL-2 
co-administration due to the adverse clinical safety profile associated with high dose IL-
2 therapy (Rosenberg, 2014). Moreover, use of the 4αβ system provides a selective 
stimulus to the CAR T cells, reducing the enrichment of undesired cell types such as 
regulatory T cells. Furthermore, directed cytokine delivery to the tumour would lower the 
effective concentration required and decrease systemic reactions. With this foundation, 
the aim of this project was to target IL-4 to the tumour microenvironment using a FAP-
specific antibody, thereby potentiating the proliferation and survival of co-administered 
CAR T cells that express the 4αβ receptor [Figure 3.1]. In particular, I set out to evaluate 
this system in support of the P28z second generation CAR that is targeted against PSMA 
(Maher et al., 2002). Human T cells engineered to express P28z have previously shown 
anti-tumour activity both in vitro (Maher et al., 2002) and in vivo against PSMA+ prostate 
tumours (Emami-Shahri et al., 2018, Zhong et al., 2010). 
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Figure 3.1 Illustration of project concept.  
Localisation of the immunocytokine (IC) and the PSMA-targeting CAR (P28z) T cells 
co-expressing the chimeric 4αβ receptor (P4) to the tumour site via targeting the stroma 
and the prostate cancer cells. In this case, the immunocytokine is shown as comprising an 
scFv (dark green and lilac rectangles) coupled to IL-4 (orange). 
 
3.1.3 Specific aims 
1. Generate a FAP-specific scFv 
2. Design and develop a FAP-targeted immunocytokine conjugated to IL-4 
3. Determine the functionality of the immunocytokine 
 
3.2 Results 
3.2.1 FAP-specific hybridoma generation and screening 
Mouse hybridomas specific for FAP were generated by GenScript following 
immunisation with the extracellular domain of the protein followed by a boost of 
HT1080-FAP+ cells. After screening of resultant hybridoma supernatants for binding to 
human (h) and murine FAP, 19 hybridoma clones were selected for further study. Murine 
FAP shares 89% homology with hFAP and cross-species binding ability was considered 
desirable for future toxicity assessments in mouse models (Niedermeyer et al., 1997). 
Antibody-containing supernatants were screened for their ability to bind to membrane-
bound FAP specificity using the HT1080 sarcoma cell line that lacks FAP, making 
A
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comparison with an engineered version that highly expresses FAP [Figure 3.2A]. Using 
this method, 7 cell lines showed differential binding to cell-bound FAP [Figure 3.2B] and 
these were subsequently subcloned by GenScript (the two hybridoma lines 27C12 and 
29E3 could not be subcloned). 
 
 
Figure 3.2 FAP-specificity screening of hybridoma supernatants. 
Unpurified supernatant was collected from the indicated hybridoma cell lines and added 
at a 1:10 dilution to A) FAP- sarcoma cell line HT1080 and B) HT1080 cells that had 
been engineered by retroviral transduction to be FAP+. C) Seven hybridoma cell lines 
showed preferential binding to HT1080-FAP when compared to unmodified H1080 cells 
and these were sent for subcloning (n=1). aFAP is a commercially available mouse IgG 
FAP-specific antibody which was used as a positive binding control. This experiment was 
performed once prior to subcloning of hybridomas. 
 
Two subclones were generated from each original clone and these were rescreened for 
production of FAP-specific antibody using the FAP- and FAP+ HT1080 cell lines [Figure 
3.3]. The two original clones that showed the highest FAP binding, 30E9 and 30H2, 
maintained the highest FAP-specificity within their subclones. One subclone was chosen 
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from each original clone and taken forward in the project as follows 30H2B1, 22F8C6, 
23D7D5 and 30E9C11 (further referred to by their subclone name which is underlined). 
All antibodies produced by these hybridomas were subclass IgG1, except C6 which was 
IgG2a. Since supernatants from 26F6A3 or 26F6A11 failed to bind membrane-bound 
FAP, these subclones were abandoned.  
 
 
Figure 3.3 FAP-specificity of hybridoma subclones. 
The subclones generated were screened again for A) FAP specific binding to 
HT1080FAP+, or B) Non-specific binding to HT1080. Unpurified supernatant was 
filtered and incubated either neat (no dilution in media) or at different dilutions in D10 
media (1:10 = 1 part subclone supernatant: 9 parts media; 1:100 = 1 part subclone 
supernatant: 99 parts media) (mean + SEM, n=3). 
 
Selected hybridoma supernatants were purified using Protein G GraviTrap columns (GE 
Healthcare). A Coomassie blue stain of an SDS-PAGE gel was performed to assess purity 
and to observe any aggregation. Appropriate banding patterns for IgG were visualised in 
reduced and non-reduced conditions. Under reduced conditions, the heavy chain can be 
seen at 55 kDa and the light chain is at 25 kDa while the non-reduced antibody is seen as 
a band at 150kDa [Figure 3.4A]. A western blot was performed using an anti-mouse IgG 
detection antibody and produced similar results as the protein stain for the reduced 
conditions [Figure 3.4B]. The two bands seen for the IgG2a C6 hybridoma in both the 
protein stain and western blot are most likely due to asymmetrical glycosylation (Ha et 
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al., 2011).  A BCA assay quantification of the newly purified hybridoma antibodies 
showed concentrations over 1mg/mL in each case [Figure 3.4C]. 
 
Figure 3.4 Purification and quantification of the hybridoma supernatant. 
Purification of the hybridoma supernatants yielded no protein contamination or 
aggregation as seen by A) Coomassie stain or B) Western blot. C) BCA assay 
quantification indicated that high protein concentrations were obtained for all purified 
antibodies. For both A) and B) the positive control was a commercially available mouse 
IgG FAP-specific antibody. 
 
Freshly purified antibody supernatants were rescreened for FAP-specificity at various 
concentrations. The first flow cytometric analysis showed relatively high binding 
capacity of the B1 and C11 antibodies and optimal binding capacity in 0.01 mg/mL at 
64.5% and 29% respectively [Figure 3.5A]. However, the following screen performed 3 
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3.5B]. All subsequent screenings indicated a further reduction in binding and no non-
specific binding [Figure 3.5C&D]. When protein levels were quantified again, 
concentrations were relatively unchanged except for C6, which had decreased by more 
than half [Figure 3.5E]. 
 
Although no protein aggregates were seen in the Coomassie blue stain [Figure 3.6A], it 
is possible that non-covalent aggregates were present but not-visible due to SDS-
mediated denaturation in the gel assay. To rescue binding capabilities, antibodies were 
spun at 18,407 x g (14,000 RPM) for 5 mins to sediment any large aggregates. The 
supernatant was tested again for FAP-specific binding [Figure 3.6]. This method appeared 
to restore some of the antibody binding capacity in B1 and C11 at 0.01 mg/mL, suggesting 
potential aggregate formation after purification. There was no non-specific binding to 





 - 117 - 
 
Figure 3.5 FAP-specificity screening of newly purified hybridoma supernatants. 
FAP-specific binding of antibody purified from hybridoma supernatants was investigated 
at various times after antibody purification using HT1080-FAP cells. A) Initial assay, 
performed immediately after purification, B) The second assay was performed 3 days 
later and C) combined analysis of the subsequent 3 assays (mean + SEM, n=3). D) No 
non-specific binding to HT1080 cells was observed at any time throughout the analysis 
(mean + SEM, n=3). There was no loss of FAP expression on the HT1080-FAP cell line 
as seen with binding of the commercial aFAP. E) A BCA assay showed that all antibody 
concentrations remained above 1 mg/mL, except for C6. 
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Figure 3.6 Screening of centrifuged and purified antibodies. 
Purified supernatant was centrifuged to remove aggregates and screened again for the 
ability to bind FAP by addition to HT1080-FAP cells at the indicated concentrations. An 
isotype control was used to set the gate. Results shown were performed in a single 
experiment. 
 
The antibodies B1 and C11 were produced, purified, quantified and screened again. This 
second production of the antibodies yielded lower concentrations that had been obtained 
previously [Figure 3.7E]. Both antibodies showed optimal FAP-binding at 0.01 mg/mL, 
albeit at lower levels than the 1st production round [Figure 3.7A]. As seen before, the 
binding capacity dropped between the first and second screening (8 days apart) and C11 
had lost most of its FAP-specificity [Figure 3.7B]. In order to exclude loss of binding 
signal due to internalisation of the antibodies during the incubation period, primary 
incubations were maintained for 15 minutes, 30 minutes and 45 minutes on ice. B1 in 
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[Figure 3.7C]. This suggests that the loss of FAP-specificity is not due to antibody 
internalisation. At no point was non-specific binding to HT1080 seen [Figure 3.7D]. 
 
 
Figure 3.7 Screening of FAP-specificity of purified antibody after 2nd round of 
production. 
Purified antibody derived from B1 and C11 were A) screened for FAP-binding after 
purification by addition to HT1080-FAP cells at the indicated concentration. B) They 
were similarly assayed once again 8 days later. C) The antibodies were tested at a 
concentration of 0.01 mg/mL with incubation times of 15, 30 and 45 minutes. A-C) 
Antibodies were screened against HT1080-FAP. D) The antibodies never bound to the 
FAP- HT1080 cell line (mean + SEM, n=3). E) A BCA assay was used to quantify the 
purified antibodies. 
 
3.2.2 Humanized scFv-Fc development from FAP-specific antibodies 
Because B1 and C11 showed optimal FAP specificity, the variable regions were 
sequenced by GenScript and scFvs designed. Codon optimisation was undertaken for 
human cell production. Two versions of the B1-scFv were designed with reversal of the 
heavy and light chain variable region positioning [Figure 3.8]. A previously validated 
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control for FAP binding. These scFv sequences were cloned into a pUC57 background 
vector for E. coli transformation and expansion. 
 
 
Figure 3.8 Design of scFvs for B1, C11 and ESC11. 
All antibody fragments were designed to contain the CSPG4 heavy chain leader sequence 
except C11 for which its codon optimised endogenous heavy chain leader sequence was 
used, the heavy chain variable region (VH), the light chain variable region (VL) and a 15 
amino-acid flexible serine-glycine linker. B1 included two orientations of the variable 
regions for testing with either the VH in the first position, or the VL in the first position. 
 
The method of Polymerase Incomplete Primer Extension (PIPE) cloning was used to 
insert the new scFv sequences into a human heavy chain IgG1 backbone. The designated 
scFvs were subcloned upstream of the human IgG hinge and Fc portion to yield scFv-IgG 
chimeric proteins for production in mammalian cells [Figure 3.9]. 
A
CSPG4&
Leader B1&VH (SGGGG)3 B1&VL
CSPG4&
Leader B1&VL (SGGGG)3 B1&VH
C11&
Leader C11&VH (SGGGG)3 C11&VL
CSPG4&
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Figure 3.9 PIPE cloning method diagram 
This diagram indicates where the scFv insert recombines into the vector by replacing the 
leader sequence (L), variable heavy chain (VH) and the constant heavy chain 1 (CH1). The 
hinge and constant heavy chain 1 (CH1) and 2 (CH2) remain in the vector. Dotted lines 
indicate the PCR fragments generated. 
 
The PCR products were visualised on an agarose gel and were of the correct predicted 
size. The backbone PCR fragments produced bands as follows 1: 3726 bp, 2: 2890 bp and 
3: 2422 bp. The scFv PCR bands were as follows: C11: 774 bp and B1HL/B1LH: 762 bp 
[Figure 3.10A]. The backbone PCR products yielded the same bands for the second round 
of PIPE cloning with ESC11 correctly sized at 813 bp [Figure 3.10B]. Sanger sequencing 
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Figure 3.10 PIPE cloning PCR product analysis. 
The PCR products were visualised on an agarose gel for A) scFv inserts C11, B1HL and 
B1LH and B) ESC11. A 1 kb ladder (L) was used. 
 
Following expression in Expi293FÔ mammalian cells and purification on a Protein G 
column, the scFv-Fcs were stained with Coomassie blue on an SDS-PAGE to assess their 
purity. This analysis revealed the presence of unidentified bands in reduced and non-
reduced conditions for B1HL, B1LH and C11 [Figure 3.11A]. Aggregation was also seen 
in the non-reduced B1HL and B1LH scFv-Fcs, indicated by the appearance of streaks and 
protein stuck in the wells. The ESC11 scFv-Fc displayed bands expected for reduced (55 
kDa) and non-reduced (110 kDa) conditions [Figure 3.11B]. The three distinct bands in 
the non-reduced condition are most likely due to alternative glycosylation. Protein yield 
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Figure 3.11 Purification and quantification of the scFv-Fc recombinant antibodies. 
Purified proteins were visualised on an SDS-PAGE with Coomassie blue stain for A) the 
hybridoma derived scFv-Fcs B1HL, B1LH and C11 (arrowed). B) The ESC11 scFv-Fc 
was visualised in reduced (ESC11-R) and non-reduced (ESC11-NR) conditions. For both 
A) and B) the Novex Sharp pre-stained protein standard was used as the ladder (L). C) 
The protein concentration was quantified using a Nanodrop. 
 
Despite the apparent contaminating bands present in the new hybridoma scFv-Fc 
preparations, they were screened against the HT1080FAP+ and FAP- cell lines to establish 
specificity of binding to FAP. Initial screening of the new scFv-Fcs indicated a high level 
of binding to FAP at concentrations of 0.1 mg/mL for both B1HL and B1LH, but 
relatively no binding for C11 [Figure 3.12A]. A small amount of non-specific binding 
was seen at the highest concentration of B1HL and B1LH. However similar to the native 
hybridoma antibodies, there was a rapid reduction in FAP binding capacity over the next 
4 weeks. The hybridoma scFv-Fcs showed a higher level of binding to the FAP- cell line 
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expression as demonstrated by maintained staining with a commercial aFAP antibody. 
To further exclude a spurious anomaly attributable to the HT1080 cells, two other cell 
lines were assessed to provide confirmatory evidence that FAP-specific binding had been 
lost.  The pancreatic stromal cell line (PS1) naturally expresses FAP and was used to 
determine specific binding capacity. The prostate cancer cell line (PL) expresses little to 
no FAP and was used to evaluate non-specific binding. The same pattern was observed 
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Figure 3.12 FAP-specificity evaluation of the hybridoma scFv-Fc antibodies. 
The hybridoma scFv-Fc engineered antibodies were first screened for their ability to bind 
to the A) HT1080-FAP (left) and HT1080 cell lines (right). B) After 7 days, binding 
analyses to HT1080-FAP (left) and HT1080 cells (right) was repeated (mean + SEM, 
n=3). C) Hybridoma scFv-Fcs were screened for their ability to bind to FAP+ PS1 cells 
(left) and FAP- PL cells (right). A commercially available aFAP antibody was used as a 
positive control and a relevant isotype was used to set the gate. 
 
By contrast to the new hybridoma-derived scFv-Fc preparations, analysis of the ESC11 
scFv-Fc confirmed high FAP-specificity [Figure 3.13A] with negligible non-specific 
binding [Figure 3.13B]. This was the case even at the lowest concentration of 0.0001 
mg/mL, suggesting a strong interaction with FAP. The binding kinetics of ESC11 scFv-
Fc were analysed by Biacore. High affinity of the ESC11 scFv-Fc for FAP was 
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indicated two kinetically different reactions. The prevailing slow KD had a value of 120 
pM and the fast KD, which makes up 9.3% of the reactions, had a value of 40 nM [Figure 
3.13C]. More than 90% of the protein-protein interaction between ESC11 scFv-Fc and 
rhFAP has a strong binding in the picomolar range. 
 
 
Figure 3.13 FAP-specificity and binding kinetics of ESC11 scFv-Fc. 
Purified ESC11 scFv-Fc was assayed for its ability to bind to A) HT1080-FAP cells, 
indicating specific binding and B) HT1080 cells, for non-specific binding (mean + SEM, 
n=3). B) Binding kinetics at different concentrations were plotted. The KDfast and the 
KDslow were calculated using a two-phase decay model fitted to the graph. 
 
3.2.3 IL-4 immunocytokine design and function 
Because ESC11 showed superior stability and FAP-specificity, this was taken forward 
into production of the immunocytokine designated eFAP-4. Recombinant human IL-4 
was linked to the C-terminus of the ESC11 scFv via a 15-amino acid serine-glycine linker 
[Figure 3.14A]. eFAP-4 was cloned into a pUC57 backbone by GenScript, and then PIPE 
cloning was used to insert the immunocytokine into the UCOE02 lentiviral vector 
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(lacking the hinge-Fc portion). The PCR fragments produced bands of predicted size 
showing backbone PCR fragment 1 at 3042 bp, fragment 2 at 2890 bp, fragment 3 at 2422 
bp and eFAP-4 at 1248 bp when analysed on an agarose gel [Figure 3.14B]. These 
products were validated by sequencing. The immunocytokine was produced in 
Expi293FÔ mammalian cell cultures again and was purified using an antigen affinity 
column (ThermoFisher Scientific). The column covalently linked aIL-4 antibodies to 
activated agarose beads to immobilise eFAP-4. The success of this method of purification 
was seen on a Coomassie blue stained SDS-PAGE gel in non-reduced conditions [Figure 
3.14C]. In the unpurified supernatant, the correct band of 49 kDa was present along with 
additional protein bands. After purification, only the eFAP-4 band remained, with no 
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Figure 3.14 Design, production and purification of the eFAP-4 immunocytokine. 
To design the immunocytokine, A) recombinant human (rh) IL-4 was conjugated to the 
previously designed FAP-specific ESC11 scFv. B) PIPE cloning products were visualised 
on an agarose gel. C) Unpurified and column purified supernatants were analysed on a 
non-reduced Coomassie blue stained SDS-PAGE gel at labelled loading concentrations. 
Arrow indicates the bands representing the eFAP-4 immunocytokine (IC). D) Purified 
eFAP-4 was quantified using a Nanodrop with a calculated extinction coefficient using 
the ExPaSy ProtParam tool.  
 
Purified eFAP-4 was assessed for FAP-specificity using HT1080-FAP cells, making 
comparison with parental HT1080 cells. The immunocytokine retained its original 
specificity for FAP and had no off-target binding activity [Figure 3.15]. While the 
percentage binding was the same across the different concentrations tested [Figure 3.15A-
B], the median fluorescence intensity was the greatest at the concentration of 0.001 
mg/mL and significantly decreased at a concentration of 0.0001 mg/mL [Figure 3.15C-
D]. For this reason, it was decided that this is the optimal immunocytokine concentration 
to bind cell-bound FAP. 
CSPG4&
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Figure 3.15 FAP-specificity of the eFAP-4 immunocytokine. 
Specificity of the eFAP-4 immunocytokine for FAP was quantified by performing 
binding studies with A) HT1080-FAP cells (specific binding) and B) HT1080 cells (non-
specific binding) (mean + SEM, n=3). C) The median fluorescent intensity (MFI) signal 
was also determined for FAP-specific binding to HT1080-FAP cells and D) FAP non-
specific binding to HT1080 cells (mean + SEM, n=3). Statistical significance was 
determined using a student’s t-test (* = p < 0.05). 
 
To confirm these findings, similar binding studies were performed using two FAP- 
prostate cancer cell lines (PLP and DU145P) and one stromal line, (MRC5hT), which 
strongly expresses FAP [Figure 3.16]. As expected, the immunocytokine did not bind the 
FAP- prostate cancer lines. By contrast, eFAP-4 and the commercially available aFAP 
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Figure 3.16 eFAP-4 binding to other cell lines. 
The eFAP-4 immunocytokine was incubated with the two FAP- prostate cancer cell lines, 
PLP and DU145P, and the FAP+ stromal cell line MRC5hT at 0.001 mg/mL. Binding of 
eFAP-4 was subsequently detected with an aIL-4 antibody. Expression of FAP in 
MRC5hT cells was confirmed with a commercial aFAP antibody. Data are representative 
of 3 replicates which yielded similar results. 
 
The functionality of the cytokine signalling properties of eFAP-4 was tested using an IL-
2 dependent murine leukaemic cell line, CTLL-2. While the parental line requires IL-2 to 
survive and proliferate, expression of 4ab renders these cells IL-4 responsive (Wilkie et 
al., 2010). Following retroviral transduction, expression of 4ab in CTLL-2 cells was 
determined by staining for the human IL-4Ra [Figure 3.17A]. CTLL-2 and CTLL-4ab 
cells were cultured for 6 days with either IL-2, IL-4 or eFAP-4 and were counted to 
monitor their expansion [Figure 3.17B]. Parental CTLL-2 cells only expanded in the 
presence of IL-2. By contrast, CTLL-4ab expanded in all cytokine conditions but failed 
to expand in the absence of cytokine support. There was no statistical difference between 
the various concentrations of IL-4 and eFAP-4, suggesting comparable 4ab chimeric 
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Figure 3.17 eFAP-4 signalling through the 4ab receptor. 
Functional binding of the IL-4 portion of eFAP-4 was validated using a CTLL-2 model 
system.  A) CTLL-2 parental cells were transduced to express the 4ab chimeric cytokine 
receptor. Expression was demonstrated by staining with anti-CD124-PE. B) Cell growth 
was determined by manual counting at days 3 and 6 post seeding of 5x104 cells/well 
(mean + SEM; n=3). CTLL-2 and CTLL-2-4ab cells were cultured with the indicated 
concentrations of IL-2, IL-4 or eFAP4. A two-way ANOVA test was used to determine 
statistical significance between the cytokine conditions (n.s. – not significant) (2 nM 
eFAP-4 vs. no cytokine = **) (** = p < 0.01). 
 
3.3 Discussion 
Fibroblast activation protein (FAP) has been validated as a tumour stroma-associated 
target for cancer immunotherapy. Co-expression of the 4ab receptor with a CAR results 
in effective expansion of CAR+ T cells when cultured with IL-4 (Wilkie et al., 2010). 
This led to the hypothesis that the anti-tumour activity of CAR+ T cells that co-express 
the 4ab receptor could be potentiated through the FAP-dependent delivery of IL-4 to the 
tumour microenvironment at high concentration. To exploit this for therapeutic benefit, I 
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would not only exert a net anti-tumour effect in its own right, but would also potentiate 
the anti-tumour activity of 4ab-expressing CAR T cells. 
 
My initial attempt to generate an in-house FAP-specific antibody via hybridoma 
technology yielded promising subclones. However, further manipulation of derived 
monoclonal antibodies demonstrated that they had poor stability. This was indicated by 
rapid loss of FAP-specificity for the native antibody conformations and a loss of 
specificity and aggregation of the hybridoma-derived engineered scFv-Fc. This could be 
explained through several factors. When FAP-binding capacity of original hybridoma-
derived antibodies was lost, they were centrifuged to remove aggregates. Rescreening of 
these antibodies showed a moderate rescue of binding. This result suggested the presence 
of aggregation, even though none could be visualised on a gel. Murine hybridoma 
aggregation can occur at many stages of production due to high temperature of the 
culturing environment, low pH during culture and purification, agitation and adsorption 
to container surfaces (Vázquez-Rey and Lang, 2011). The occurrence of these obstacles 
in both the native conformation and engineered version of the hybridoma antibodies, but 
not the ESC11 engineered antibody, suggests that there is an inherent stability issue with 
the hybridoma variable domains. The scFv-Fc antibody format has been validated 
(Powers et al., 2001) and shown to be compatible with successful expression in 
mammalian cells (Cao et al., 2009, Jager et al., 2013). Therefore, I think a reasonable 
explanation for the instability of the hybridoma-derived antibodies could be due to 
imperfect folding interactions of the variable domains. This could lead to an increased 
incidence of unfolding and subsequent aggregation of the protein (Honegger, 2008). 
Future manipulation of these FAP-specific hybridomas could investigate the benefits of 
humanisation through cloning of the CDRs into an established human IgG1 backbone. 
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This would remove the majority of the variable domains and could allow for greater 
protein expression and stability. 
 
In order to move forward with the project, the validated FAP-specific antibody ESC11 
was selected. This human Fab was originally produced via phage display and cloned into 
an IgG1 backbone for further testing. Preliminary assessment showed strong binding to 
human and mouse FAP, no cross-reactivity with the closely related CD26 protein and 
overnight internalisation of the antibody upon antigen recognition (Fischer et al., 2012). 
Internalisation was later shown to ensue when the antibody had a bivalent format, and 
monovalent Fabs did not share this characteristic. For this reason, I designed a 
monovalent immunocytokine in which the variable domain sequences of the ESC11 
heavy and light chain were joined to generate an scFv. The binding kinetics seen in this 
study indicate a stronger affinity of ESC11 to hFAP than previously described (10 nM) 
(Renner et al., 2012). This is probably due to the format of the scFv tested. The original 
publication analysed the binding affinity of a Fab fragment while I produced and tested a 
dimeric scFv-Fc. Analysis of this material demonstrated that it had a slower off-rate and 
thus a higher KD (MacKenzie et al., 1996). The ESC11 antibody also binds to murine 
FAP with a KD of approximately 51 nM (Renner et al., 2012). 
 
The CTLL-2 murine cell line provided a convenient model system to test the ability of 
eFAP-4 to signal through the 4ab chimeric receptor. CTLL-2 cells are absolutely growth 
factor dependent and are generally propagated in IL-2 for this reason (Gillis and Smith, 
1977). Cells engineered to express 4ab can also be cultured in human IL-4. Binding of 
this cytokine is harnessed to deliver an IL-2/15 signal through the chimeric receptor, 
which can associate with the endogenous mouse common gamma chain that is also 
present in these cells (Wilkie et al., 2010). Since human IL-4 is inactive on the mouse IL-
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4 receptor orthologue, CTLL-2 cells that do not express 4ab cannot survive in human IL-
4. Addition of the eFAP-4 immunocytokine to CTLL-4ab but not parental CTLL-2 cells 
elicited strong proliferation that rivalled the effect of rhIL-4 alone. This immunocytokine 
also maintained comparable binding specificity and strength for FAP as was detected 
using the parental antibody. The functionality of both ends of eFAP-4 have been validated 
and further testing will be undertaken with human CAR+ T cells. 
 
3.4 Summary 
• Two hybridoma cell lines, B1 and C11, showed superior FAP-specificity and were 
used to design scFv-Fc antibodies along with ESC11. 
• Instability of the hybridoma-derived scFv-Fcs led to the advancement of the 
ESC11 engineered antibody only. 
• ESC11 displayed high specificity and affinity for membrane-bound and soluble 
FAP. 
• The immunocytokine eFAP-4 fully retains the binding capacity of the ESC11 
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 Chapter 4: Effects of eFAP-4 on P4 CAR T cells in vitro 
4.1 Introduction 
4.1.1 Prostate Specific Membrane Antigen (PSMA) as a target for immunotherapy 
Prostate Specific Membrane Antigen was first identified as a transmembrane 
glycoprotein expressed by the prostate cancer cell line LNCaP (Horoszewicz et al., 1987, 
Israeli et al., 1993). Enzymatic activity of PSMA has been seen with the neurotransmitter 
neuropeptide N-acetylaspartylglutamate (NAAG) and polyglutamated folates (Carter et 
al., 1996, Pinto et al., 1996). More recently, the folate hydrolase activity of PSMA has 
been implicated in prostate tumour progression through phosphoinositide 3-kinase (PI3K) 
activation using vitamin B9 as a substrate (Kaittanis et al., 2018). While strong mRNA 
expression is seen in prostate malignancies, detectable levels of PSMA are found in 
normal prostate tissue, brain tissue, salivary glands and the small intestine (Israeli et al., 
1994). Protein expression is low in normal prostate epithelia and benign hyperplasia, but 
increased expression correlates with the aggressiveness of the disease, Gleason score and 
resistance to hormone therapy (Kawakami and Nakayama, 1997). In fact, PSMA 
expression in prostate tumours has been shown to increase following androgen 
deprivation therapy (Wright et al., 1996). The highest PSMA intensity is seen in 
metastases, making it a good marker for metastatic disease (Wright et al., 1995). Apart 
from prostate cancer tissue, PSMA is also a marker of neovasculature found in many 
common solid tumours. Renal cell, urothelial, colon, lung, breast, testicular, 
neuroendocrine, glioblastoma, melanoma, pancreatic and prostate carcinomas as well as 
soft tissue sarcoma have shown PSMA+ vasculature that is not present in healthy tissue 
endothelium (Chang et al., 1999b, Liu et al., 1997, Silver et al., 1997). The selective 
expression in malignant tissues designates PSMA as a potential therapeutic target. 
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Since the discovery of PSMA, numerous therapeutic applications have been developed to 
exploit this tumour specific antigen. Clinical trials have been designed to test PSMA 
targeting therapies including dendritic cell vaccines, DNA or recombinant protein 
vaccines as well as naked or radio-/drug-conjugate antibodies (Olson et al., 2007). While 
many current clinical trials focused on PSMA entail the use of imaging modalities, one 
specific PSMA targeting radiopharmaceutical has progressed to a phase III trial. A 
lutetium-177 conjugated ligand specific for the catalytic region of PSMA demonstrated 
an acceptable toxicity profile in patients with metastatic castrate-resistant prostate cancer 
(Rahbar et al., 2018, Rahbar et al., 2017). As yet, no PSMA targeting drugs have been 
FDA approved for cancer treatment and one indium labelled version of the aPSMA 
antibody implicated in its discovery has been approved for prostate cancer imaging in 
patients (Bander, 2006). 
 
Good xenograft models of metastatic prostate cancer do not currently exist.  To address 
this limitation, the castrate resistant cell line PC3 was orthotopically implanted in the 
prostate of immune-compromised mice and draining lymph node metastases were 
harvested and re-implanted with the development of the derivative cell line PC3-LN3 
(PL) (Sanderson et al., 2006). This generated an aggressive prostate cancer cell line with 
metastatic potential. Thus, PL was selected for this project along with a more indolent 
established castrate resistant line DU145. Both of these cell lines are PSMA negative and 
were engineered to express PSMA for this project. 
 
4.1.2 P4 CAR development 
Following the discovery of PSMA, using the 7E11 monoclonal antibody which targeted 
the cytoplasmic tail of the protein (Horoszewicz et al., 1987), additional extracellular 
domain binding antibodies were developed. The J591 antibody was produced through 
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hybridomas generated following LNCaP and primary prostate cancer cell immunisation 
in mice. This antibody binds to permeabilised sections of prostate cancer and vasculature 
of other solid tumours similar to 7E11, but also stains viable PSMA+ cells unlike 7E11 
(Liu et al., 1997). The scFv portion of the antibody was used to generate a 1st generation 
CAR construct that demonstrated cytotoxicity towards patient derived cells and cell lines 
expressing PSMA in vitro and in vivo (Gong et al., 1999). Secretion of IL-2 by J591 CAR 
T cells was significantly increased when the target cell line co-expresses PSMA and 
CD80, resulting in co-stimulation of the T cells (Gade et al., 2005, Gong et al., 1999). 
The CAR was developed into a 2nd generation construct, P28z, that exhibits superior IL-
2 secretion, CD8 and CD4 subset expansion and restimulation capacity compared to the 
1st generation CAR (Maher et al., 2002). Further engineering to incorporate an alternative 
4-1BB co-stimulation region into the CAR construct resulted in even greater cytokine 
secretion, T cell activation and persistence in mouse tumour models as well as efficacy 
against PSMA+ vasculature of primary ovarian tumours (Santoro et al., 2015, Zhong et 
al., 2010). The J591 scFv has been used to demonstrate proof of concept for delivering 
activation and co-stimulation through separate constructs targeting different antigens, 
with a PSCA-specific CAR alone delivering a suboptimal T cell activation signal. Due to 
a lack of strictly tumour specific antigens, this new type of dual targeted CAR 
demonstrates enhanced tumour discernment as it requires two points of tumour associated 
antigen recognition for effective T cell activation (Kloss et al., 2013). The 2nd generation 
CAR P28z is used in the present study and co-expressed with 4ab for CAR T cell specific 
enrichment (Wilkie et al., 2010), giving rise to the nomenclature ‘P4’. Phase I trials are 
ongoing with different PSMA targeting CAR motifs, including P28z, for metastatic 
castration resistant prostate cancer and two trials for bladder and cervical cancer 
(clinicaltrials.gov NCT04053062, NCT03356795, NCT03089203, NCT03185468, 
NCT01140373, and NCT03692663; accessed on 23rd August 2019). 
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To recapitulate the stromal compartment in prostate cancer for in vitro and in vivo 
investigation of the immunocytokine with P4 CAR T cells, the cell lines MRC5 and PS1 
were utilised. Shown in this chapter, these mesenchymal lines both express endogenous 
FAP, rendering them suitable to evaluate FAP-dependent immunocytokine targeting. 
Previous investigations performed by members of our lab indicated no murine stromal 
recruitment for PLP prostate cancer xenograft models. This suggested that endogenous 
FAP expression within the murine stroma was not a reliable target for the 
immunocytokine, which crosses the species barrier. For this reason, we moved to develop 
a human stroma/prostate cancer model and characterise the growth patterns, antigen 
expression and efficacy of the therapy in vitro for subsequent in vivo studies. 
 
4.1.3 Specific aims 
1. Develop and characterise reporter gene engineered PCa and stromal cell lines. 
2. Establish an in vitro PCa/stroma model for drug development. 
3. Validate P4 CAR T cell efficacy against PCa cell lines and co-cultures with 
MRC5hT. 
4. Establish signalling capabilities of eFAP-4 through the 4ab receptor expressed on 
human T cells. 
5. Analyse the effects of eFAP-4 on CAR T cells during killing assays in vitro. 
 
4.2 Results 
4.2.1 Development and characterisation of cell lines in vitro 
Two castrate resistant prostate cancer cell lines were used in this project: PC3-LN3 (PL), 
a derivative of PC3, and DU145. Both are PSMA- and were retrovirally transduced to 
express PSMA along with the reporter gene ffLuciferase-tdTomato (LT). The PL line 
stably expressed LT at around 95%. When transduced to express both PSMA and LT 
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(PLP), the double positive population reached 100% [Figure 4.1A]. DU145 also highly 
expressed the LT reporter with 95.7% positivity, but the PSMA+ population (DU145P) 
had a decreased proportion of LT+ cells, at around 87% [Figure 4.1B]. The LT negative 
DU145P percentage remained constant throughout the project and never outgrew the LT 
expressing cells [data not shown]. 
 
 
Figure 4.1 Transduction of PCa cell lines with LT and PSMA. 
Retroviral vectors encoding the LT reporter and/ or PSMA were transduced into the cell 
lines A) PL and B) DU145. The parental double negative cell lines were stained with an 
isotype control for the aPSMA antibody and used to set the gate. A commercially 
available antibody was used to stain PSMA. The LT reporter was detected through 
tdTomato expression in the PE channel. 
 
The newly generated prostate cancer cell lines were then analysed for specific antigen 
expression and growth kinetics. No FAP expression was detected in any of the cell lines 
and PSMA expression was restricted to the transduced LT-PLP and LT-DU145P cells 
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difference in growth rates between these derivatives of the same cell lines. However, the 
sublines of PL and DU145 showed a significant difference in expansion [Figure 4.2B]. 
LT-PL and LT-PLP cells underwent more rapid proliferation than LT-DU145 and LT-
DU145P cells, suggesting that PL could be used to model more aggressive prostate cancer 
and DU145 could reflect a more indolent malignancy. 
 
 
Figure 4.2 Characterisation of PCa lines. 
PL and DU145 derivatives LT-PL, LT-PLP, LT-DU145 and LT-DU145P were 
characterised in terms of A) FAP and PSMA expression by flow cytometry and B) growth 
kinetics in D10 media. Significant differences between groups were determined using a 
two-way ANOVA (mean + SEM, n=3) (* = p < 0.05; ** = p < 0.01). 
 
For differential imaging of cell lines, the far-red reporter gene mNeptune was used for 
stroma identification. The cDNA was cloned into an SFG vector by GenScript and was 
visualised on an agarose gel after restriction digestion [Figure 4.3A]. The mNeptune 
insert was seen with a predicted band size of 737 bp and the SFG backbone at 6334 bp. 
This plasmid was then used to engineer a stable retroviral packaging cell line 293vec-
RD114 (RD114). This resulted in a 65.6% population expression of mNeptune [Figure 
4.3B]. The RD114 pseudotyped virus derived from these packaging cell lines was used 
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Figure 4.3 Development of an mNeptune packaging cell line. 
The reporter gene mNeptune was cloned into an SFG retroviral backbone. A) Successful 
cloning was confirmed by electrophoresis. The plasmid was digested using the restriction 
enzymes NcoI and XhoI that flank the insert. A 1 kb ladder was used. B) This plasmid 
was transduced into the 293vec-RD114 pseudotyped retroviral packaging cell line. The 
untransduced parental cells were used to set the gate. Expression of mNeptune was 
detected in the APC channel. 
 
Two stromal cell lines were used for this project, namely human telomerase transduced 
MRC5hT cells and the pancreatic stromal cell line, PS1. Both were transduced to express 
the mNeptune reporter. MRC5hT showed a positive population of 70.6% after one 
addition of viral supernatant. This increased to 94.5% mNeptune positive after an 
additional round of transduction [Figure 4.4A]. The PS1 cells were initially transduced to 
express 29.4% mNeptune and were sorted using FACS to yield a 90.7% positive 
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Figure 4.4 Transduction of stromal cells with mNeptune. 
A) MRC5hT and B) PS1 were transduced with SFG mNeptune. MRC5hT were 
transduced with viral supernatant twice to achieve a strongly positive population. PS1 
were transduced once and then flow sorted on a BD FACSAria I sorter. The untransduced 
parental lines were used to set the indicated gates. 
 
Expression of FAP in the mNeptune expressing stromal cell lines was assessed using flow 
cytometry. Both the mN-MRC5hT and the mN-PS1 expressed 76% and 81% FAP 
respectively [Figure 4.5A]. Both cell lines were then stained for PSMA and FAP to 
demonstrate antigen expression in the stroma. As expected, neither cell line expressed 
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Figure 4.5 Antigen expression in stromal cell lines. 
mN-MRC5hT and mN-PS1 cells were assessed for A) mNeptune and FAP dual 
expression and B) FAP and PSMA expression (mean + SEM, n=3). An isotype control 
was used to set the gate for FAP and PSMA expression. Commercially available 
antibodies were used to detect FAP and PSMA. 
 
4.2.2 Influence of prostate cancer and stromal cells on one another 
In order to ultimately test the immunocytokine/ CAR T cell immunotherapy approach, I 
wished to establish cell models whereby PCa and stromal cells were co-cultured, both in 
vitro and in vivo. First, the growth kinetics of the PCa cell lines were analysed when 
cultured in conditioned media (CM) derived from the stromal cell lines. When PL/PLP 
and DU145/DU145P cells were cultured in 100% MRC5hT CM, 50% MRC5hT CM or 
fresh D10 for 96 hours, no significant difference in expansion was observed [Figure 4.6A-
B]. When the same experiment was conducted using PS1 CM there was a significant 
decrease in expansion of the PL and PLP cells when cultured in either 100% or 50% PS1 
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Figure 4.6 PCa growth kinetics in stromal cell conditioned media. 
The impact of MRC5hT CM on in vitro expansion was assessed in A) PL/PLP cultures 
and B) DU145/DU145P cultures. The cell line is listed followed by the media conditions 
in the key to each panel. Significance was determined using a two-way ANOVA (mean 
+ SEM, n=3). 
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Figure 4.7 PCa growth kinetics in stromal cell conditioned media. 
The impact of PS1 CM on in vitro expansion was assessed in A) PL/PLP and B) 
DU145/DU145P cultures. The cell line is listed followed by the media conditions in the 
key to each panel. Significance was determined using a two-way ANOVA (mean + SEM, 
n=3) (* = p < 0.05; ** = p < 0.01). 
 
Stromal cell growth was also investigated when these cells were cultured in the presence 
of CM derived from PCa cell lines. Expansion of MRC5hT cells did not seem to be 
affected by any of the PCa CM, whether added at 100% or 50% CM [Figure 4.8A-B]. By 
contrast, PS1 growth was slowed in response to the addition of both 100% and 50% CM 
from PL/PLP and DU145/DU145P cells [Figure 4.9A-B]. None of the growth kinetic 
variations that affected the stromal cell lines reached significance. 
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Figure 4.8 Stromal cell growth kinetics in PCa conditioned media. 
MRC5hT growth rate was evaluated in A) PL/PLP CM and B) DU145/DU145P CM. The 
cell line is listed followed by the media conditions in the key to each panel. Significance 
was determined using a two-way ANOVA (mean + SEM, n=3). 
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Figure 4.9 Stromal cell growth kinetics in PCa conditioned media. 
PS1 growth was seen in A) PL/PLP CM and B) DU145/DU145P CM. The cell line is 
listed followed by the media conditions in the key to each panel. Significance was 
determined using a two-way ANOVA (mean + SEM, n=3). 
 
Next, I investigated FAP expression in stromal cells, when cultured in PCa conditioned 
media. While FAP expression in MRC5hT cells proved relatively consistent across these 
experiments [Figure 4.10A-B], expression of FAP on PS1 cells was more variable [Figure 
4.10C-D]. There was an observed decrease in FAP expression in PS1 cells when cultured 
in PLP CM while an increase was noted in the presence of DU145 and DU145P CM at 
72-hours. Nonetheless, these changes did not reach statistical significance. 
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Figure 4.10 FAP expression in stromal cell lines in PCa conditioned media. 
FAP expression on MRC5hT cultured in A) PL/PLP CM (n=3) and B) DU145/DU145P 
CM (n=3). FAP expression on PS1 cultured in C) PL/PLP CM (n=2-3) and D) 
DU145/DU145P CM (n=4) (mean + SEM). A commercially available aFAP antibody 
was used to stain FAP and an isotype was used to set the gate on each condition. Statistical 
analysis was performed using a student’s t-test. 
 
Because of the distinctive growth patterns of each cell line it was necessary to establish 
an optimal co-culture ratio of stroma:PCa to avoid PCa outgrowth. At various plated 
ratios of PS1:PL, PL tended to moderately outgrow PS1 at 96-hours when compared to 
24-hours [Figure 4.11A-B]. A similar pattern was seen with co-cultures of PS1 and PLP 
[Figure 4.11C-D]. At 96-hours, the PS1:PL/PLP plating ratio of 4:1 resulted in the stroma 
occupying around 70% of the co-culture. This ratio was chosen for future experiments. 
The same ratio plating determination was performed for PS1:DU145/DU145P. Although 
DU145 and DU145P did not outgrow PS1 as efficiently, they still became the 
predominant cell in co-cultures at the 1:1 plating ratio at 96-hours [Figure 4.11E-H]. The 
4:1 PS1:DU145/DU145P ratio also yielded a co-culture that was around 70% stromal at 
96-hours. Thus, this plating ratio was chosen for future evaluation. 
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Figure 4.11 Co-culture ratio determination of PS1 and PCa lines. 
Various plating ratios were observed for PS1:PL at A) 24-hours and B) 96-hours. The 
same was done for PS1:PLP at C) 24-hours and D) 96-hours, PS1:DU145 at E) 24-hours 
and F) 96-hours and PS1:DU145P at G) 24-hours and H) 96-hours. The resulting 
proportions of each cell line were determined by flow cytometry and are represented as 
percentages of the whole co-culture (mean + SEM, n=3). 
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MRC5hT is a slower growing cell line than PS1 [data not shown]. Both PL and PLP cells 
overgrew the co-culture by 96-hours at a 1:1 seeding ratio leaving MRC5hT making up 
only around 4% of the total cell content [Figure 4.12A-D]. At an 8:1 plating density of 
MRC5hT:PL/PLP, the proportion of stromal cells at 96-hours was around 60%. This ratio 
was chosen for future analysis. The optimal plating ratio for MRC5hT and 
DU145/DU145P was determined in a similar manner. As seen previously, 
DU145/DU145P does not expand as rapidly as PL/PLP and did not take over the co-
culture with MRC5hT as extensively [Figure 4.12E-G]. At 96-hours, all ratios above 4:1 
resulted in the stromal cells comprising at least 50% of the co-culture with DU145 and 
DU145P. However, to ensure that stroma was the predominant cell type in the culture, an 
8:1 seeding ratio was chosen. This produced a culture that was approximately 70% 
MRC5hT cells at the 96-hour time point. 
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Figure 4.12 Co-culture ratio determination of MRC5hT and PCa lines. 
Different plating ratios were observed for MRC5hT:PL at A) 24-hours and B) 96-hours. 
The same was done for MRC5hT:PLP at C) 24-hours and D) 96-hours, MRC5hT:DU145 
at E) 24-hours and F) 96-hours and MRC5hT:DU145P at G) 24-hours and H) 96-hours. 
The resulting proportions of each cell line were determined by flow cytometry and are 
represented as percentages of the whole co-culture (mean + SEM, n=3). 
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At the pre-determined optimal PS1:PCa plating ratio of 4:1, the effect of co-culture on 
the growth of both tumour and stromal cells was measured. PS1 stromal cells and PL/PLP 
tumour cells were plated at 4x104 cells/well either as a mono-culture of either PS1 or the 
tumour cell line, or as a co-culture comprising 3.2 x 104 PS1 cells mixed with 0.8 x 104 
PL or PLP cells. Control cells were plated alone but at their co-culture seeding densities 
(e.g. 3.2 x 104 PS1 cells alone or 0.8 x 104 PL or PLP cells alone) to determine the true 
effect of the other cell line on growth kinetics and thereby establish the impact of cell 
confluency. Cell growth was monitored each day over 4 days. The presence of PS1 cells 
did not alter the growth rate of PL or PLP cells, when compared to the corresponding 
tumour cell monocultures that had been plated at co-culture densities (0.8x104 cells). 
Nonetheless, when PS1 cells were established in co-culture with PL or PLP tumour cells, 
a small trend was noted (statistically not significant) whereby the stromal cells expanded 
more quickly [Figure 4.13A-B]. The possibility that this was an artefact of confluency 
and not due to PCa cell influence was ruled out by the demonstration that 4x104 PS1 cells 
plated in mono-culture exhibited similar growth to PS1 cells that had been plated alone 
at co-culture density (3.2x104). 
 
 - 153 - 
 
Figure 4.13 Growth kinetics of PS1 and PL/PLP in co-culture. 
Co-cultures were established in which 3.2 x 104 PS1 cells were mixed with 0.8 x 104 PL 
cells A) or PLP cells B). Growth rates of PCa and stromal cells were monitored by flow 
cytometry. The key to each panel indicates the particular cell line followed by the 
condition in which the growth was observed (mono-cultures lines = green, purple, brown 
and black; co-culture lines = red and blue) (mean + SEM, n=3). 
 
The presence of DU145 and DU145P did not have an effect on PS1 growth rate in co-
culture [Figure 4.14A-B]. All mono-cultures and co-cultures of PS1 with 
DU145/DU145P expanded equivalently. Additionally, DU145 and DU145P cells did not 
proliferate differently based on culture composition.   
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Figure 4.14 Growth kinetics of PS1 and DU145/DU145P in co-culture. 
Co-cultures were established in which 3.2 x 104 PS1 cells were mixed with 0.8 x 104 
DU145 cells A) or DU145P cells B). Growth rates of PCa and stromal cells in co-culture 
were monitored by flow cytometry. The key to each panel indicates the particular cell line 
followed by the condition in which the growth was observed (mono-cultures lines = 
green, purple, brown and black; co-culture lines = red and blue) (mean + SEM, n=3). 
 
When seeded at a stroma:PCa ratio of 8:1, the presence of PL or PLP tumour cells 
significantly increased the expansion rate of MRC5hT cells [Figure 4.15A-B]. This effect 
was evident by 72-hours in culture. However, neither PL or PLP growth was affected by 
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Figure 4.15 Growth kinetics of MRC5hT and PL/PLP in co-culture. 
Co-cultures were established in which 3.2 x 104 MRC5hT cells were mixed with 0.8 x 
104 PL cells A) or PLP cells B). Growth rates of PCa and stromal cells in co-culture were 
monitored by flow cytometry. The key to each panel indicates the particular cell line 
followed by the condition in which the growth was observed (mono-cultures lines = 
green, purple, brown and black; co-culture lines = red and blue). Significance was 
determined using a two-way ANOVA (mean + SEM, n=3) (* = p < 0.05; ** = p < 0.01; 
*** = p < 0.001). 
 
Analysis of DU145/DU145P cells in co-culture with MRC5hT cells also showed a 
significant growth advantage for MRC5hT cells in these co-cultures [Figure 4.16A-B]. 
DU145P tumour cells also demonstrated a significant increase in expansion when 
cultured with MRC5hT cells, when compared to a mono-culture of these stromal cells 
that had been plated at the same seeding density [Figure 4.16B]. 
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Figure 4.16 Growth kinetics of MRC5hT and DU145/DU145P in co-culture. 
Co-cultures were established in which 3.2 x 104 MRC5hT cells were mixed with 0.8 x 
104 DU145 cells A) or DU145P cells B).  Growth rates of PCa and stromal cells in co-
culture were monitored by flow cytometry. The key to each panel indicates the particular 
cell line followed by the condition in which the growth was observed (mono-cultures 
lines = green, purple, brown and black; co-culture lines = red and blue). Significance was 
determined using a two-way ANOVA (mean + SEM, n=3) (* = p < 0.05; *** = p < 0.001). 
 
Expression of FAP was analysed in the stromal cells when co-cultured with PCa cells, 
making comparison with stromal cell mono-cultures. PS1 cells showed a time-dependent 
decrease in the expression of FAP in every culture condition [Figure 4.17A-B], although 
this difference was only significant at 72-hours for the mono-cultures of PS1 seeded at 
co-culture density. This difference was only noted when measuring the percentage of 
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Figure 4.17 FAP expression in PS1 cells in PCa co-culture. 
Expression of FAP was analysed in the different PS1 culture conditions by flow 
cytometry. Data are expressed as A) percentage of positive cells and B) median 
fluorescence intensity. Commercially available antibodies were used to stain FAP and an 
isotype control was used to set the gate. The key to each panel indicates whether PS1 was 
co-cultured with tumour cells or cultured alone and whether cells were seeded at 
monoculture or co-culture density. Statistical significance was determined using a 
student’s t-test (mean + SEM, n=3) (* = p < 0.05). 
 
Expression of FAP in MRC5hT cells was not influenced by time or co-culture with the 
PL or PLP PCa cell lines [Figure 4.18A-B]. Cells remained between 40-60% FAP 
positive under all conditions. The MRC5hT stromal line was chosen for further drug 
development because of the increased stability of FAP expression and growth kinetics in 
co-cultures compared to PS1.  
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Figure 4.18 FAP expression in MRC5hT cells in PCa co-culture. 
Expression of FAP was analysed in the different culturing conditions of MRC5hT by flow 
cytometry. Data are expressed as A) percentage of positive cells and B) median 
fluorescence intensity. Commercially available antibodies were used to stain FAP and an 
isotype control was used to set the gate. The key to each panel indicates whether MRC5hT 
was co-cultured with tumour cells or cultured alone and whether cells were seeded at 
monoculture or co-culture density (mean + SEM, n=3). 
 
4.2.3 Functional validation of eFAP-4 signalling through the 4ab in human CAR 
T cells 
After validation of eFAP-4 signalling through the 4ab chimeric receptor in a murine 
leukaemia cell line CTLL2 [Figure 3.17], function was assessed in human T cells 
expressing P4 or the truncated control P4Tr construct in which P28z lacks an intracellular 
signalling domain. The expansion of P4 or P4Tr CAR T cells was similar in the presence 
of IL-4 or eFAP-4. With the P4 construct, both IL-4 and eFAP-4 elicited a greater degree 
of cell expansion than IL-2 and significantly more expansion than CAR T cells when 
cultured without cytokine [Figure 4.19A]. P4Tr CAR T cells expanded less well overall, 
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but once again, significantly more proliferation was seen in cultures with IL-4 or eFAP-
4 compared to IL-2 or no cytokine over a 10-day period [Figure 4.19B]. 
 
 
Figure 4.19 CAR T cell expansion with different cytokines. 
Human T cells were engineered by retroviral transduction to express the P28z or PTr 
CARs together with the 4ab chimeric cytokine receptor, known as P4 (A) or P4Tr (B) 
respectively. T cells were then cultured in 100 IU/mL IL-2, 2 nM IL-4 or 2 nM eFAP-4, 
which was repeatedly added every 2 days. Cell number was evaluated by trypan exclusion 
at the indicated time points (mean + SEM, n=4). Significance was determined using a 
two-way ANOVA (* = p < 0.05; ** = p < 0.01). 
 
These expansion cultures were also analysed for variations in the CD8+:CD4+ T cell ratio 
over 10-days. Although there was donor variability, there was a trend for P4 cells cultured 
in IL-2 to shift towards a higher CD8:CD4 ratio over the 10-day culture period [Figure 
4.20A]. For the P4Tr CAR T cells the only visible change was a decrease in the CD8:CD4 
ratio in IL-4 [Figure 4.20B]. 
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Figure 4.20 CD8+:CD4+ T cell ratio in different cytokine conditions. 
The ratio of CD8+:CD4+ CAR T cells expanded with IL-2, IL-4 and eFAP-4 as described 
in Figure 4.17 was observed in T cell cultures expressing the A) P4 construct, or the B) 
P4Tr construct (mean + SEM, n=4). Commercially available antibodies were used to stain 
CD8 and CD4 prior to analysis by flow cytometry. Baseline CD8:CD4 ratios were 
determined at day 0 and deviations were recorded as an increase or decrease of that ratio. 
 
Next, in vitro P4 CAR T cell cytotoxicity was quantified in co-cultures with newly 
established PCa/MRC5hT monolayers. MRC5hT+PCa cells, PCa alone, or MRC5hT 
cells alone were co-cultured with P4 or P4Tr expressing CAR T cells for 24 hours at an 
effector to target ratio of one T cell to two target cells (combining tumour and stromal 
cells). PSMA-dependent tumour cell killing by P4-engineered T cells was observed 
[Figure 4.21A]. Some antigen independent ‘bystander killing’ of MRC5hT cells was also 
seen in the PSMA expressing MRC5hT+PCa co-cultures. A small amount of bystander 
killing of MRC5hT was also seen for P4Tr in the MRC5hT alone culture [Figure 4.21B]. 
Activation of P4 CAR T cells was associated with antigen-specific secretion of IFN-γ and 
IL-2 [Figure 4.21C-D]. There was a statistically significant reduction in cell viability for 
DU145 in the presence of the P4 CAR but this was modest in comparison to the PSMA 
expressing cell lines and was not associated with cytokine secretion by the CAR T cells 
[Figure 4.21A and C-D]. 
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Figure 4.21 CAR T cell killing of PCa/MRC5hT monolayers.  
Cell viability of monolayers following co-cultivation with either P4 or P4Tr CAR T cells 
(E:T ratio 1:2) was determined by flow cytometry at 24-hours as A) PCa cell line death, 
or B) MRC5hT cell death (n=3). PCa cell lines that were co-cultured are labelled (co-
culture). MRC5hT that were co-cultured with specific PCa cell lines are specified in 
parentheses. Cytokine production by P4 and P4Tr CAR T cells was quantified for C) IFN-
g and D) IL-2. All data show mean + SEM of n=3 independent biological replicates. All 
cultures had an effector to target (E:T) ratio of 1:2. Significant cell death compared to 
baseline was determined using a student’s t-test (** = p < 0.01; *** = p < 0.001; **** = 
p < 0.0001). 
 
4.2.4 Effect of eFAP-4 addition on restimulated co-cultures of P4 CAR T cells with 
PCa/stroma monolayers 
To ensure that IL-4 and eFAP-4 did not have intrinsic anti-cancer characteristics, PCa 
and MRC5hT cells were cultured with these cytokines and cell viability was measured. 
No reduction in cell viability at 72-hours was observed for mono-cultures, or 
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when compared to cultures without IL-4 or eFAP-4[Figure 4.22A-B]. DU145P cells 
cultured alone expanded more than other conditions in IL-4 alone [Figure 4.22B]. 
 
 
Figure 4.22 eFAP-4 and IL-4 influence on viability of monolayers. 
Cell viability was determined by MTT assay after 72-hours of culture of 1 x 105 cells with 
A) 2 nM eFAP-4, or B) 2 nM IL-4 (mean + SEM, n=3). Viability was compared to 
cultures without eFAP-4 or IL-4, which was considered 100% cell viability. Significance 
was determined using a student’s t-test (* = p < 0.05). 
 
CAR T cells were added to monolayers of either PCa cells, MRC5hT or MRC5hT+PCa 
combined cultures (comprising stromal and tumour cells at the predetermined optimal 
ratio of 8:1 respectively). T cell/monolayer cultures were initiated at an effector to target 
ratio of 1:2 and cultures were supplemented with 2 nM of IL-4, eFAP-4 or no cytokine. 
Cytotoxicity was evaluated after 72-96 hours by MTT assay in a re-stimulation co-culture 
experiment, whereby T cells were transferred to a new monolayer every 72-96 hours. 
When P4 CAR T cells were co-cultured with PLP alone, the presence of IL-4 or eFAP-4 
resulted in sustained elimination of the PCa cells over 17 restimulations. Cytotoxicity was 
lost between the 4th and 6th restimulation when P4 CAR T cells were restimulated in this 
manner, but without cytokine supplementation [Figure 4.23A]. When MRC5hT cells 
were present in the monolayer, a similar pattern was seen. However, the magnitude of 
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presumably because the MRC5hT cells were surviving to a greater degree, given their 
PSMA negative status [Figure 4.23B]. 
 
 
Figure 4.23 CAR T cell killing of PLP and MRC5hT+PLP monolayers. 
P4 and P4Tr CAR T cells were added to monolayers at an initial E:T ratio of 1:2. Tumour 
cell viability was measured after 72-96 hours by MTT assay and T cells were restimulated 
on a new monolayer. Cell viability was compared to monolayers not receiving CAR T 
cells or cytokine supplementation (considered 100%; dotted black line). Efficacy was 
assessed alone or with either 2 nM eFAP-4 or IL-4 on monolayers of A) PLP, or B) 
MRC5hT+PLP (mean + SEM, n=4). Dotted coloured lines in the legend represent the 
P4Tr counterpart for each condition. 
 
Similar restimulation assays were established between CAR T cells and DU145P tumour 
cells, cultured alone or with MRC5hT stromal cells. For co-cultures of P4 CAR T cells 
with DU145P alone, the same pattern of improved killing with IL-4 and eFAP-4 was 
seen, albeit with an ameliorated depth of repeat monolayer elimination compared to PLP 
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containing cultures [Figure 4.24A]. For MRC5hT+DU145P antigen specific killing was 
seen, and IL-4 or eFAP-4 supplementation enhanced depth and duration of restimulation 
cytotoxicity. Ultimately though, the presence of the stromal cells conferred significant 
protection from CAR T cell mediated killing of the PSMA expressing tumour cells 
manifested by a marked reduction in the number of restimulations the CAR T cells 
sustained [Figure 4.24B]. 
 
 
Figure 4.24 CAR T cell killing of DU145P and MRC5hT+DU145P monolayers. 
P4 and P4Tr CAR T cells were added to monolayers at an initial E:T ratio of 1:2. Tumour 
cell viability was measured after 72-96 hours by MTT assay and T cells were restimulated 
on a new monolayer. Cell viability was compared to monolayers not receiving CAR T 
cells or cytokine supplementation (considered 100%; dotted black line). Efficacy was 
assessed alone or with either 2 nM eFAP-4 or IL-4 on monolayers of A) DU145P, or B) 
MRC5hT+DU145P (mean + SEM, n=4). Dotted coloured lines in the legend represent 
the P4Tr counterpart for each condition. 
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When CAR T cells were cultured with monolayers that contained only MRC5hT cells, 
non-specific killing of these stromal cells was not seen in any culture conditions [Figure 
4.25]. Moreover, as expected, P4Tr CAR T cells were unable to kill in any given 
condition [Figure 4.23-4.25]. 
 
 
Figure 4.25 CAR T cell non-specific killing of MRC5hT monolayers. 
P4 and P4Tr CAR T cells were added to monolayers at an initial E:T ratio of 1:2. Tumour 
cell viability was measured after 72-96 hours by MTT assay and T cells were restimulated 
on a new monolayer. Cell viability was compared to monolayers not receiving CAR T 
cells or cytokine supplementation (considered 100%; dotted black line). Efficacy was 
assessed alone or with either 2 nM eFAP-4 or IL-4 on monolayers of MRC5hT (mean + 
SEM, n=4). Dotted coloured lines in the legend represent the P4Tr counterpart for each 
condition. 
 
Cytokine production in the co-culture assays described above was quantified by ELISA. 
Production of IFN-g was consistent with observed patterns of cytotoxicity [Figure 4.26A-
E]. No IFN-g was produced by P4 CAR T cells when co-cultured with MRC5hT 
monolayers [Figure 4.26E]. 
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Figure 4.26 IFN-g production by CAR T cells in PCa/MRC5hT cultures. 
P4 and P4Tr CAR T cells were restimulated on A) PLP, B) DU145P tumour monolayers 
or C) MRC5hT+PLP, D) MRC5hT+DU145P stroma/tumour monolayers as described in 
Figure 4.21-23. Stimulation on E) MRC5hT monolayers served as negative control. IFN-
g secretion was assessed by ELISA in cultures without cytokine support or supplemented 
with either 2 nM eFAP-4 or IL-4. Dotted coloured lines represent the P4Tr counterpart 
for each condition (mean + SEM, n=4). 
 
Production of IL-2 by CAR T cells was also quantified by ELISA. High levels were seen 
at 72-hours after co-culture of P4 T cells with DU145P, MRC5hT+PLP and 
MRC5hT+DU145P cells during the 1st antigen stimulation in every cytokine condition. 
Levels tapered and became undetectable after the 3rd stimulation [Figure 4.27A-D]. 
Cultures with PLP exhibited peaks of IL-2 production in the P4+eFAP-4 condition at late 
stimulation points [Figure 4.27A]. P4Tr CAR T cells never produced detectable IL-2. 
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Figure 4.27 IL-2 production by CAR T cells in PCa/MRC5hT cultures. 
P4 and P4Tr CAR T cells were restimulated on A) PLP, B) DU145P tumour monolayers 
or C) MRC5hT+PLP, D) MRC5hT+DU145P stroma/tumour monolayers as described in 
Figure 4.21-23. Stimulation on E) MRC5hT monolayers served as negative control. IL-2 
secretion was assessed by ELISA in cultures without cytokine support or supplemented 
with either 2 nM eFAP-4 or IL-4. Dotted coloured lines represent the P4Tr counterpart 
for each condition (mean + SEM, n=4). 
 
Expansion of P4 T cells was significantly enhanced in co-culture with PLP target cells 
over multiple restimulations when IL-4 or eFAP-4 supplementation was present. In the 
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eFAP-4 in supporting expansion [Figure 4.28A&C]. In the P4 DU145P cultures, only IL-
4 supplementation resulted in expansion [Figure 4.28B]. For MRC5hT+DU145P and 
MRC5hT alone very minimal expansion was seen [Figure 4.28D-E]. There was no 
proliferation of P4Tr CAR T cells. 
 
 
Figure 4.28 Proliferation of CAR T cells on PCa/MRC5hT monolayers. 
P4 and P4Tr CAR T cells were restimulated on A) PLP, B) DU145P tumour monolayers 
or C) MRC5hT+PLP, D) MRC5hT+DU145P stroma/tumour monolayers as described in 
Figure 4.21-23. Stimulation on E) MRC5hT monolayers served as negative control. CAR 
T cell proliferation was assessed in cultures without cytokine support or supplemented 
with either 2 nM eFAP-4 or IL-4. Dotted coloured lines represent the P4Tr counterpart 
for each condition (mean + SEM, n=4). 
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When CD8+:CD4+ ratios were studied by flow cytometry at baseline, antigen stimulation 
3 and, where possible, at the time of the last stimulation there was a suggestion that the 
presence of IL-4 or eFAP-4 in the co-culture may increase the proportion of CD4+ cells. 
Significant donor variability was observed [Figure 4.29A-E]. The decrease in the 
CD8+:CD4+ ratio was statistically significant at the 3rd antigen stimulation on monolayers 
of MRC5hT+PLP. This significance was seen between cultures of P4 and P4 
supplemented with eFAP-4 or IL-4 [Figure 4.29C]. 
 
The expression of exhaustion marker PD-1 was analysed on P4 CAR T cells. Again, high 
donor variability was observed. No significant differences were seen [Figure 4.30A-D]. 
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Figure 4.29 CD8+:CD4+ T cell ratio in different cytokine conditions during killing 
assays. 
P4 and P4Tr CAR T cells were restimulated on A) PLP, B) DU145P tumour monolayers 
or C) MRC5hT+PLP, D) MRC5hT+DU145P stroma/tumour monolayers as described in 
Figure 4.21-22. Stimulation on E) MRC5hT monolayers served as negative control. Flow 
cytometry was used to determine the ratio of CD8+:CD4+ P4 CAR T cells in cultures 
without cytokine support or supplemented with either eFAP-4 or IL-4. Commercially 
available antibodies were used for CD8 and CD4. Baseline CD8:CD4 ratios were 
determined before antigen stimulation and deviations were recorded as an increase or 
decrease of that ratio. This was assessed after 3 antigen stimulations (Ag. Stim 3) and 
after the last stimulation (Last Stim). A no data (n.d.) point is noted when there were only 
3 antigen stimulations in a given condition or there were not enough cells to analyse the 
last stimulation. Statistical significance was determined using a student’s t-test (* = p < 
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Figure 4.30 PD-1 expression in P4 CAR T cells during killing assays. 
P4 and P4Tr CAR T cells were restimulated on A) PLP, B) DU145P tumour monolayers 
or C) MRC5hT+PLP, D) MRC5hT+DU145P stroma/tumour monolayers as described in 
Figure 4.21-22. Stimulation on E) MRC5hT monolayers served as negative control. Flow 
cytometry was used to determine the expression of PD-1 on P4 CAR T cells in cultures 
without cytokine support or supplemented with either eFAP-4 or IL-4. An isotype control 
was used to set the gate and a commercially available antibody was used to stain PD-1. 
This was assessed after 3 antigen stimulations (Ag. Stim 3) and after the last stimulation 
(Last Stim). A no data (n.d.) point is noted when there were only 3 antigen stimulations 
in a given condition or there were not enough cells to analyse the last stimulation (mean 
+ SEM, n=2-4). E) there is no data for the last stim condition. 
 
Expression of the activation marker CD44 was analysed [Figure 4.31A-E] (Forster-
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cells in the presence of eFAP-4 between the 3rd and final restimulation of MRC5hT+PLP. 
At the last stimulation, CD44 levels were higher on the P4 CAR T cells co-cultured with 
MRC5hT+PLP supplemented with eFAP-4 when compared to IL-4 [Figure 4.31C]. 
MRC5hT cultures were only assessed at the 3rd antigen stimulation and while CD44 
expression appears higher in P4+eFAP-4 and P4+IL-4 conditions compared to P4 alone, 
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Figure 4.31 CD44 expression in P4 CAR T cells during killing assays. 
P4 and P4Tr CAR T cells were restimulated on A) PLP, B) DU145P tumour monolayers 
or C) MRC5hT+PLP, D) MRC5hT+DU145P stroma/tumour monolayers as described in 
Figure 4.21-22. Stimulation on E) MRC5hT monolayers served as negative control. Flow 
cytometry was used to determine the expression of CD44 on P4 CAR T cells in cultures 
without cytokine support or supplemented with either eFAP-4 or IL-4. An isotype control 
was used to set the gate and a commercially available antibody was used to stain CD44. 
This was assessed after 3 antigen stimulations (Ag. Stim 3) and after the last stimulation 
(Last Stim). A no data (n.d.) point is noted when there were only 3 antigen stimulations 
in a given condition or there were not enough cells to analyse the last stimulation (mean 
+ SEM, n=2-4). E) there is no data for the last stim condition. 
 
A pilot analysis of cytokine dependence was undertaken. In a single experiment, cultures 
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cytokine supplementation continued and in group 2 no further IL-4 or eFAP-4 was given. 
Disruption of the PLP monolayer remained consistent across all conditions while CAR T 
cell expansion continued in the cytokine supplemented cultures, but not when eFAP-4 or 
IL-4 was removed [Figure 4.32A-B]. P4 killing of DU145P was completely abrogated 
within 2 stimulations after IL-4 removal [Figure 4.32C] and expansion was flat in group 
1 and 2 [Figure 4.32D]. P4 CAR T cells on MRC5hT+PLP cultures continued to kill over 
80% of the monolayers regardless of cytokine supplementation [Figure 4.32E]. Removal 
of cytokine support from MRC5hT+PLP cultures resulted in loss of expansion [Figure 
4.32F]. This pilot experiment suggests an ongoing dependence of the presence of 
cytokine/immunocytokine with implications for dosing in vivo. 
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Figure 4.32 P4 CAR T cell killing and expansion after cytokine removal. 
After 15 restimulation cycles, P4 CAR T cells killing and proliferation were assessed with 
eFAP-4 or IL-4 and assessed upon removal of the cytokine in cultures of A-B) PLP, C-
D) DU145P and E-F) MRC5hT+PLP (n=1). Solid lines represent group 1 with continued 
supplementation of either 2 nM eFAP-4 or IL-4 and dotted lines represent cultures in 
group 2 in which all cytokine support was deprived from these cultures. Subsequent 
restimulations were carried out as described in Figure 4.21-4.23 and MTT assays were 
used to observe cell viability (A, C, E). T cell number was counted at each restimulation 
(B,D,F). 
 
CD8+:CD4+ CAR T cell ratio was analysed in cultures for which the cytokine had been 
withdrawn. There did not appear to be an effect of cytokine removal on the CD8:CD4 
ratio in cultures of PLP [Figure 4.33A]. The CD8:CD4 ratio decreased upon removal of 
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eFAP-4 condition on MRC5hT+PLP, removal of eFAP-4 showed a decrease in the 
CD8:CD4 ratio by more than half [Figure 4.33C]. 
 
 
Figure 4.33 CD8+:CD4+ P4 CAR T cell ratio after cytokine removal. 
P4 CAR T cell CD8:CD4 ratio was assessed with eFAP-4 or IL-4 and assessed upon 
removal of the cytokine in cultures of A) PLP, C) DU145P and E) MRC5hT+PLP (n=1). 
Commercially available antibodies were used for CD8 and CD4. Baseline CD8:CD4 
ratios were determined before antigen stimulation and deviations were recorded as an 
increase or decrease of that ratio. This data was collected after the last stimulation. 
 
The exhaustion and activation markers PD-1 and CD44 were examined on P4 CAR T 
cells after cytokine removal. Expression of PD-1 and CD44 increased in CAR T cells 
upon removal of either eFAP-4 or IL-4 from PLP cultures [Figure 4.34A-B]. Both 
markers remained relatively consistent on T cells in DU145P cultures with and without 
IL-4 [Figure 4.34C-D]. PD-1 expression was upregulated on P4 CAR T cells in 
MRC5hT+PLP cultures that had eFAP-4 removed compared to supplementation. There 
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cultures [Figure 4.34E]. Expression levels of CD44 on CAR T cells in these co-cultures 
were not affected by cytokine/immunocytokine removal [Figure 4.34F]. 
 
 
Figure 4.34 PD-1 and CD44 expression in P4 CAR T cells after cytokine removal. 
P4 CAR T cell expression of PD-1 and CD44 was assessed with eFAP-4 or IL-4 and 
assessed upon removal of the cytokine in cultures of A-B) PLP, C-D) DU145P and E-F) 
MRC5hT+PLP (n=1). An isotype was used to set the gate and a commercially available 




This chapter explored the development of human prostate cancer/stroma models for in 
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engineered to express PSMA and the reporter gene LT for in vitro and in vivo tracking. 
Two stromal cell lines, MRC5hT and PS1, were engineered to express a far-red reporter 
gene, mNeptune. These reporters showed utility in flow cytometric analysis through 
identification of distinct cell populations in co-cultures. All the cell lines were 
characterised for their growth kinetics and FAP/PSMA expression in mono-cultures, PCa 
or stroma condition media, or in co-cultures. These investigations led to selection of an 
in vitro PCa/stroma model for further analysis of the CAR+ T cells with the eFAP-4 
immunocytokine. 
 
The ability of eFAP-4 to sustain human CAR T cell expansion through the expression of 
the 4αβ receptor was confirmed. P4 CAR T cell mediated specific killing of PSMA+ cells 
was established. Culture of cell lines with eFAP-4 and IL-4 alone did not result in tumour 
cell cytotoxicity. When in culture with P4 CAR T cells, eFAP-4 and IL-4 increased the 
expansion and persistence of the T cells and augmented their potential to kill PCa/stroma 
monolayers. These cytokines did not enhance the CAR T cell non-specific killing of 
MRC5hT monolayers alone. 
 
A significant decrease in the CD8:CD4 ratio was seen in P4 CAR T cells on 
MRC5hT+PLP monolayers when supplemented with eFAP-4 or IL-4. This indicates 
skewing towards a CD4+ T cell enriched population in cytokine supplemented cultures. 
A recent study demonstrated a similar enrichment of CD4+ CAR T cells co-expressing an 
IL-4 chimeric receptor that recognises IL-4 and delivers an IL-7 signal. The CD4+ 
population in IL-4 containing cultures secreted higher levels of IL-2 and exhibited 
elevated mitochondrial activity compared to the CD8+ CAR T cells, but did not express 
regulatory markers. However, both populations were necessary to achieve tumour 
abrogation (Sukumaran et al., 2018). While CD8+ T cells are the main effector cell 
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populations, it is widely accepted that long-lived memory immunity is dependent on the 
CD4+ subset. CD4+ T cells help generate CD8+ memory T cells through interactions with 
CD40 (Rocha and Tanchot, 2004). An HIV envelope-specific CAR demonstrated 
increased persistence of the transgenic T cells when CD4+ and CD8+ arms were co-
injected versus CD8+ CAR T cells alone (Mitsuyasu et al., 2000). Against leukaemia 
cells, CD4+ CAR T cell proliferate faster and produce more IFN-g, IL-2 and TNF-a while 
the CD8+ subset is more cytotoxic in vitro (Sommermeyer et al., 2016). There is evidence 
that a mixture of subsets has higher anti-tumour effects. When naïve CD4+ and central 
memory CD8+ CAR T cells are combined, they have a synergistic effect in in vivo 
leukaemia models compared to injection of only one of the subsets (Sommermeyer et al., 
2016). In a second model system, intrapleural injection of a mesothelin targeting CAR 
shows an expansion of the CD4+ subset and prolonged efficacy is dependent on early 
activation of CD4+ T cells. In this model, complete tumour regression is accomplished 
and maintained with CD4+ CAR T cells alone and less than 50% elimination after 
treatment with the pure CD8+ CAR T cell subset. Once again, a combination of CD4+ and 
CD8+ CAR T cells demonstrated the greatest anti-tumour potential (Adusumilli et al., 
2014). Even signalling through the endogenous TCR increases exhaustion in CD8+ CAR 
T cells that is not detectable in CD4+ CAR T cells (Yang et al., 2017). These observations 
have led one group clinically developing specified CD4:CD8 ratios for CAR T cells as 
opposed to the widely donor variable CD8:CD4 ratio initially seen in transduced PBMCs 
(Turtle et al., 2016). Therefore, it is potentially beneficial that eFAP-4 addition increases 
the CD4+ CAR T cell population in our PCa/stroma model and could partially explain the 
increased persistence of the T cells.  
 
Effects of eFAP-4 and IL-4 on CD44 and PD-1 expression, CD8:CD4 ratio, monolayer 
destruction and expansion of P4 CAR T cells are all comparable on PLP containing 
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cultures in this study, suggesting similar signalling capabilities through the 4ab receptor. 
However, IL-4 outperformed eFAP-4 on DU145P cultures. DU145P cell lines were more 
resistant to treatment in general with P4 CAR T cells as evident by the decrease in T cell 
expansion, cytokine secretion and destruction of DU145P containing monolayers. There 
was an even greater resistance to cell death when cultured with MRC5hT. The decrease 
in cell death for monolayers containing MRC5hT might be explained by the survival of 
these cells due to their PSMA- negative status. While bystander killing of the MRC5hT 
was observed in PSMA+ monolayers co-cultured with P4, it was incomplete and 
approximately 50% of the MRC5hT survived [Figure 4.21]. Future experiments could 
aim to delineate which cell population is surviving in these PCa/stroma monolayers. This 
could be accomplished through luciferase assays instead of MTT assays as this would be 
specific for the viability of the LT-PCa cells only. Removal of each cytokine from 
cultures resulted in a continuation of monolayer disruption for PLP and MRC5hT+PLP 
cultures, but a complete reversal of cytotoxicity for DU145P. In all cases, removal of 
cytokine decreased T cell expansion. 
 
4.4 Summary 
• FAP+ MRC5hT and PS1 cells were engineered to express mNeptune. 
• PL and DU145 were engineered to express PSMA and LT. 
• In vitro co-cultures PCa/ stromal co-culture models were established. 
• eFAP-4 elicits a proliferation signal similar to IL-4 in human T cells expressing 
4ab. 
• eFAP-4 and IL-4 increase expansion, cytokine release and cytotoxicity of CAR T 
cells against PCa/MRC5hT cultures. 
• eFAP-4 and IL-4 comparatively decreased the CD8:CD4 ratio in MRC5hT+PLP 
cultures. 
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 Chapter 5: Efficacy of eFAP-4 and P4 CAR T cells in vivo 
5.1 Introduction 
5.1.1 Current in vivo models for prostate cancer 
Preclinical prostate cancer research relies heavily on models using immortalized cell 
lines. The repertoire of human prostate cancer cell lines available is limited, with the 
majority of studies utilising PC3, DU145 and LNCaP. This panel is clearly not 
representative of the diversity of human prostate cancer given the heterogeneity of patient 
derived samples and xenografts (Namekawa et al., 2019). Xenografts are useful for 
translational drug development, offering humanised models that enable the evaluation of 
drugs designed to target human antigens and cells. Unfortunately, this type of in vivo 
model overlooks the immune system’s influence on drug efficacy because of the immune-
deficiency of the mice. Syngeneic and transgenic models provide a means to 
incorporating the host’s immunity into the prostate cancer model. Nonetheless, there is a 
lack of murine prostate cancer cell lines and transgenic models are expensive, technically 
challenging and tumour development is unreliable. Patient-derived xenograft (PDX) 
models of prostate cancer offer a further alternative solution in which some degree of 
tumour heterogeneity is maintained. Organoids derived from PDX cultures can engraft in 
immunocompromised mice and retain the histology seen in the original biopsy (Gao et 
al., 2014a). Counterbalancing this however, PDX models are difficult to culture, establish 
in vivo and reproduce (Russell et al., 2015). Incorporation of stromal components of the 
tumour microenvironment into organoids could greatly enrich the experimental yields of 
these models for cancer immunotherapy development (Neal et al., 2018). 
 
The establishment of prostate cancer xenografts in the extremely immune-deficient 
mouse model NOD-SCID-IL2Rg-/- (NSG) has been well documented. NSG mice have 
an improved rate of engraftment for human cell lines (malignant and hematopoietic) and, 
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despite their immune compromised nature, they have been used widely for selected 
immunotherapy studies (Shultz et al., 2014). These mouse models of PCa have a 
particular value in the assessment of metastases as the lack of a functional immune system 
aids in tumour cell dissemination (Hudson et al., 2015, Mussawy et al., 2018, Vormoor 
et al., 2014). Moreover, humanised models based on NSG mice can provide additional 
insights into disease biology. Illustrating this, one study showed that the ability of prostate 
cancer cell lines to metastasise can partially be explained by overexpression of CD47 on 
tumour cells, enabling them to avoid phagocytosis in a reconstituted innate immune 
system (Rivera et al., 2015). The NSG mouse is also used to model bone metastases 
(common in human prostate cancer) and the effect of drug intervention on lesions in the 
bone marrow (Eswaraka et al., 2014). Additionally, without the host immune system’s 
influence on the tumour, such models offer a means to test cellular therapies and their 
specific effects on progression (Nada et al., 2017, Roth and Harui, 2015). 
 
5.1.2 Stroma compartment in vivo 
The tumour microenvironment plays an important role in disease progression. Non-
cancerous cells of the stroma often assist in immune evasion and metastasis. The tumour 
stroma is both a focus for targeted therapy development and enhanced understanding of 
interactions between cancer cells and their surroundings. Recapitulating this environment 
in vivo is crucial and has been approached in different ways. PDX models are often 
implanted with endogenous human stromal cells from the tumour, but over time and 
passage this is replaced with host murine stroma. Murine stromal elements have been 
detected in different carcinoma xenografts, including prostate cancer, indicating an ability 
for the mouse stroma to partially support the human tumour growth (Bradford et al., 2016, 
Delitto et al., 2015, Mo et al., 2018). Stromal FAP expression is often found in these 
models and has shown to be of mouse origin (Niedermeyer et al., 1997). Accordingly, 
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NSG mice are also able to recruit host stromal cells to the site of human PDX tumours 
and replace the human fibroblasts completely after multiple passages in vivo (Maykel et 
al., 2014, Braekeveldt et al., 2016). 
 
Xenografts in NSG mice derived from the human PC3 and DU145 PCa cell lines have 
been shown to recruit murine stroma. Establishment of a stroma is inversely correlated 
with SOCS1 expression in the prostate cancer cells (Villalobos-Hernandez et al., 2017). 
However, initial studies of PCa xenografts in our lab showed a lack of murine stroma 
recruitment. To ensure the presence of the stromal compartment and to observe stroma-
tumour interactions that do not cross the species barrier, fibroblasts can be co-
administered. Reactive prostate stromal cell lines and cancer-associated fibroblasts taken 
from patients express a different gene signature compared to normal prostatic tissue 
fibroblasts and are able to promote prostate cancer engraftment, vascularisation and 
growth in vivo (Dakhova et al., 2014, Minciacchi et al., 2017, Tuxhorn et al., 2002b, 
Wilkinson et al., 2013). Non-prostatic stromal cells have been used to represent the 
prostate tumour microenvironment, including the murine fibroblast line NIH3T3 and the 
bone marrow derived stromal cells Hs5 via a co-culture injection (Bruzzese et al., 2014, 
Chen et al., 2013a). Bone marrow-derived mesenchymal stem cells have also been shown 
to be recruited to the prostate tumour in both transgenic and xenograft models (Placencio 
et al., 2010). In this project, I aimed to create a model of the tumour microenvironment 
in which human stromal FAP expression is seen, as is the case in human prostate cancer 
(Tuxhorn et al., 2002a). The human foetal lung fibroblast cell line MRC5 is a reactive 
fibroblast that naturally expresses endogenous FAP. Co-injection of MRC5 cells with 
malignant cells has been successfully demonstrated in in vivo models leading to its use in 
this study (Chen et al., 2013b, Jiang et al., 2005, Kanaji et al., 2017, Wang et al., 2012). 
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5.1.3 Specific aims 
1.  Establish an in vivo PCa/stroma model for drug development. 




5.2.1 Establishment of prostate cancer/stroma co-culture in vivo 
The results presented above indicate that the PCa/MRC5hT combination provides a 
useful in vitro PCa/stroma model in which both PSMA (tumour) and FAP (stroma) co-
expression are maintained. Consequently, an in vivo model was next established using 
these cells. Given the in vitro results, cells were mixed at an 8:1 cell (MRC5hT:PCa) ratio 
such that a total of 9x105 of MRC5hT+PL, MRC5hT+PLP, MRC5hT+DU145 or 
MRC5hT+DU145P cells were administered to NSG mice by subcutaneous injection. 
Ratios of PCa and stromal cell types were analysed by flow cytometry before 
subcutaneous administration and it was observed that the injected cultures contained 
between 12-15% of respective PCa cells and between 83-86% MRC5hT cells, in keeping 
with the 8:1 stromal to tumour cell target ratio [Figure 5.1A-B]. 
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Figure 5.1 Ratio confirmation of injected MRC5hT:PCa co-cultures. 
The indicated tumour/ stromal cell mixtures were analysed by flow cytometry prior to 
injection in NSG mice. Ratios were determined by detection of the PCa cells through 
tdTomato expression and MRC5hT through mNeptune expression in A) MRC5hT+PL, 
MRC5hT+PLP, B) MRC5hT+DU145 and MRC5hT+DU145P. 
 
Tumour growth was imaged in vivo using bioluminescence of the luciferase expressing 
PCa cells. A clear demarcation between the PL and DU145 sublines can be seen at day 
10 and result in in vivo tumour models with distinctive growth kinetics [Figure 5.2A]. 
The PL/PLP tumours present a rapidly growing model of disease, requiring sacrifice at 
day 21 due to tumour size. The DU145/DU145P tumours, in keeping with the kinetics 
observed in vitro, are more indolent with the model extending out to 43 days. The weight 
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Figure 5.2 In vivo establishment of PCa/stroma tumour. 
Indicated MRC5hT+PCa combinations were injected subcutaneously. A) BLI was 
performed to track tumour growth (mean + SEM, n=3 mice per group). B) Weight of the 
mice was recorded at each imaging time point. Statistical significance was determined 
using a two-way ANOVA (** = p < 0.01). 
 
Tumours harvested from the mice described above were analysed for the presence of both 
PCa cells and MRC5hT using flow cytometry. This was carried out using the gating 
strategy in Figure 5.3. Zombie Green™ dye was used to stain dead cells and a single cell 
suspension was selected [Figure 5.3A-B]. A control containing LT-PL + PL cells was 
used to set the gate for tdTomato+ cells and a second control with mNeptune-MRC5hT + 
MRC5hT was used to set the gate for mNeptune+ cells [Figure 5.3C-D]. 
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Figure 5.3 Gating strategy for flow cytometric analysis of tumours. 
Harvested tumours were analysed by A) dead cell stain with Zombie Green™, gated on 
the negative population and B) single cell suspension was gated for using side scatter area 
(SSC-A) and side scatter height (SSC-H). C) LT-PL+PL controls were used to gate for 
tdTomato+ cells and D) mNeptune-MRC5hT+MRC5hT controls were used to set the 
parameter for mNeptune+ cells. This strategy was applied to all subsequent flow 
cytometric analysis. 
 
Mice with PL/PLP tumours were sacrificed at day 21 and animals with DU145/DU145P 
tumours were culled at between day 37 and 43. Tumours were harvested and half was 
processed into a single cell suspension and half was snap-frozen. The fresh single cell 
suspension was analysed for the presence of both PCa and stromal cells. In the case of 
MRC5hT+PL-injected mice, a tdTomato+ population was detected in all three tumours. 
No mNeptune MRC5hT cells were detected [Figure 5.4A]. When stained for human 
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Figure 5.4 MRC5hT+PL tumour analysis. 
MRC5hT+PL tumour cells collected from the mice were evaluated for A) presence of 
both cell types through tdTomato and mNeptune expression and B) FAP and PSMA 
expression. Commercially available antibodies were used for FAP and PSMA and an 
isotype was used to set the gate. Data shown is from each mouse in the group (n=3). 
 
For the day 21 MRC5hT+PLP tumours, none of the animals had detectable mNeptune 
signal and 2 of 3 had low levels of tdTomato [Figure 5.5A]. The third animal had a very 
distinct tdTomato+ population of 13.9%. This animal differed from the other 2 in the 
group as significant intra-abdominal ascites had developed. This was harvested and 
analysed [Figure 5.5, MRC5hT+PLP - 3]. The single cell preparation was much more 
rapid for this animal and as such, cell death/loss in preparation was attenuated. No FAP 
expression was seen. PSMA was detected [Figure 5.5B]. Mouse 3 had a non-specific peak 
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Figure 5.5 MRC5hT+PLP tumour analysis. 
MRC5hT+PLP tumour cells collected from the mice were evaluated for A) presence of 
both cell types through tdTomato and mNeptune expression and B) FAP and PSMA 
expression. Commercially available antibodies were used for FAP and PSMA and an 
isotype was used to set the gate. Data shown is from each mouse in the group (n=3). 
 
In light of the difficulty in establishing a good yield of live cells for flow cytometry with 
the PL/PLP+MRC5hT model, a different method was used to prepare a single cell 
suspension from harvested MRC5hT+DU145 and MRC5hT+DU145P tumours. This 
included a tissue digestion step which improved the live cell yield for analysis. Only 2 of 
3 mice had visible tumours at day 43 in the MRC5hT+DU145 group and 2 of 3 mice had 
no tissue collected in the MRC5hT+DU145P group due to an unexpected death and 
illness before day 43. From the tumours collected, a tdTomato+ cell population was seen 
in each case, but no definitive mNeptune population [Figure 5.6A]. No FAP was detected 
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in any tumour. A PSMA+ population was clearly visible in the MRC5hT+DU145P 
tumour preparation [Figure 5.6B] 
 
 
Figure 5.6 MRC5hT+DU145 and MRC5hT+DU145P tumour analysis. 
MRC5hT+DU145/DU145P tumour cells collected from the mice were evaluated for A) 
presence of both cell types through tdTomato and mNeptune expression and B) FAP and 
PSMA expression. Commercially available antibodies were used for FAP and PSMA and 
an isotype was used to set the gate. Data shown is from collected tumours from the group 
(MRC5hT+DU145: n=2; MRC5hT+DU145P: n=1). 
 
The frozen tumours were sectioned for further investigation. Haematoxylin and Eosin 
(H&E) staining of day 21 MRC5hT+PLP and day 43 MRC5hT+DU145P tumour sections 
showed the presence of the cuboidal PCa cells, but exhibited poor stromal inclusion in 
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Figure 5.7 H&E stain of tumour sections 
An H&E stain was performed on tumour sections for A) MRC5hT+PLP and B) 
MRC5hT+DU145P. Representative images are shown together with a scale bar.  
 
Fluorescence microscopy was performed on MRC5hT+PLP tumours in order to detect 
MRC5hT stromal cells and PLP tumour cells by virtue of their expression of the 
mNeptune and tdTomato fluorescence reporter genes respectively. DAPI was used to 
visualise cell nuclei. Although signal was detected in the mNeptune channel, this 
appeared to overlap completely with the tdTomato+ area [Figure 5.8]. It was assumed that 
this phenomenon was due to spectral overlap of tdTomato and mNeptune. This bleeding 
effect from tdTomato was not seen during flow cytometry due to compensation controls 
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Figure 5.8 Fluorescence microscopy of the MRC5hT+PLP tumour. 
The fluorescent reporter tdTomato (red) and mNeptune (white) were visualised. DAPI 
(blue) was used to locate the cell nuclei. Image was taken on a Nikon A1R inverted 
confocal microscope. The 405nm laser was used for DAPI excitation. The 561nm laser 
was used for tdTomato and mNeptune excitation. DAPI, tdTomato and mNeptune were 
detected in the ranges 450/50, 525/50 and 595/50 nm respectively. Representative images 
are shown together with a scale bar.  
 
Fluorescence microscopy was also undertaken on a single MRC5hT+DU145P tumour. A 
similar pattern was seen to the MRC5hT+PLP tumours with clear DAPI staining and an 
overlapping detection signal of tdTomato and mNeptune in the tissue most likely due to 






 - 194 - 
 
Figure 5.9 Fluorescence microscopy of the MRC5hT+DU145P tumour. 
The fluorescent reporter tdTomato (red) and mNeptune (white) were visualised. DAPI 
(blue) was used to locate the cell nuclei. Image was taken on a Nikon A1R inverted 
confocal microscope. The 405nm laser was used for DAPI excitation. The 561nm laser 
was used for tdTomato and mNeptune excitation. DAPI, tdTomato and mNeptune were 
detected in the ranges 450/50, 525/50 and 595/50 nm respectively. Representative images 
are shown together with a scale bar.  
 
Using both flow cytometry and fluorescence microscopy for mNeptune emission and 
flow cytometry for human FAP expression, no definite evidence of persistence of 
mNeptune expressing cells in tumours was apparent. I concluded therefore that the 
MRC5hT stromal cells had not survived in these tumour models. A new in vivo 
experiment was undertaken in which MRC5hT+PL and MRC5hT+PLP cells were 
embedded in matrigel to facilitate stroma engraftment. Once again, subcutaneous tumour 
xenograft engraftment was demonstrated by bioluminescence [Figure 5.10A]. Mice were 
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Figure 5.10 In vivo imaging of MRC5hT+PL/PLP tumour progression in matrigel. 
Mixtures of MRC5hT+PL and MRC5hT+PLP cells were suspended in matrigel and 
injected in NSG mice using the subcutaneous route. A) Tumour growth was assessed 
using bioluminescence imaging (mean + SEM, n=4). B) The weight of the mice was 
recorded throughout the experiment. 
 
Three of four mice had visible tumours, which were collected from the MRC5hT+PL 
matrigel group and revealed high levels of tdTomato expression between 53% and 62%. 
No mNeptune expression was detected by flow cytometry [Figure 5.11A]. When stained 
for FAP and PSMA, all 3 tumours were negative for both [Figure 5.11B]. 
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Figure 5.11 Flow cytometric analysis of MRC5hT+PL tumours established in 
matrigel.  
Single cell suspensions were prepared from three subcutaneous MRC5hT+PL tumours 
following engraftment in NSG mice. Flow cytometry was performed to evaluate A) the 
presence of tumour and stromal cells through tdTomato and mNeptune expression; B) 
FAP and PSMA expression. Commercially available antibodies were used to detect FAP 
and PSMA and an isotype control was used to set the gate. Data shown is from collected 
tumours from the group (n=3). 
 
All 4 tumours were harvested from the MRC5hT+PLP in matrigel group although mouse 
2 had only ascites.  Again, high levels of tdTomato was detected in the 4 tumours but no 
mNeptune expression was seen [Figure 5.12A]. Staining showed no expression of human 
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Figure 5.12 MRC5hT+PLP in matrigel tumour analysis. 
MRC5hT+PLP tumour cells were collected and evaluated for A) presence of both cell 
types through tdTomato and mNeptune expression and B) FAP and PSMA expression. 
Commercially available antibodies were used for FAP and PSMA and an isotype was 
used to set the gate. Data shown is from collected tumours from the group (n=4). 
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Haematoxylin and Eosin staining and fluorescence microscopy were used to visualise the 
cells in sections prepared from MRC5hT+PLP tumours that had been established in 
matrigel. The H&E stain showed the presence of the PLP cells in the tissue and no 
apparent stroma [Figure 5.13A]. Applying the same detection filters as before, 
fluorescence microscopy showed a clear staining of the cell nucleus with DAPI. The 
signal for both tdTomato and mNeptune again was overlapping indicating the possibility 
of spectral overlap and a false positive signal for mNeptune [Figure 5.13B]. 
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Figure 5.13 H&E stain and fluorescence microscopy of the MRC5hT+PLP tumour 
in matrigel.  
The MRC5hT+PLP matrigel tumour section was visualised with A) H&E staining and B) 
fluorescence microscopy for tdTomato (red), mNeptune (white) and DAPI (blue). Images 
were taken on a Nikon A1R inverted confocal microscope. The 405nm laser was used for 
DAPI excitation. The 561nm laser was used for tdTomato and mNeptune excitation. 
DAPI, tdTomato and mNeptune were detected in the ranges 450/50, 525/50 and 595/50 
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To determine whether the MRC5hT cells were engrafting in these subcutaneous tumours, 
live fluorescence imaging of the mNeptune reporter was conducted alongside 
bioluminescence imaging of the PCa cells. MRC5hT+DU145 and MRC5hT+DU145P 
cells were injected in matrigel and bioluminescence imaging showed tumour growth for 
both groups with MRC5hT+DU145 tumours progressing more quickly after day 29 
[Figure 5.14A-B]. In vivo fluorescence imaging detected signal in the mNeptune channel 
and showed a significant increase in signal in the two MRC5hT+PCa groups compared 
to MRC5hT injected alone, suggesting further bleed through from the tdTomato into the 
mNeptune detection channel [Figure 5.14C-D]. The signal was taken from a region of 
interest drawn around the injection site. Throughout the imaging sessions, weight of the 
mice was monitored [Figure 5.14E]. 
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Figure 5.14 In vivo imaging of MRC5hT+DU145 and MRC5hT+DU145P tumours 
in matrigel.  
Subcutaneous tumours comprising MRC5hT+DU145 and MRC5hT+DU145P cells were 
established in matrigel and were monitored using A-B) Bioluminescence and C-D) far-
red fluorescence imaging. A) and C) are representative images at day 28. E) Weights of 
the mice were monitored throughout the experiment. B) and D) statistical significance 
was determined using a two-way ANOVA (mean + SEM, n=3) (* = p < 0.05). 
 
Tumours were collected at day 35 and H&E staining of the MRC5hT+DU145P matrigel 
tumour sections once again showed the PCa cells, but no morphologically stromal cells 
[Figure 5.15A]. Fluorescence microscopy detected tdTomato and only background noise 
in the mNeptune channel [Figure 5.15B]. This differs from the mNeptune bleed through 
previously seen perhaps due to a lower tdTomato signal and images acquired at a lower 
magnification (10x). 
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Figure 5.15 H&E stain and fluorescence microscopy of the MRC5hT+DU145P 
tumour in matrigel.  
The MRC5hT+DU145P matrigel tumour section was visualised with A) H&E staining 
and B) fluorescence microscopy for tdTomato (red), mNeptune (white) and DAPI (blue). 
Images were taken on a Nikon A1R inverted confocal microscope. The 405nm laser was 
used for DAPI excitation. The 561nm laser was used for tdTomato and mNeptune 
excitation. DAPI, tdTomato and mNeptune were detected in the ranges 450/50, 525/50 
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Tissues from the previous in vivo experiments were analysed for murine stroma 
recruitment and intratumoural presence of FAP by immunohistochemistry. Tumours 
consisting of MRC5hT+PLP cells exhibited areas positive for the murine stromal marker 
α smooth muscle actin (αSMA) suggesting that these tumours were able to recruit murine 
stroma [Figure 5.16A]. There was also positive staining for FAP in the tissue although 
there were high levels of background in the FAP stain [Figure 5.16B]. Because the FAP 
antibody crosses the species barrier, this could be either human FAP expressed in the 
MRC5hT or murine FAP from recruited stroma.  
 
Another section of MRC5hT+PLP tumours exhibited murine αSMA at low levels and 
mostly on the fringe of the tissue [Figure 5.17A]. There were higher levels of FAP 
staining throughout the section [Figure 5.17B]. 
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Figure 5.16 Immunohistochemical detection of stromal markers in MRC5hT+PLP 
tumours.  
Tumour sections were stained for A) murine αSMA, or B) murine/human FAP to 
visualise stromal tissue. A counterstain was used to visualise the nuclei (blue). A section 
is shown for 1 of 2 tumours. Arrows indicate areas positive for relevant antigen detection 
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Figure 5.17 Immunohistochemical detection of stromal markers in MRC5hT+PLP 
tumours.  
Tumour sections were stained for A) murine αSMA, or B) murine/human FAP to 
visualise stromal tissue. A counterstain was used to visualise the nuclei (blue). A section 
is shown for 2 of 2 tumours. Arrows indicate areas positive for relevant antigen detection 
(brown). Images are shown together with a scale bar.  
 
Finally, a sample of MRC5hT+DU145P tumour tissue was probed for αSMA and FAP. 
The MRC5hT+DU145P tissue demonstrated murine αSMA, suggesting endogenous 
stroma recruitment in vivo [Figure 5.18A]. In contrast to the MRC5hT+PLP tumours, the 
MRC5hT+DU145P sections exhibited non-specific background staining for FAP, with a 
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Figure 5.18 Immunohistochemical detection of stromal markers in 
MRC5hT+DU145P tumours.  
Tumour sections were stained for A) murine αSMA, or B) murine/human FAP to 
visualise stromal tissue. A counterstain was used to visualise the nuclei (blue). A single 
tumour was investigated. Arrows indicate areas positive for relevant antigen detection 
(brown). Images are shown together with a scale bar.  
 
An in vivo experiment was carried out in an attempt to confidently detect mNeptune and 
thus the engraftment of the stromal cells in these PCa/stroma tumour models without 
potential bleed through from the tdTomato reporter. A mono-culture of mNeptune+ 
MRC5hT cells or a co-culture also containing PLP or DU145P that had not been 






 - 207 - 
were monitored using in vivo fluorescence imaging. There was an increase in 
fluorescence signal in all of the groups including the background mice that were not 
injected with anything [Figure 5.19A]. The signal was taken from a region of interest 
drawn around the injection site. The weights of the mice were recorded during imaging 
sessions [Figure 5.19B]. 
 
 
Figure 5.19 Fluorescence in vivo imaging of tumour progression in matrigel. 
Engraftment of MRC5hT alone, MRC5hT+PLP and MRC5hT+DU145P in matrigel were 
assessed with A) fluorescence imaging of mNeptune (mean + SEM, n=3). B) The weight 
of the mice was recorded throughout the experiment. 
 
At day 23, tumours were harvested, sectioned and imaged for mNeptune expression. 
MRC5hT+PLP tumours showed sections of high mNeptune signal that corresponded with 
increased DAPI staining [Figure 5.20A]. mNeptune signal was detected in 
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MRC5hT+DU145P tumour sections at lower levels [Figure 5.20B]. However, there was 
a lack of a negative control comprising of fluorescently negative tumour tissue and 
therefore high autofluorescence from the tumour in areas of dense cellularity could be the 
source of signal in the mNeptune detection channel. The mNeptune reporter was not 
informative for in vivo imaging of engraftment and tumour growth and sufficient 
MRC5hT presence could not be definitively detected. 
 
 
Figure 5.20 Fluorescence microscopy of the MRC5hT+PCa tumour in matrigel.  
Tumour sections of A) MRC5hT+PLP and B) MRC5hT+DU145P were visualised with 
using fluorescence microscopy for mNeptune (white) and DAPI (blue). Representative 
image of 3 tumours/group. Images were taken on a Nikon A1R inverted confocal 
microscope. The 405nm laser was used for DAPI excitation. The 561nm laser was used 
for mNeptune excitation. DAPI and mNeptune were detected in the ranges 450/50 and 
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5.2.2 In vivo efficacy of P4 CAR T cells with eFAP-4 
The core hypothesis underlying this thesis is that PSMA-targeted CAR T cell 
immunotherapy of prostate cancer can be potentiated by a stromal targeted 
immunocytokine that delivers a selective growth signal to the CAR T cells at that 
location. However, the data presented in the preceding sections of this chapter 
demonstrate that engraftment of MRC5hT cells in subcutaneous tumours is inefficient to 
allow testing of this hypothesis using an in vivo model. To circumvent this issue, I elected 
to express FAP in the LT-PLP tumour cell line. The 293vec-RD114 cell line was 
transduced with a FAP-SFG retroviral plasmid at high levels [Figure 5.21A]. The virus-
containing supernatant from these cells was used to successfully transduce LT-PLP cells. 
Expression of FAP was detectable in the transduced cells with a commercial antibody 
[Figure 5.21B]. In addition, when the eFAP-4 immunocytokine was added to these cells, 
binding could be detected using anti-IL-4 antibody [Figure 5.21B]. Expression of FAP 
had no effect on in vitro cell growth over a 72-hour period [Figure 5.21C]. 
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Figure 5.21 Generation of LT-PLPFAP.  
A) A FAP-SFG RD114 pseudotyped retrovirus was produced in the 293vec-RD114 
packaging line. B) The LT+ and PSMA+ prostate cancer cell line LT-PLP was transduced 
with FAP-SFG. Expression of FAP was detected using a commercially available αFAP 
antibody and with eFAP-4 followed by αIL-4-PE secondary antibody. C) The growth of 
parental LT-PLP and LT-PLPFAP cells was compared over 72 hours in D10 media. Cells 
were quantified using trypan blue exclusion and haemocytometer (mean + SEM, n=3). 
 
LT-PLPFAP cells were used in an in vivo pilot study to assess anti-tumour activity of 
eFAP-4 when combined with P4 CAR T cells [Figure 5.22A]. LT-PLPFAP cells 
demonstrated expression of the CAR target antigen PSMA and the immunocytokine 
target antigen FAP before injection. These cells also demonstrated high expression of the 
reporter gene LT [Figure 5.22B]. Human T cells transduced with P4 or P4Tr showed high 
levels of CAR expression through detection of the CAR scFv using a polyclonal PE-
conjugated goat anti-mouse immunoglobulin (GAM-PE), or detection of 4αβ expression 
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expression and calculate what number of T cells was required to deliver 1x106 CAR+ T 
cells for treatment. 
 
 
Figure 5.22 Pilot eFAP-4 efficacy study plan and cell analysis.  
A) Male NSG mice received a subcutaneous injection of LT-PLPFAP cells in the right 
flank on day 0. On day 12, either eFAP-4, IL-4 or PBS was injected IP and, 20 minutes 
later, CAR T cells were administered IV. Upward pointing arrows indicate time-points of 
eFAP-4/IL-4 or PBS injection. Mice were monitored for tumour growth (BLI) and 
toxicity until the end of the study at day 57. B) LT-PLPFAP tumour cells injected on day 
0 were positive for the reporter gene tdTomato, PSMA and FAP. C) Expression of the P4 
and P4Tr CARs were detected on the surface of human T cells by staining with goat anti 
mouse-PE (GAM-PE – detects anti-PSMA scFv) or αCD124 (detects 4ab) before 
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Pooled bioluminescence data from the treatment groups showed that tumours progressed 
at similar rates [Figure 5.23A]. Individual mice in the P4 + eFAP-4 and P4Tr + IL-4 
survived until termination of the study at day 57 and displayed lower tumour burden. 
Weight was monitored throughout the experiment and no toxicity was seen in any of the 




Figure 5.23 In vivo imaging of tumour progression and weight assessment.  
Treatments groups were monitored for A) tumour growth using bioluminescence (mean 
+ SEM, n=3). B) The weight of the mice was recorded at each imaging time point. 
 
Individual mice in each treated group are represented [Figure 5.24A-G]. The 
bioluminescence signal did not always correspond with tumour volume measured with 
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callipers at the end point. There was an apparent decrease in signal at time points that 
mice were sacrificed (due to the tumour size reaching home office limits). This was 
evident for mice in the PBS and P4Tr groups [Figure 5.24A&E]. One mouse in the P4 + 
eFAP-4 group exhibited tumour regression dropping below the limit of detection (106 p/s) 
on day 43 and showing no palpable tumour. There was subsequent tumour progression 
afterwards until the termination of the study at day 57 [Figure 5.24C]. One mouse in the 
P4Tr + IL-4 demonstrated low bioluminescence signal and no palpable tumour until day 
47. However, this individual presented with 2 logs lower signal compared to the other 
two mice in the group at the first imaging session. This suggests a miss-injection of lower 
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Figure 5.24 Individual in vivo imaging of tumour progression.  
Tumour growth in mice was monitored via bioluminescence imaging and individual 
values are shown for A) PBS, B) P4, C) P4 + eFAP-4, D) P4 + IL-4, E) P4Tr, F) P4Tr + 
eFAP-4 and G) P4Tr + IL-4 (n=3). 
 
Bioluminescence images show the progression of the individual tumours up until day 40 
for groups treated with P4 CAR T cells with/without eFAP-4 or IL-4 [Figure 5.25]. The 
P4 + eFAP-4 treated mouse that survived until the end of the experiment showed an 
increase in tumour burden followed by a regression starting at day 27, 15-days post CAR 
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Figure 5.25 Individual bioluminescence images of P4 CAR T cell treated groups. 
Bioluminescence images of mice in the PBS, P4, P4 + eFAP-4 and P4 + IL-4 groups are 
shown from day 2 to day 40 after LT-PLPFAP inoculation. The scale bar indicates a 
logarithmic scale for radiance ranging from 5x106 – 7x1010. Crosses indicate the loss of 
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Bioluminescence images show the progression of the individual tumours up until day 40 
for control groups treated with P4Tr CAR T cells with/without eFAP-4 or IL-4 [Figure 
5.26]. The P4Tr + IL-4 treated mouse that survived until the end of the experiment had 
no/low tumour burden signal until day 23. This signal remained low until day 40 
indicating an error in tumour cell inoculation. 
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Figure 5.26 Individual bioluminescence images of P4Tr CAR T cell treated groups. 
Bioluminescence images of mice in the PBS, P4Tr, P4Tr + eFAP-4 and P4Tr + IL-4 
groups are shown from day 2 to day 40 after LT-PLPFAP inoculation. The scale bar 
indicates a logarithmic scale for radiance ranging from 5x106 – 7x1010. Crosses indicate 
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The final two weeks of imaging in this pilot study showed the increasing tumour growth 
in the remaining mice [Figure 5.27A]. The last mouse in the P4Tr + eFAP-4 group was 
culled on day 43 due to tumour size. Both mice in the P4 + eFAP-4 and P4Tr + IL-4 
groups exhibited tumour progression until day 57 when they were sacrificed because of 
tumour size. A survival curve of the treatment groups shows a tend towards survival 
benefit for the P4 + eFAP-4 and P4Tr + IL-4 groups [Figure 5.27B]. This benefit did not 
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Figure 5.27 Individual bioluminescence images from day 43-57 and survival data. 
A) Bioluminescence images of surviving mice in the P4 + eFAP-4, P4Tr + eFAP-4 and 
P4Tr + IL-4 groups are shown from day 43 to day 57 after LT-PLPFAP inoculation. The 
scale bar indicates a logarithmic scale for radiance ranging from 5x106 – 7x1010. Crosses 
indicate the loss of the animal due to reaching home office limits on tumour volume or 
close to ulceration. B) Survival is represented as a Kaplan-Meier curve. Log-rank and 
Gehan-Wilcoxon statistical tests were used to determine non-significance (n=3). 
 
5.3 Discussion 
Establishment of a human PCa/stroma xenograft in NSG mice proved challenging as the 
engraftment of the MRC5hT was not definitively shown. While scattered mNeptune 
signal was detected using fluorescence microscopy imaging of some tumour sections, this 
might have been an artefact of tdTomato expression in the PCa cells. While the peak 
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emission that continually decreases up to around 700 nm (Shaner et al., 2004). The 
mNeptune variant that was used in this study has a brightness of 17.5 and an emission 
peak at 652 nm and ranging up to 800 nm (Li et al., 2014b). Therefore, tdTomato could 
have bled into the mNeptune channel during in vivo fluorescent imaging and microscopy 
causing a false positive. This overlap was not an issue for flow cytometry because 
compensation was applied. Additionally, mNeptune signal could have been an artefact of 
autofluorescence of the tumour tissue. Tumour H&E stains did not indicate the presence 
of stroma. Immunohistochemistry analysis indicated that there were low levels of FAP 
expression in the MRC5hT+PLP tumours. Because the antibody used to detect FAP 
crosses the species barrier, it is unknown if the source was human or murine in these 
tumours. The MRC5hT+PLP and MRC5hT+DU145P tumours also showed low level 
expression of murine αSMA, further suggesting the recruitment of some murine stroma. 
Because of the low level of FAP expression, this recruitment was not considered to be 
sufficient to test the P4+eFAP-4 therapy (the ESC11 scFv having specificity for both 
human and murine FAP).  
 
To monitor mNeptune+ MRC5hT engraftment in the absence of any possible 
contamination by tdTomato-derived fluorescence, I co-injected these stromal cells with 
tdTomato- PCa cells and undertook in vivo fluorescence imaging. While there was an 
increase in signal throughout the experiment, there was also an increase in fluorescence 
of the background mice. Indeed, the MRC5hT alone group had the highest signal, but no 
tumour was visible for excision. Further analysis of sectioned tumours showed signal in 
the mNeptune detection channel for MRC5hT+PLP tumours using fluorescent 
microscopy. Because there was no negative control tissue, it is unclear whether this was 
autofluorescence from the tumour tissue. A limitation of the fluorescence microscopy 
used in this study was the lack of a negative control tissue. A sufficient control would 
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have been a resected xenograft tumour of the untransduced cell lines, and thus negative 
for all fluorescent reports. Because the aim of mNeptune expression was for in vivo 
detection, no animals were used for mNeptune- MRC5hT injection. Future in vivo 
experiments could utilise a different reporter gene for conclusive detection of MRC5hT 
engraftment. This could be done by putting the firefly luciferase reporter into the 
MRC5hT cells instead of the PCa cells, or using a different bioluminescence reporter 
such as renilla luciferase, allowing for dual bioluminescent in vivo imaging of the cell 
types (Wendt et al., 2011). 
 
It is unclear why the MRC5hT cells were not detectable in the digested tumours when 
examining either mNeptune-derived fluorescence or FAP expression. In my hands, these 
cells were very sensitive to handling and it is possible that the MRC5hT did not survive 
the digestion. However, the lack of conclusive evidence of the MRC5hT presence in vivo 
or in the retrieved tumours suggests an initial engraftment issue or poor 
persistence/expansion. While the MRC5 cell line has previously been established in NSG 
mice, issues with engraftment have been noted using senescent MRC5 (da Silva et al., 
2019). In my study, MRC5 cells transduced to express human telomerase (hT) were used 
to circumvent senescence although they had not been validated for in vivo engraftment 
potential previously (Ahmed et al., 2008). Additionally, MRC5hT cultures have shown 
variability in their ability to continue proliferating with growth arrest occurring in G1 
phase and/or phases of “growth crisis” in which rate of cell death matches cell doubling 
(MacKenzie et al., 2000).  Alternative cell lines could be used to recapitulate the stroma. 
PS1 were not selected for in vivo study because of perceived unsatisfactory in vitro 
growth kinetics. The in vivo use of these stromal cells could be revisited to assess their 
utility in the PCa/stroma model. Additionally, a prostate cancer stromal cell line could be 
used to model a more physiological microenvironment as these cells have shown to 
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engraft and promote tumour growth with PCa cells in vivo (Tuxhorn et al., 2002b). One 
of the prostate stromal cell lines, HPS-19I, generated by the Rowley group was FAP+ and 
was targeted by a FAP-specific CAR (Kakarla et al., 2013). 
 
As FAP expression is the key defining factor of stroma in this study, an in vivo model of 
FAP and PSMA co-expressing LT-PLPFAP cells was used for a pilot efficacy study of 
eFAP-4 with P4 CAR T-cells. The cells successfully expressed both antigens and did not 
exhibit differential growth kinetics from the parental line. A higher tumour burden model, 
in which the rapidly expanding xenograft could not be controlled by P4 CAR T cells, was 
used to allow for demonstration of improved efficacy (Emami-Shahri et al., 2018). This 
was indeed the case in my pilot study. Interleukin-4 did not seem to improve P4 CAR T 
cell efficacy at the dosage administered. One mouse receiving eFAP-4 and P4 CAR T 
cells demonstrated partial tumour regression and prolonged survival. The LT-PLPFAP 
tumour ultimately progressed owing to incomplete eradication. One study showed anti-
tumour activity with an IL-4 based immunocytokine at a dosage of 568 pmol every 48-
hours for 8 injections (Hemmerle and Neri, 2014). The dosage of eFAP-4 in my pilot 
study was administered at less than half this concentration and half the number of 
injections. Administration of a higher dose given more consistently in the LT-PLPFAP 
prostate cancer model might lead to a greater anti-tumour efficacy for eFAP-4 with P4 
CAR T cells. Future in vivo experiments should optimise the treatment protocol by 
establishing a dose response curve for the immunocytokine administered with 1x106 
CAR+ T cells. This could determine a therapeutic window for eFAP-4 with P4 CAR T 
cells. Additionally, a larger cohort of mice might help distinguish any significant 
improvement in survival or tumour control between the different treatment groups. A 
biodistribution study would also confirm the ability of eFAP-4 to traffic to the tumour. 
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5.4 Summary 
• Engraftment of MRC5hT stromal cells in vivo in PCa/stroma xenograft models 
proved inadequate, leading to the establishment of a tumour model in which 
PSMA and FAP were co-expressed in LT-PLP cells. 
• A pilot efficacy study of eFAP-4 with P4 CAR T cells demonstrated the safety of 
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 Chapter 6: Discussion 
6.1 Overview of findings 
The aim of this thesis was to develop an IL-4 immunocytokine targeted to FAP in order 
to increase P4 CAR T cell proliferation in the tumour microenvironment and thereby 
enhance in vivo efficacy against castrate resistant prostate cancer. 
 
Targeted delivery of cytokines using the immunocytokine format has been shown to 
increase their therapeutic efficacy and to reduce systemic toxicity (Borsi et al., 2003, Liu 
et al., 2006). In this project, development of the immunocytokine was first addressed 
through generation and screening of hybridomas for FAP specificity. Fibroblast 
activation protein is commonly upregulated in the stroma of epithelial tumours and was 
chosen as the target for the scFv employed in the immunocytokine (Garin-Chesa et al., 
1990). Antibodies derived from several hybridoma clones demonstrated FAP-specificity 
upon screening of unpurified supernatant. However, selected subclones produced 
antibodies that exhibited marked instability and a rapid loss of FAP-binding after 
purification and manipulation. To overcome this, I designed an scFv derived from a FAP-
specific antibody with a published nucleotide sequence available in the literature (Fischer 
et al., 2012). This was engineered into a scFv-Fc format which showed comparable 
binding to FAP as that seen with a commercially available antibody. This scFv was 
developed into an IL-4 immunocytokine, termed eFAP-4. Testing of both the scFv and 
cytokine components of this fusion molecule confirmed that both FAP-specificity and IL-
4 functionality were retained.   
 
Interleukin-4 was chosen as the delivered cytokine to enable specific enrichment of CAR 
T cells co-expressing the 4αβ receptor. The 4αβ receptor couples the IL-4 ectodomain to 
the transmembrane and endodomain of IL-2/IL-15 receptor b. Addition of IL-4 to T cells 
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that express this chimeric cytokine receptor enables the selective enrichment and 
expansion of these cells (Wilkie et al., 2010), an approach that is currently in use in a 
Phase I clinical trial. The cytokine signalling capabilities of the eFAP-4 fusion proved 
comparable to that of an equimolar amount of unmodified recombinant human IL-4. 
When the 4αβ chimeric receptor is introduced into the IL-2 dependent murine T cell line, 
CTLL-2, these cells proliferate in response to IL-4. Culturing CTLL-4αβ with 
recombinant IL-4, eFAP-4 or IL-2 allowed robust validation of the IL-4 component of 
the immunocytokine, which promoted comparable expansion of these cells to that seen 
with IL-4 or IL-2. Donor human PBMCs engineered to express a CAR and the 4αβ 
receptor also proliferated in response to eFAP-4 in a manner comparable with IL-4 and 
IL-2. Consequently, I concluded that these investigations demonstrate a functional FAP-
targeting IL-4 immunocytokine. 
 
In order to test the efficacy of eFAP-4 in combination with CAR T cells, the PSMA-
targeted P4 vector was selected. P4 comprises a second generation PSMA-targeting CAR 
co-expressed 4αβ. P4 CAR T cells proliferate in response to IL-4 and demonstrate anti-
tumour efficacy in vitro and in vivo against PSMA+ prostate cancer cell lines (Emami-
Shahri et al., 2018, Maher et al., 2002, Wilkie et al., 2010, Zhong et al., 2010).  
 
To generate a model for in vitro and in vivo testing of P4 and eFAP-4, I set out to develop 
a co-culture system that includes both PSMA+ malignant and FAP+ stromal components. 
The prostate cancer cell lines DU145 and a PC3 derivative named PL were selected. The 
PC3 derived sub-line PL was previously developed as a line with a more aggressive 
phenotype (Sanderson et al., 2006). The DU145 line is more indolent in vitro and as a 
xenograft. In contrast to naturally occurring prostate cancer in man, neither of these cell 
lines expressed endogenous PSMA. Consequently, both cell lines were successfully 
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transduced with retroviral vectors to co-express PSMA and the firefly luciferase-
tdTomato (LT) bioluminescence and fluorescence reporter genes. Similarly, the stromal 
cell lines MRC5hT and PS1 were transduced successfully with the far-red fluorescence 
reporter mNeptune. Maintained expression of endogenous FAP was confirmed in these 
cells after this intervention. MRC5hT cells had been transduced with human telomerase 
by another group, to allow for extended passage time (Ahmed et al., 2008). Growth 
kinetics, antigen expression and optimised co-culture ratios were characterised for these 
PCa:stromal cell combinations in vitro. Prostate cancer/MRC5hT monolayers were 
advanced for further therapeutic investigation. 
 
P4 transduced T cells demonstrated PSMA specific cytotoxicity in MRC5hT+PCa mixed 
co-cultures. Bystander killing of the MRC5hT cells was seen in the presence of PSMA+ 
but not PSMA- tumour cells. Dual targeting of the stroma and the malignant cells of 
tumours has demonstrated superior efficacy for CAR T cell therapy compared to the 
targeting of stroma or tumour cells alone (Kakarla et al., 2013). Therefore, this bystander 
killing effect of the stroma could be beneficial for P4 CAR T cell therapy. When P4 CAR 
T cells were co-cultured with either IL-4 or eFAP-4 on PCa or MRC5hT+PCa monolayers 
cytotoxicity, proliferation and cytokine secretion was enhanced over multiple 
restimulation cycles when compared to CAR T cells alone. The increase in anti-tumour 
efficacy was greater for PLP-containing compared to DU145P cultures. Studies have 
shown a greater cell death resistance in DU145 compared to PC3 from serum deprivation, 
CAR T cell treatment, or treatment with doxorubicin and tumour necrosis factor-related 
apoptosis-inducing ligand (TRAIL) (Sanchez et al., 2013, Tang et al., 1998, Voelkel-
Johnson et al., 2002). The in vitro efficacy data seen in this project correlates with the 
observation of reduced susceptibility to cell death for DU145 compared to PC3 and thus 
PC3-derived PLP was selected for further studies. 
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Supplementation of MRC5hT+PLP+P4 co-cultures with both IL-4 and eFAP-4 resulted 
in a shift towards a lower CD8:CD4 ratio over time. The immunocytokine eFAP-4 
upregulated the activation marker CD44 on P4 CAR T cells co-cultured with 
MRC5hT+PLP monolayers. Altogether, eFAP-4 enhances P4 CAR T cell anti-tumour 
activity in vitro in a manner broadly comparable to IL-4. 
 
The MRC5hT:PCa co-culture model was taken in vivo for further characterisation and 
therapeutic development of eFAP-4. Using in vivo fluorescence imaging, flow cytometric 
analysis and fluorescence microscopy, I was unable to demonstrate convincing evidence 
of engraftment of the MRC5hT stromal cell line in vivo. Difficulty establishing the MRC5 
cell line in vivo has been demonstrated by others (da Silva et al., 2019). Tissue 
autofluorescence limited the utility of mNeptune as a live imaging fluorescence reporter 
gene in this project. This could be overcome by using a different reporting gene such as 
firefly or renilla luciferase to offer a definitive analysis of MRC5hT engraftment. There 
was evidence of murine stroma recruitment in the MRC5hT+PLP tumours and FAP 
expression at low levels. Future in vivo investigation could rely on FAP expression from 
murine stroma for further eFAP-4 development as the scFv crosses the species barrier 
(Renner et al., 2012).  
 
In order to set up a pilot efficacy study to evaluate eFAP-4 in combination with P4 CAR 
T cells, LT-PLP cells were engineered to co-express the FAP target. The resulting LT-
PLPFAP tumours were established in vivo and growth was observed using 
bioluminescence imaging. A higher tumour burden model was used based on previous 
reports of P4 efficacy in low but not high tumour burden models of PLP (Emami-Shahri 
et al., 2018). In this pilot study, P4 CAR T cells alone were insufficient to control tumour 
growth. The eFAP-4 immunocytokine was administered at a modest dosage of 4 
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intraperitoneal injections of 250 pmols. At this dose, there was a suggestion of a delayed 
tumour progression compared to P4 CAR T cells alone or with the equivalent dose of IL-
4. There was anti-tumour activity indicated by a partial regression seen in one of the P4 
+ eFAP-4 treated mice. Tumour bioluminescence fell below the limit of detection before 
relapsing. No dose limiting toxicities were seen. An improved survival trend was also 
seen with P4 + eFAP-4 compared to other treatment groups, although this did not reach 
significance. Further in vivo work with larger cohorts is needed to establish an optimised 
dose and treatment schedule for the eFAP-4 immunocytokine with P4 CAR T cells in 
prostate cancer models. 
 
6.2 Limitations 
There is increasing evidence that interactions between different cell types within the 
tumour microenvironment are crucial for disease progression. Therapeutic investigation 
utilising in vitro monolayers and in vivo tumours of solely cancer cells may not reflect 
the activity of the drug in patients. Here, this limitation was partially addressed through 
the co-culture of prostate cancer cells with stromal cell lines, although ultimately it proved 
difficult to translate this model in vivo. Additionally, drug efficacy against monolayers 
has shown to be superior when compared to efficacy against cancer spheroids (Lal-Nag 
et al., 2017, Shan et al., 2018). Three-dimensional in vitro cancer cell cultures are more 
representative of the histology, gene expression and architecture of in vivo tumours (Lee 
et al., 2013). These 3D models have been used to assess CAR T cell efficacy (Dillard et 
al., 2018). Multicellular spheroids incorporate a variety of cell types present in the tumour 
and recapitulate the cell-cell interactions within the microenvironment (Lazzari et al., 
2018). These multicellular spheroids could be used as representative xenografts in 
immunodeficient mice that lack many cell types found in tumours. In order to better 
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model the tumour microenvironment, future directions for this project could utilise 
spheroids in CAR T cell drug development. 
 
The cell line used in the in vivo pilot efficacy investigation constituted forced expression 
of the target antigens PSMA and FAP. This may result in higher levels of protein 
expression compared to endogenously expressing cell lines. Higher antigen expression in 
the tumour would theoretically enable greater targeting and efficacy of the eFAP-4 
immunocytokine and P4 CAR T cells. Cell lines that endogenously express the target 
antigens could be used in co-cultures to represent physiological levels such as the prostate 
cancer cell line LNCaP. Patient-derived xenografts would produce a model most similar 
to primary tumours, but are known to be difficult to culture and reproduce for drug 
development (Russell et al., 2015). 
 
Due to time constraints of this project, approximately 1 mg of eFAP-4 was produced for 
experimental analysis. The 250 pmol dose used in the pilot efficacy study therefore was 
determined by resource availability. Suggestion of an increase in efficacy in the P4 + 
eFAP-4 treated group warrants further investigation to establish an optimal dosing 
concentration. Immunocytokine studies in vivo vary widely in effective dosages and thus 
it was difficult to predict the concentration needed for the pilot study (Bauer et al., 2004, 
Borsi et al., 2003, Carnemolla et al., 2002, Hemmerle and Neri, 2014, Kawalkowska et 
al., 2016, Kermer et al., 2012, Muller et al., 2008, Quattrone et al., 2015). A study utilising 
a CD20-targeting IL-2 immunocytokine co-injected with CD19-specific CAR T cells 
observed efficacy at doses of 7 x 30 pmol/injections spanning 3 weeks and 107 CAR+ T 
cells (Singh et al., 2007). For further in vivo analysis, more eFAP-4 should be generated 
and biodistribution/pharmacokinetic studies utilised to assess the in vivo activity of eFAP-
4 and influence dosing frequency. Additionally, a dose curve and treatment schedule 
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should be established to assess a therapeutic window for co-administration with P4 CAR 
T cells.  
 
6.3 Conclusions 
There is an unmet clinical need to improve the efficacy and safety of CAR T cell 
immunotherapy for solid tumours. This project aimed to address this need by developing 
a system for intratumoural CAR T cell enrichment, with the support of a tumour-specific 
immunocytokine. To achieve this, I developed a stable FAP-specific IL-4 
immunocytokine, designated eFAP-4, which exhibited comparable signalling capabilities 
to IL-4 in primary human CAR T cells expressing the 4αβ chimeric receptor. Addition of 
eFAP-4 resulted in increased persistence/enrichment of P4 CAR T cells in restimulation 
killing assays of prostate cancer and stroma cell lines in vitro. The prolongation of this 
effect suggested dependence on continued immunocytokine supplementation. Translation 
of this therapy to an in vivo pilot study indicated a potential increase in survival and 
tumour growth control for P4 + eFAP-4 treated mice. The implications of this therapy in 
the clinic could provide a dose dependent and reversible strategy to increase CAR T cell 
efficacy. Additional investigations are needed to assess the true potential of CAR T cell 
combination therapy with eFAP-4. 
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